



*The University of Sydney*  
**at Westmead Hospital**

**Australian General Practice Statistics and Classification Centre**  
**Family Medicine Research Centre**



# BEACH

***BETTERING THE EVALUATION AND CARE OF HEALTH***

**Ischaemic Heart Disease at encounters with  
patients aged 45 and over (12 month data)  
April 2000 – March 2001**

November 2008

Enquiries to: Helena Britt

Telephone: (02) 9845 8151

## Explanatory notes for Problem Report

### Background

This report represents a summary of the data collected from April 2000 until March 2008 inclusive. It provides information on problems managed that the GP recorded as diseases classified as ischaemic heart disease – see Table A for confidence intervals around the rubrics, and Table B for code descriptions).

Each year, BEACH collects data from around 1,000 GPs, who each record details about 100 consecutive consultations, thus providing an annual database of approximately 100,000 records.

### Summary of BEACH data

BEACH Year	Number of GPs  Raw (weighted)	Number of encounters  Raw (weighted)	Number of problems managed  Raw (weighted)	Number of medications (prescribed, GP supplied, over the counter)  Raw (weighted)	Number of prescribed medications  Raw (weighted)
April 1998- March 1999	984 (969.0)	98,400 (96,900.9)	145,183 (140,823.7)	107,451 (106,320.0)	91,427 (90,709.9)
April 1999- March 2000	1047 (1048.6)	104,700 (104,856.3)	156,576 (153,857.1)	113,555 (115,431.5)	96,925 (98,371.8)
April 2000- March 2001	999 (993.1)	99,900 (99,307.3)	147,518 (143,528.3)	108,179 (107,399.6)	91,602 (91,647.2)
April 2001- March 2002	983 (969.7)	98,300 (96,972.9)	144,372 (139,091.8)	102,352 (101,349.9)	85,304 (85,332.1)
April 2002- March 2003	1008 (1009.9)	100,800 (100,987.0)	149,976 (146,335.7)	103,289 (104,813.3)	83,755 (85,161.4)
April 2003- March 2004	1000 (1000.0)	100,000 (98,876.7)	150,126 (144,674.0)	103,774 (103,210.1)	85,023 (85,073.4)
April 2004- March 2005	953 (954.0)	95,300 (94,385.8)	141,489 (137,329.9)	95,672 (95,816.3)	77,913 (78,711.1)
April 2005- March 2006	1017 (1017.3)	101,700 (101,993.0)	152,802 (149,087.9)	105,340 (106,492.6)	85,600 (87,543.6)
April 2006- March 2007	930 (930.0)	93,000 (91,804.7)	140,886 (136,333.2)	93,140 (93,193.5)	75,495 (76,430.4)
April 2007- March 2008	953 (953.1)	95,300 (95,897.7)	147,724 (145,078.0)	96,488 (98,439.3)	76,440 (79,051.3)

The participating GPs are randomly selected from the HIC list of active GPs (those who provided more than 375 GP services in the previous quarter). The research instrument used for each consultation is a single page recording form. An example of the recording forms can be found in Appendix 1 of the BEACH annual report, General practice activity in Australia 2006-07 <<http://www.aihw.gov.au/publications/gep/gpaa06-07/gpaa06-07-x03a.pdf>>. The recording form contains the following variables:

- Date of encounter
- Medicare Benefits Schedule (MBS) item number (up to three)/form of payment/indirect encounters (e.g. telephone consults)
- Patient age and sex
- Patient status to practice (new or seen before)
- Health care card status of patient
- Patient post code and ethnic background
- Patient's reasons for encounter (up to three per encounter)
- Diagnoses/problems managed (up to four)
- Status of each problem to the patient (new/old)
- Whether problems are work related
- Medications prescribed (up to four per problem)
- Over the counter medications recommended
- Medications provided by the GP
- Name, strength and regimen of medication
- Number of repeats for medication
- Medication status - new or continued
- Other treatments (up to two per problem)
- Pathology tests ordered (up to five)
- Imaging ordered (up to two)
- Referrals and hospital admissions (up to two).

## Statistical Analysis

The confidence interval (CI) is calculated as the rate estimate  $\pm$  (1.96 x standard error). The CI is interpreted as “we are 95% confident that the true population value lies between the lower and upper value”. Please note that in some cases, if there were less than three observations (n) in the row, no 95% CIs are provided as data were insufficient to calculate a meaningful estimate. The analysis used procedures in SAS v9.1 that calculate standard errors which adjust for the cluster survey design<sup>1</sup>. Keep in mind when reading the report, where BEACH data are reported in a standard set of categories (e.g. types of Medicare claimable encounters), a missing category means there were no occurrences of the event (e.g. home visits missing indicates no home visits were done for this condition/group of conditions). Also, where the most common 30 or 60 cases are listed (e.g. most frequent reasons for encounter, table 3.3), only the 30 or 60 with the highest frequency of occurrence have been printed. While there may have been other cases with a lower frequency of occurrence, the list has been cut off at 30 or 60.

### **TABLE A: Summary of encounters with at least one Ischaemic heart disease problem (listed at ICPC-2 rubric/grouper level) – Apr00-Mar01**

This table presents:

- The ICPC-2 rubrics that together make up “Ischaemic heart disease”, and the number of encounters in which each rubric appears at least once; and
- The number of encounters where Ischaemic heart disease was managed at least once.

The number of observations, % of encounters, 95% CIs and the national annual estimated encounters, where at least one of the selected problem/s was managed, are provided for each ICPC rubric/grouper. An introduction to ICPC-2 is available from <[www.fmrc.org.au/icpc2](http://www.fmrc.org.au/icpc2)>. The denominator used to calculate the column labelled '% of all encs' is also provided as a footnote. This represents the total number of patients with the selected characteristic/s of interest (e.g. age, sex, state Aboriginal/Torres Strait Islander status, etc.) on which the calculation of management rates of the selected problem are based.

The “National annual estimated encs” gives the estimated number of encounters in a year for general practice across Australia, at which the condition is managed. It is calculated as [*the number of encounters with at least one specified condition managed (n) / the total number of recorded encounters within the specified study period*] X the number of general practice consultations claimed from Medicare in the specified year. If you have requested encounters for a selected patient characteristic/s (e.g. sex, age, state) this column will be restricted to the national annual estimate of consultations with those selected patient characteristic/s.

---

<sup>1</sup> SAS Institute. SAS/STAT® User's guide, Version 9.1. Cary, NC: SAS Institute Inc, 2003.

The table below lists the number of non-specialist GP Medicare services for each specified BEACH year (April-March)<sup>2</sup>. If your report is based on multiple BEACH years (e.g. 2003-04 to 2005-06) the rate has been extrapolated to the *average* annual GP consultations over the multiple years E.g. (96,300,000+ 98,200,000 + 101,100,000) / 3.

	<b>BEACH year</b>	<b>Annual GP consultations<sup>^</sup></b>
1	1998-99	102,600,000
2	1999-00	101,500,000
3	2000-01	100,600,000
4	2001-02	99,900,000
5	2002-03	96,900,000
6	2003-04	96,300,000
7	2004-05	98,200,000
8	2005-06	101,100,000
9	2006-07	103,400,000
10	2007-08	109,500,000
11	2008-09	109,500,000 *

<sup>^</sup>Annual GP consultations are rounded to the nearest 100,000.

Available online at : <http://www.health.gov.au/internet/main/publishing.nsf/Content/medstat-mar08-tables-b>

Then select Table b1 – Number of services

\* Estimation as data is not yet available

### **TABLE B: Summary of Ischaemic heart disease problems (grouped by ICPC-2 rubric/grouper) – Apr00-Mar01**

This table provides a similar output to that of table A, except it is problem-based. It counts each problem once, even when more than one problem classified as Ischaemic heart disease is managed at an encounter. The number of observations, % of selected problems, per 100 of all encounters, 95% confidence intervals, the % of all problems and the national annual estimate of the listed problems managed by GPs (for each ICPC rubric and for the total selected morbidity) annually across Australia in the period used in this analysis. The denominator used to calculate the column labelled '*per 100 all encs*' is provided as a footnote. This represents the total number of patients with the selected characteristic/s of interest (e.g. age, sex, state Aboriginal/Torres Strait Islander status, etc.) on which the calculation of management rates of the selected problem are based. The denominator used to calculate the column labelled '*% of all problems*' is also provided as a footnote. This represents the number of problems managed at encounters with patients who have the characteristic/s of interest (e.g. age, sex, state Aboriginal/Torres Strait Islander status, etc.) on which the calculation of management rates of the selected problem are based.

<sup>2</sup> Medicare Australia. 2006. Medicare Benefits Schedule (MBS) statistics reports. <http://www.health.gov.au/internet/main/publishing.nsf/Content/medstat-mar08-tables-b>.

The “national annual estimated probs” gives the estimated number of GP contacts with the specified condition in the selected year across Australia. It is calculated as  $[the\ number\ of\ specified\ problems\ managed\ (n) / the\ total\ number\ of\ recorded\ encounters\ within\ the\ specified\ study\ period] \times the\ number\ of\ general\ practice\ consultations\ claimed\ from\ Medicare\ in\ the\ specified\ year$ . If you have requested encounters for a selected patient characteristic/s (e.g. sex, age, state) this column will be restricted to the national annual estimate of consultations with those selected patient characteristic/s.

#### **TABLE C: Summary of Ischaemic heart disease problems (listed at ICPC-2 PLUS code level) – Apr00-Mar01**

This table has been included for your information, to show how GPs express the concept of problems classified to Ischaemic heart disease. Information on the BEACH coding system - ICPC-2 PLUS can be found at <<http://www.fmrc.org.au/icpc2plus>>. Statistical work should rely on tables A and B (the classified data) rather than on the terms used by GPs to describe the concept (table C). Refer to table B for the calculation used for the “national annual estimated probs”.

### **SECTION 1: SUMMARY OF DATABASE & GENERAL PRACTITIONERS**

#### **TABLE 1a: Summary of data base: services – Ischaemic heart disease - Apr00-Mar01**

A frequency count, rate per 100 encounters (%), and 95% CI are provided for each data point.

Definitions of the categories are as follows:

**Encounter (enc):** Any professional interchange between a patient and a GP.

**Direct encounters:** Encounters where there is a face-to-face meeting of the patient and the GP.

**No charge:** Encounters where no fee (Medicare bulk billing or other) is received for the service provided.

**MBS items by GPs:** Encounters claimable through the MBS. The following groups are claimable through the relevant MBS item numbers.

**Short surgery consults:** (Level A) A short encounter which requires limited examination and management.

**Standard surgery consults:** (Level B) An encounter of less than 20 minutes duration, which requires an examination of the patient and an implementation of a management plan in relation to at least one of the problems.

**Long surgery consults:** (Level C) An encounter with duration between 20 and 40 minutes, which involves taking a detailed history and implementing a management plan for at least one of the problems.

**Prolonged surgery consults:** (Level D) An encounter with a duration of more than 40 minutes, which involves taking an exhaustive history, a comprehensive examination, the arrangement of necessary investigations and implementing a management plan for at least one of the problems.

**Home visits:** Encounters that take place in the patient’s home and a MBS home visit item number(s) are recorded.

**Hospital:** Encounters that take place with a patient in a hospital setting, and a MBS hospital item number(s) are recorded.

**Residential aged care facility:** Encounters that take place in a residential aged care facility (RACF) and an MBS RACF item number is recorded.

**Case conferences:** Encounters that are covered by a MBS item number for a case conference.

**Chronic disease management:** Encounters that are covered by a MBS chronic disease management item number(s).

**GP mental health care:** Encounters that are covered by a MBS GP mental health care plan item number(s).

**Health assessments:** Encounters that are covered by a MBS item number for a health assessment.

**Incentive payments:** Encounters where MBS incentive payment items are recorded.

**Other items:** Medicare item numbers that do not identify the place of encounter and are not covered by any of the above item numbers.

**Worker's compensation:** Encounters claimable through Worker's Compensation.

**Other paid (hospital, state etc):** All other direct services covered by other funding services e.g. insurance, employer, state health dept, hospitals, etc.

**Direct encounters with practice nurse item only:** Encounters where a practice nurse item number was the only item number recorded though the patient was said to have been seen by the GP.

**Indirect encounters:** Encounters where there is no face-to-face meeting between the patient and the GP but a service is provided (e.g. prescription, referral).

**Indirect encounters with practice nurse item only:** Encounters where a practice nurse item number was the only item number recorded, and the patient was said *not* to have been seen by the GP.

**Unspecified practice nurse item only:** Encounters where a practice nurse item number was the only item number recorded, and it is unknown whether the patient was/wasn't seen by the GP.

#### **TABLE 1a 2: Summary of data base: services – Ischaemic heart disease – Apr00-Mar01**

This table will only be valid if **all** of your data are from the period April 2005 onwards. If your data are based on years that cross April 2005, this table is not valid. This is because, prior to April 2005 only one item number could be recorded. From April 2005 onwards, up to three Medicare item numbers could be recorded on an encounter form. The denominator for the column titled “per 100 encs” is all encounters (from table 1a). This table is useful when allocating direct costs against management of a selected problem.

#### **TABLE 1b: Summary of data base: patients – Ischaemic heart disease – Apr00-Mar01**

Number of observations (n), rate per 100 problems, and 95% confidence intervals (CI) are provided for each data point.

This table describes the characteristics of the patients whose encounters are included in this report.

**Sex and age** distributions are provided. The age groupings correspond with significant trends in GP service use.

**HCC card:** Encounters with patients who hold an Australian Government health care card (HCC).

**VA card:** Encounters with Veteran's Affairs card holders (not necessarily charged through VA).

**NESB:** Encounters with patients whose primary language spoken at home is not English (non-English speaking background).

**Aboriginal only:** Patients who identify themselves as being Aboriginal and not Torres Strait Islander.

**Torres Strait Islander only:** Patients who identify themselves as being Torres Strait Islander and not Aboriginal.

**Aboriginal & Torres Strait Islander:** Patients who identify themselves as being both an Aboriginal and a Torres Strait Islander.

**Aboriginal and/or TSI:** Patients who are Aboriginal or Torres Strait Islanders, or both.

**New to practice:** Patients who had not been seen previously in this practice.

**Seen previously:** Patients who had been seen previously in this practice.

**State/territory:** The patients' state/territory is provided, based on the postcode reported by the patient.

**RRMA** (Rural, Remote & Metropolitan Areas classification) classifies the patients' locations to one of 7 categories <[www.ruraldoc.com.au](http://www.ruraldoc.com.au)>.

**ASGC** (Australian Standard Geographical Classification) classifies the patients' locations to one of 5 categories <[www.abs.gov.au](http://www.abs.gov.au)>.

#### **TABLE 1c: Summary of data base: Problem management – Apr00-Mar01**

Number of observations (n), rate per 100 problems, and 95% confidence intervals (CI) are provided for each data point.

**General practitioners** is the number of GPs who recorded encounters that are included in this report (i.e. those who managed "Ischaemic heart disease" within the specified data period).

**Problem managed:** A formal statement of the providers' understanding of a health problem presented by the patient, family or community. It can be described in terms of a disease, symptom/complaint, social problem or ill-defined condition managed at the encounter (up to four per encounter).

**New problems:** The first presentation of a problem, including the first presentation of a recurrence of a previously resolved problem but excluding the presentation of a problem first assessed by another provider.

**Old problems:** A previously assessed problem that requires ongoing care. Includes follow-up for a problem or an initial presentation of a problem previously assessed by another provider.

**Work related:** A problem that is viewed as having resulted or been significantly exacerbated from a work-related activity or workplace exposures.

#### **At least 1:**

**Medication**—problems for which at least one medication was recommended.

**Other treatment**—problems for which at least one treatment other than medication was given.

**Referral**—problems that the GP referred to at least one other health professional.

**Imaging order**—problems for which at least one imaging test was ordered.

**Pathology order**—problems for which at least one pathology test was ordered.

**Medications:** include any medications that are prescribed, advised for over-the-counter (OTC) purchase or provided from the GP's own supplies (GP supplied). Up to four medications can be recorded for each problem.

**Other treatments** (up to two per problem) include non-pharmacological treatments and are divided into:-

**Clinical** (e.g. advice, counselling)

**Procedural** (e.g. bandage, physical therapies, excisions).

**Referrals** (up to two per encounter) is any *new* referral or admission of the patient for this problem to:

**Allied health services** (e.g. physiotherapist, social worker, community services).

**Specialist** (e.g. surgeon, psychiatrist).

**Emergency department** of a hospital.

**Hospital** (either private or public).

**Referral NOS** are referrals that are not otherwise specified (i.e. they cannot be grouped in any of the above).

**Pathology:** Includes pathology tests ordered or undertaken in the management of this problem (Up to five per encounter).

**Imaging:** Includes imaging tests ordered or undertaken in the management of this problem (Up to two per encounter).

**Other investigations** include diagnostic procedures ordered or undertaken by the GP at the encounter e.g. “electrical tracings\*”, which includes electrocardiogram and echocardiogram.

#### **TABLE 1d: General practitioners – Table of age by sex – Ischaemic heart disease – Apr00-Mar01**

This table displays the distribution of male and female GPs that have been included in this analysis, by their age group. These data were collected from the GP Profile Questionnaire which is completed by all GPs participating in the BEACH project (see Appendix 2 in BEACH annual report, General practice activity in Australia 2006-07, <<http://www.aihw.gov.au/publications/gep/gpaa06-07/gpaa06-07-x03a.pdf> >).

#### **TABLE 1e: Summary of database: GP characteristics - Ischaemic heart disease – Apr00-Mar01**

This table displays the characteristics of the GPs that have been included in this analysis. These data were also collected from the GP Profile Questionnaire. Definitions of the categories are as follows:

**Years in general practice:** The number of years the GP has been in general practice.

**Sessions:** The number of consulting sessions per week for each GP (1 session = approx. 4 hours e.g. a morning session).

**Size of practice:** The number of GPs in the participating GPs main practice (including the participating GP).

**Practice state:** The state which the GPs main practice is in.

**RRMA of main practice** (Rural, Remote & Metropolitan Area Classification) classifies the location of the practice to one of 7 categories <[www.ruraldoc.com.au](http://www.ruraldoc.com.au)>.

**ASGC of main practice** (Australian Standard Geographical Classification) classifies the location of the practice to one of 5 categories <[www.abs.gov.au](http://www.abs.gov.au)>.

**Country of Graduation:** The GPs reported country of graduation.

**>50% consults NESB:** (non-English speaking background) the GPs assessment of the proportion of their consultations conducted in a language other than English.

**Hold FRACGP** is whether the participating GP is a Fellow of the Royal Australian College of General Practitioners.

**Practice accredited** is whether the practice is accredited.

## SECTION 2: AGE BY SEX

### TABLE 2.1: Age by sex of patient at encounter – Ischaemic heart disease – Apr00-Mar01

This table displays the distribution of male and female patients that have been included in this analysis, by their age group.

### TABLE 2.2: Age by sex of patient at encounter – new Ischaemic heart disease – Apr00-Mar01

This table displays the age-sex distribution (similar to table 2.1) of patients who are having Ischaemic heart disease managed for the first time (i.e. it is a new problem).

## SECTION 3: REASONS FOR ENCOUNTER – ALL

### TABLE 3.1: Number of reasons for encounter by sex of patient – Ischaemic heart disease – Apr00-Mar01

**Reasons for encounter** (RFE) reflect the patients' expressed demand for care as perceived and recorded by the GP. Up to three RFEs can be recorded at each encounter. A RFE is not directly linked to a problem managed. This table gives the number of RFEs recorded for encounters where Ischaemic heart disease was one of the problems managed. RFEs have been grouped using ICPC-2 PLUS chapter headings which correspond approximately to the main body systems with additional chapters for social and psychological problems. Problems which cross multiple body systems are grouped together as "General & unspecified".

### TABLE 3.2: Reasons for encounter (RFEs) – ICPC chapter – Ischaemic heart disease – Apr00-Mar01

Each RFE is coded using ICPC-2 PLUS and classified to ICPC-2. There are seventeen chapters in ICPC-2 which are mainly based on body systems. Details on these chapters can be found at <[www.fmrc.org.au/icpc2/tech.htm](http://www.fmrc.org.au/icpc2/tech.htm)>. This table shows the distribution of RFEs by ICPC-2 chapter at the encounters where Ischaemic heart disease was managed.

### TABLE 3.3: Top 30 reasons for encounters (RFEs) – Ischaemic heart disease – Apr00-Mar01

This table shows the 30 most common RFEs recorded at the encounters where Ischaemic heart disease was a problem. The RFE label is the individual ICPC rubric label unless denoted by \*, which indicates a grouping of multiple ICPC rubrics under the same RFE (concept) label. Number of observations (n), % of total RFEs, rate per 100 encounters, 95% confidence interval (CI) are provided for each data point.

## **SECTION 4: REASONS FOR ENCOUNTER – NEW**

### **TABLE 4.1: Number of reasons for encounter by sex of patient – New Ischaemic heart disease – Apr00-Mar01**

This table gives the number of RFEs recorded for encounters where Ischaemic heart disease was one of the problems managed and was classified as a ‘new’ problem, that is, it had not previously been dealt with by a medical practitioner.

### **TABLE 4.2: Reasons for encounter (RFEs) – ICPC chapter – New Ischaemic heart disease – Apr00-Mar01**

This table shows the RFEs by ICPC chapter (similar to table 3.2) for encounters where Ischaemic heart disease was managed and was classified as a “new problem” (see definition table 1c).

### **TABLE 4.3: Top 30 reasons for encounters (RFEs) – New Ischaemic heart disease – Apr00-Mar01**

This table shows the most common RFEs (similar to table 3.3) for encounters where Ischaemic heart disease was managed and was classified as a “new problem” (see definition table 1c).

## **SECTION 5: PROBLEMS MANAGED - ALL**

### **TABLE 5.1: Number of problems by sex of patient – Ischaemic heart disease – Apr00-Mar01**

Up to four problems managed can be recorded at each encounter. This table gives the number of problems managed by GPs at encounters with males and females where at least one of the problems managed was Ischaemic heart disease.

### **TABLE 5.2: Other problems managed – ICPC chapter – Ischaemic heart disease – Apr00-Mar01**

This table includes all diagnoses, diseases, ill-defined conditions and complaints, other than Ischaemic heart disease, managed by the GP (i.e. co-morbidity managed) at the selected encounters. The problems are listed here by ICPC chapter. Number of observations (n), % of total problems managed, rate per 100 encounters, 95% confidence interval (CI) are provided for each data point.

### **TABLE 5.3: Top 30 other problems managed – Ischaemic heart disease – Apr00-Mar01**

This table lists the 30 most common diagnoses, diseases, ill-defined conditions and complaints, other than Ischaemic heart disease (i.e. co-morbidity managed), managed by the GP at the selected encounters. The problems are listed here by the individual ICPC rubric label unless denoted by \*, which indicates a grouping of multiple ICPC rubrics under the same problem (concept) label, e.g. “Hypertension\*” groups the ICPC rubrics of Hypertension Uncomplicated (K86) and Hypertension Complicated (K87). (See Appendix 5 of the BEACH annual report, General practice activity in Australia 2006-07, < <http://www.aihw.gov.au/publications/gep/gpaa06-07/gpaa06-07-xx03b.pdf> >). Number of observations (n), % of total problems managed, rate per 100 encounters, 95% confidence interval (CI) are provided for each data point.

## **SECTION 6: PROBLEMS MANAGED – NEW**

### **TABLE 6.1: Number of problems by sex of patient – New Ischaemic heart disease – Apr00-Mar01**

This table shows the number of problems managed by patient sex (similar to table 5.1) for encounters where Ischaemic heart disease was managed and was classified as a “new problem” (see definition table 1c).

### **TABLE 6.2: Other problems managed – ICPC chapter – New Ischaemic heart disease – Apr00-Mar01**

This table shows the co-morbidities managed by the GP (similar to table 5.2) for encounters where Ischaemic heart disease was managed and was classified as a “new problem” (see definition table 1c).

### **TABLE 6.3: Top 30 other problems managed – New Ischaemic heart disease – Apr00-Mar01**

This table shows the 30 most common co-morbidities managed by the GP (similar to table 5.3) for encounters where Ischaemic heart disease was managed and was classified as a “new problem” (see definition table 1c).

## **SECTION 7: MEDICATIONS – ALL**

### **TABLE 7.1: Frequency of medication provision – Ischaemic heart disease – Apr00-Mar01**

This table displays the distribution of medications, by the form of provision (prescribed, advised for OTC purchase, or GP supplied). Up to four medications can be recorded for each problem. Number of observations (n), rate per 100 problems managed, 95% confidence interval (CI), % of all medications and 95% confidence interval (CI) are provided for each data point.

### **TABLE 7.2.1: Top 30 medications prescribed (grouped by 4 digit ATC code) – Ischaemic heart disease – Apr00-Mar01**

This table displays the prescribed medications for Ischaemic heart disease grouped according to the Anatomical Therapeutic Chemical (ATC) classification index<sup>3</sup> at the 4 digit level (note: over-the-counter and GP supplied medications have not been included). Number of observations (n), rate per 100 Ischaemic heart disease problems managed, 95% confidence interval (CI), % of prescribed medications for selected problems, and 95% confidence interval (CI) are provided for each data point.

---

<sup>3</sup> Anatomical Therapeutic Chemical (ATC) classification index, WHO Collaborating Centre for Drug Statistics Methodology.

**TABLE 7.2.2: Top 30 medications prescribed (grouped by 5 digit ATC code) – Ischaemic heart disease – Apr00-Mar01**

This table displays the most frequently prescribed medications for Ischaemic heart disease grouped according to the Anatomical Therapeutic Chemical (ATC) classification index<sup>1</sup> at the 5 digit level (note: Over-the-counter and GP supplied medications have not been included). Number of observations (n), rate per 100 Ischaemic heart disease problems managed, 95% confidence interval (CI), % of prescribed medications for selected problems, and 95% confidence interval (CI) are provided for each data point.

**TABLE 7.2.3.1: Top 60 brands of prescribed medications in alphabetic order – Ischaemic heart disease – Apr00-Mar01**

This table lists the medications that were prescribed for Ischaemic heart disease at brand level (i.e. Over-the-counter and GP supplied medications have not been included). The medications are listed here in alphabetic order. Number of observations (n), % of prescribed medications for Ischaemic heart disease, rate per 100 problems managed, 95% confidence interval (CI), % of all prescribed medications and 95% confidence interval (CI) are provided for each data point. Please note that some of the medications are listed as their generic names as that is how the GP has labelled it.

**TABLE 7.2.3.2: Top 60 brands of prescribed medications in frequency descending order – Ischaemic heart disease – Apr00-Mar01**

This table lists the medications that were prescribed for Ischaemic heart disease at brand level (note: OTC and GP supplied medications have not been included). The medications are listed here in descending order of frequency. Please note that some of the medications are listed as their generic names as that is how the GP has labelled it.

**TABLE 7.2.4: Prescribed medications (generic and products within each generic) – Ischaemic heart disease – Apr00-Mar01**

This table lists only prescribed medications. The data are presented in three levels –

*Total prescribed Ischaemic heart disease medications*

*Generic medications recorded in the management of Ischaemic heart disease*

*Individual product recorded in the management of Ischaemic heart disease*

At each level, the number of observations (n) and a percentage of total prescribed medications. For the generic and individual level, the medications are expressed as a rate per 100 problems, and a percentage of medications given for Ischaemic heart disease. Also, at the individual product level, the percentage of medications accounted for by each product within the relevant generic group, is shown.

**TABLE 7.3: Medications (generic and products within each generic) – Ischaemic heart disease – Apr00-Mar01**

This table lists all medications (prescribed, OTC and GP supplied). The data are presented in three levels –

*Total* Ischaemic heart disease medications

*Generic* medications recorded in the management of Ischaemic heart disease

*Individual product* recorded in the management of Ischaemic heart disease

At each level, the number of observations (n) and a percentage of all medications given. For the generic and individual level the medications are expressed as a rate per 100 Ischaemic heart disease problems and as a percentage of medications given for Ischaemic heart disease are shown. Also, at the individual product level, the percentage of medications accounted for by each product within the relevant generic group, is shown.

**TABLE 7.4: Prescribed daily dose (generic level) – Ischaemic heart disease – Apr00-Mar01**

Medications that are prescribed by the GP, for which complete regimen and dosage (in micrograms, milligrams or grams) information are recorded, are included in the calculation of the prescribed daily dose (PDD). The number of medications (n), the mean, median, minimum and maximum prescribed daily doses for each generic medication are shown. Please note: there will be fewer medications included in this table than in table 7.1 because complete dosage and regimen information are required for calculation of PDD.

**SECTION 8: MEDICATIONS – NEW****TABLE 8.1: Frequency of medication provision – New Ischaemic heart disease – Apr00-Mar01**

This table shows the distribution of medications, by the form of provision (similar to table 7.1) for encounters where Ischaemic heart disease was managed and was classified as a “new problem” (see definition table 1c).

**TABLE 8.2.1: Top 30 medications prescribed (grouped by 4 digit ATC code) – New Ischaemic heart disease – Apr00-Mar01**

This table displays the prescribed medications for Ischaemic heart disease (similar to 7.2.1) for encounters where Ischaemic heart disease was managed and was classified as a “new problem” (see definition table 1c).

**TABLE 8.2.2: Top 30 medications prescribed (grouped by 5 digit ATC code) – New Ischaemic heart disease – Apr00-Mar01**

This table displays the most frequently prescribed medications for Ischaemic heart disease (similar to table 7.2.2) for encounters where Ischaemic heart disease was managed and was classified as a “new problem” (see definition table 1c).

**TABLE 8.2.3.1: Top 60 brands of prescribed medications in alphabetic order – New Ischaemic heart disease – Apr00-Mar01**

This table lists the medications that were prescribed for Ischaemic heart disease in alphabetic order (similar to table 7.2.3.1) for encounters where Ischaemic heart disease was managed and was classified as a “new problem” (see definition table 1c).

**TABLE 8.2.3.2: Top 60 brands of prescribed medications in frequency descending order – New Ischaemic heart disease – Apr00-Mar01**

This table lists the medications that were prescribed for Ischaemic heart disease in frequency descending order (similar to table 7.2.3.2) for encounters where Ischaemic heart disease was managed and was classified as a “new problem” (see definition table 1c).

**TABLE 8.2.4: Prescribed medications (generic and products within each generic) – New Ischaemic heart disease – Apr00-Mar01**

This table lists only prescribed medications (similar to table 8.2.4) for encounters where Ischaemic heart disease was managed and was classified as a “new problem” (see definition table 1c).

**TABLE 8.3: Medications (generic and products within each generic) – New Ischaemic heart disease – Apr00-Mar01**

This table lists all medications (similar to table 7.3) for encounters where Ischaemic heart disease was managed and was classified as a “new problem” (see definition table 1c).

**TABLE 8.4: Prescribed daily dose (generic level) – New Ischaemic heart disease – Apr00-Mar01**

This table shows the prescribed daily doses for each generic medication (similar to table 7.4) for encounters where Ischaemic heart disease was managed and was classified as a “new problem” (see definition table 1c).

**SECTION 9: CLINICAL TREATMENTS & PROCEDURES**

If your report is based on data from April 2005 onwards, clinical and procedural treatments are a combination of those done by the GP and the practice nurse.

**TABLE 9.1.1: Top 10 Clinical treatments – Ischaemic heart disease – Apr00-Mar01**

Up to two non-pharmacological treatments can be recorded for each problem. These treatments are coded using ICPC-2 PLUS. This table lists the 10 most common clinical treatments performed by a GP for all cases of Ischaemic heart disease. Clinical treatments include general and specific advice, counselling or education, family planning, and administrative processes. An asterisk (\*) denotes multiple ICPC-2 or ICPC-2 PLUS codes.

**TABLE 9.1.2: Top 10 Procedural treatments – Ischaemic heart disease – Apr00-Mar01**

This table lists the 10 most common procedural treatments recorded by a GP for all cases of Ischaemic heart disease. Procedural treatments include therapeutic actions and diagnostic procedures undertaken at the encounter. However, they do not include injections for immunisations or vaccinations given by either the GP or the practice nurse, as these have already been counted as medications. An asterisk (\*) denotes multiple ICPC-2 or ICPC-2 PLUS codes.

**TABLE 9.2.1: Top 10 Clinical treatments – New Ischaemic heart disease – Apr00-Mar01**

This table lists the 10 most common clinical treatments performed by a GP (similar to table 9.1.1) for encounters where Ischaemic heart disease was managed and was classified as a “new problem” (see definition table 1c).

**TABLE 9.2.2: Top 10 Procedural treatments – New Ischaemic heart disease – Apr00-Mar01**

This table lists the 10 most common procedural treatments recorded by a GP (similar to table 9.1.2) for encounters where Ischaemic heart disease was managed and was classified as a “new problem” (see definition table 1c).

**SECTION 10: REFERRALS****TABLE 10.1.1: Top 10 Referrals to medical specialists – Ischaemic heart disease – Apr00-Mar01**

Up to two referrals or admissions can be recorded for each encounter. Only *new* referrals are recorded. Continuation referrals are not included. This table displays referrals to medical specialists for Ischaemic heart disease. For information on referrals to hospital, emergency department, and other medical services and referrals, please refer to table 1c.

**TABLE 10.1.2: Top 10 Referrals to allied health professionals – Ischaemic heart disease – Apr00-Mar01**

Up to two referrals or admissions can be recorded for each encounter. Only *new* referrals are recorded. Continuation referrals are not included. This table displays referrals to allied health professionals for Ischaemic heart disease. For information on referrals to hospital, emergency department, and other medical services and referrals, please refer to table 1c.

**TABLE 10.2.1: Top 10 Referrals to medical specialists – New Ischaemic heart disease – Apr00-Mar01**

This table displays referrals to medical specialists for Ischaemic heart disease (similar to table 10.1.1) for encounters where Ischaemic heart disease was managed and was classified as a “new problem” (see definition table 1c).

**TABLE 10.2.2: Top 10 Referrals to allied health professionals – New Ischaemic heart disease – Apr00-Mar01**

This table displays referrals to allied health professionals for Ischaemic heart disease (similar to table 10.1.2) for encounters where Ischaemic heart disease was managed and was classified as a “new problem” (see definition table 1c).

**SECTION 11: PATHOLOGY TESTS ORDERED****TABLE 11.1.1: Pathology orders across MBS pathology groups – Ischaemic heart disease – Apr00-Mar01**

This table presents all pathology tests ordered or undertaken in the management of Ischaemic heart disease. Tests are displayed by Medicare Benefits Schedule (MBS) group. Up to five pathology tests may be recorded at each encounter. A pathology test order may be for a single test (e.g. Pap smear, HbA1c) or for a battery of tests (e.g. lipids, full blood count). Where a battery of tests was ordered, the battery name was recorded rather than each individual test.

**TABLE 11.1.2: Pathology orders at individual test level – Ischaemic heart disease – Apr00-Mar01**

This table presents all individual pathology tests ordered or undertaken in the management of this problem. Tests are displayed at the individual test level. Up to five pathology tests may be recorded at each encounter. A pathology test order may be for a single test (e.g. Pap smear, HbA1c) or for a battery of tests (e.g. lipids, full blood count). Where a battery of tests was ordered, the battery name was recorded rather than each individual test.

**TABLE 11.2.1: Pathology orders across MBS pathology groups – New Ischaemic heart disease – Apr00-Mar01**

This table presents all pathology tests ordered or undertaken in the management of Ischaemic heart disease (similar to table 11.1.1) for encounters where Ischaemic heart disease was managed and was classified as a “new problem” (see definition table 1c).

**TABLE 11.2.2: Pathology orders at individual test level – New Ischaemic heart disease – Apr00-Mar01**

This table presents all individual pathology tests ordered or undertaken in the management of this problem (similar to table 11.2.2) for encounters where Ischaemic heart disease was managed and was classified as a “new problem” (see definition table 1c).

**SECTION 12: IMAGING TESTS ORDERED****TABLE 12.1.1: Imaging tests ordered by MBS group – Ischaemic heart disease – Apr00-Mar01**

This table presents all imaging tests ordered or undertaken for the management of Ischaemic heart disease. Tests are displayed by Medicare Benefits Schedule (MBS) group. Up to three imaging tests may be recorded at each encounter. A single imaging test may be ordered for more than one problem, and conversely more than one test may be ordered for the same problem.

**TABLE 12.1.2: Imaging tests ordered at ICPC-2 PLUS level – Ischaemic heart disease – Apr00-Mar01**

This table presents all imaging tests ordered or undertaken in the management of this problem. Tests are displayed at ICPC-2 PLUS level. Up to three imaging tests may be recorded at each encounter.

**TABLE 12.2.1: Imaging tests ordered by MBS group – New Ischaemic heart disease – Apr00-Mar01**

This table presents all imaging tests ordered or undertaken for the management of Ischaemic heart disease at an MBS group level (similar to table 12.1.1) for encounters where Ischaemic heart disease was managed and was classified as a “new problem” (see definition table 1c).

**TABLE 12.2.2: Imaging tests ordered at ICPC-2 PLUS level – New Ischaemic heart disease – Apr00-Mar01**

This table presents all imaging tests ordered or undertaken for the management of Ischaemic heart disease at an ICPC-2 PLUS level (similar to table 12.1.2) for encounters where Ischaemic heart disease was managed and was classified as a “new problem” (see definition table 1c).

Table A: Summary of encounters with at least one IHD in patients aged 45+ problem (listed at ICPC-2 rubric level) - Apr00-Mar01  
with national annual estimated encounters

Encounters with at least one:	ICPC-2 rubric	n	% of all encs	Lower 95% CI	Upper 95% CI	National annual estimated encs	Lower 95% CI	Upper 95% CI
IHD in patients aged 45+ problem		1289	2.56	2.37	2.76	1298000	1199000	1397000
Ischaemic heart disease without angina	K76	920	1.83	1.65	2.01	926000	836000	1017000
Ischaemic heart disease with angina	K74	375	0.75	0.65	0.84	378000	330000	425000

Refer to explanatory notes for the base used in calculation of national annual estimated encounters,  
and the number of estimated encounters is rounded at the nearest 1000.

The denominator used to calculate column labelled '% of all encs' is 50275 .

\* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 5, <[www.aihw.gov.au/publications/index.cfm/subject/19](http://www.aihw.gov.au/publications/index.cfm/subject/19)>).

BEACH Survey Report - Analysis date: 21NOV08

Table B: Summary of IHD in patients aged 45+ problems (grouped by ICPC-2 rubric) - Apr00-Mar01  
with national annual estimated problems

IHD in patients aged 45+ problems	ICPC-2 rubric	n	% of selected problems	Per 100 all encs	Lower 95% CI	Upper 95% CI	% of all problems	National annual estimated probs	Lower 95% CI	Upper 95% CI
Ischaemic heart disease without angina	K76	921	71.06	1.83	1.65	2.01	1.11	927000	837000	1018000
Ischaemic heart disease with angina	K74	375	28.94	0.75	0.65	0.84	0.45	378000	330000	425000
Total IHD in patients aged 45+		1296	100.00	2.58	2.38	2.77	1.56	1305000	1205000	1405000

Refer to explanatory notes for the base used in calculation of national annual estimated encounters, and the number of estimated encounters is rounded at the nearest 1000.

The denominators used to calculate column labelled 'per 100 all encs' and '% of all problems' are 50275 and 82894 respectively.

\* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 5, <[www.aihw.gov.au/publications/index.cfm/subject/19](http://www.aihw.gov.au/publications/index.cfm/subject/19)>).

BEACH Survey Report - Analysis date: 21NOV08

Table C: Summary of IHD in patients aged 45+ problems (listed at ICPC-2 plus code level)- Apr00-Mar01

IHD in patients aged 45+ problems	ICPC-2 plus code	n	% of selected problems	Per 100 all encls	% of all problems	National annual estimated probs
Disease;ischaemic heart	K76014	734	56.64	1.46	0.89	739000
Angina pectoris	K74001	337	26.00	0.67	0.41	339000
Coronary artery disease	K76003	99	7.64	0.20	0.12	100000
Coronary heart disease	K76013	51	3.94	0.10	0.06	51000
Ischaemia;myocardial;chronic	K76008	20	1.54	0.04	0.02	20000
IHD with angina	K74007	17	1.31	0.03	0.02	17000
Angina;unstable	K74004	15	1.16	0.03	0.02	15000
Infarction;myocardial;old	K76007	11	0.85	0.02	0.01	11000
Spasm;artery;coronary	K74003	3	0.23	0.01	0.00	3000
Disease;ischaem heart;chronic	K76015	3	0.23	0.01	0.00	3000
Insufficiency;coronary	K74006	2	0.15	0.00	0.00	2000
IHD without angina	K76018	2	0.15	0.00	0.00	2000
Pain;angina	K74002	1	0.08	0.00	0.00	1000
Disease;atherosclerotic;heart	K76005	1	0.08	0.00	0.00	1000
		.	.	.	.	.
Total IHD in patients aged 45+		1296	100.00	2.58	1.56	1305000

Refer to explanatory notes for the base used in calculation of national annual estimated encounters, and the number of estimated encounters is rounded at the nearest 1000.

BEACH Survey Report - Analysis date: 21NOV08

Table 1a: Summary of data base: services - IHD in patients aged 45+ Apr00-Mar01

Data	n	%	Lower 95% CI	Upper 95% CI
General practitioners	579	.	.	.
Encounters	1289	.	.	.
Direct encounters	1076	97.20	96.2	98.2
No charge	3	0.27	0.0	0.8
MBS items by GPs	1065	96.21	95.0	97.4
- Short surgery consults	7	0.63	0.2	1.1
- Standard surgery consults	766	69.20	65.9	72.5
- Long surgery consults	188	16.98	14.6	19.4
- Prolonged surgery consults	13	1.17	0.5	1.9
- Home visits	45	4.07	2.6	5.5
- Hospital	3	0.27	0.0	0.7
- Residential aged care facility	23	2.08	1.0	3.2
- Health assessments	2	0.18	0.0	0.4
- Other items	18	1.63	0.3	2.9
Worker's compensation	2	0.18	0.0	0.4
Other paid (hospital, state etc)	6	0.54	0.1	1.0
Indirect encounters	31	2.80	1.8	3.8
Missing	182	.	.	.

The indirect encounters with item numbers (eg: chronic disease management item or case conference item) are counted under both MBS items by GPs and indirect encounters. Therefore, the number of no charge, medicare paid, worker's compensation and other paid do not always add up to the number of direct encounters.

During the BEACH study period April 1998 to March 2005, GPs were instructed to record the lowest Medicare item number (e.g.: an A1 item number) if multiple item numbers applied.

From April 2005 onwards, multiple Medicare item numbers (up to 3) could be recorded on an encounter form. The lowest item from the encounter was selected and analysed in this table.

This provides comparable results to those reported before April 2005.

BEACH Survey Report - Analysis date: 21NOV08

Table 1b: Summary of data base: patients - IHD in patients aged 45+ - Apr00-Mar01

Data	n	%	Lower 95% CI	Upper 95% CI
Patients	1289	.	.	.
- Males	751	58.86	55.9	61.8
- Females	525	41.14	38.2	44.1
- Missing sex	13	.	.	.
- 45-64 years	316	24.52	21.7	27.3
- 65-74 years	401	31.11	28.6	33.6
- 75+ years	572	44.38	41.2	47.6
- HCC card	764	59.27	56.1	62.4
- VA card	176	13.65	11.5	15.8
- NESB	73	5.66	4.0	7.4
- Aboriginal only	6	0.47	0.1	0.8
- Aboriginal and/or TSI	6	0.47	0.1	0.8
- New to practice	41	3.18	2.1	4.3
- Seen previously	1248	96.82	95.7	97.9
- ACT	24	1.93	0.6	3.2
- NSW	511	41.18	35.9	46.4
- VIC	294	23.69	19.4	28.0
- QLD	182	14.67	11.1	18.2
- SA	81	6.53	4.2	8.8
- WA	89	7.17	4.7	9.7
- TAS	48	3.87	1.7	6.0
- NT	12	0.97	0.0	1.9
- Missing state	48	.	.	.
RRMA- Capital	754	61.05	56.0	66.1
- Other Metro	96	7.77	4.9	10.7
- Large Rural	80	6.48	4.3	8.7
- Small Rural	95	7.69	5.1	10.3
- Other Rural	191	15.47	11.8	19.1
- Remote Central	11	0.89	0.0	1.8
- Other remote, Offshore	8	0.65	0.1	1.2
- Missing rrma	54	.	.	.
ASGC- Major Cities	808	65.37	60.5	70.2

BEACH Survey Report - Analysis date: 21NOV08

Table 1b: Summary of data base: patients - IHD in patients aged 45+ - Apr00-Mar01

Data	n	%	Lower 95% CI	Upper 95% CI
- Inner Regional	293	23.71	19.5	27.9
- Outer Regional	113	9.14	6.2	12.1
- Remote	19	1.54	0.4	2.6
- Very Remote	3	0.24	0.0	0.6
- Missing ASGC	53	.	.	.

BEACH Survey Report - Analysis date: 21NOV08

Table 1c: Summary of data base: Problem management IHD in patients aged 45+ Apr00-Mar01

Data	n	Rate per 100 probs	Lower 95% CI	Upper 95% CI
General practitioners	579	.	.	.
Encounters	1289	.	.	.
Problems managed	1296	100.00	100.00	100.00
- New problems	117	9.03	7.36	10.70
- Old problems	1179	90.97	89.30	92.64
- Work related	4	0.31	0.01	0.61
At least 1 Medication	892	68.83	65.70	71.96
At least 1 Other treatment	218	16.82	14.38	19.26
At least 1 Referral	135	10.42	8.70	12.13
At least 1 Imaging	34	2.62	1.73	3.51
At least 1 Pathology	191	14.74	12.45	17.02
Medications	1533	118.29	110.03	126.54
- Prescribed	1439	111.03	103.11	118.96
- Advised OTC	13	1.00	0.47	1.54
- GP supplied	81	6.25	2.80	9.70
Other treatments	245	18.90	15.99	21.82
- Clinical	190	14.66	11.89	17.43
- Procedural	55	4.24	3.07	5.42
Referrals	135	10.42	8.70	12.13
- Hospital	13	1.00	0.46	1.55
- Specialist	108	8.33	6.83	9.83
- Allied health services	8	0.62	0.19	1.04
- Emergency department	3	0.23	0.00	0.49
- Other referral	3	0.23	0.00	0.49
Pathology	423	32.64	26.65	38.62
Imaging	35	2.70	1.77	3.63

Table 1d: General practitioners - IHD in patients aged 45+ Apr00-Mar01

The FREQ Procedure

Table of gpage by gpsex

gpage(GP age)	gpsex(GP sex)		
	Male	Female	Total
Frequency			
Percent			
Row Pct			
Col Pct			
< 35 years	11	15	26
	1.91	2.61	4.52
	42.31	57.69	
	2.52	10.79	
35-44 years	90	54	144
	15.65	9.39	25.04
	62.50	37.50	
	20.64	38.85	
45-54 years	160	43	203
	27.83	7.48	35.30
	78.82	21.18	
	36.70	30.94	
55+ years	175	27	202
	30.43	4.70	35.13
	86.63	13.37	
	40.14	19.42	
Total	436	139	575
	75.83	24.17	100.00

Frequency Missing = 4

BEACH Survey Report - Analysis date: 21NOV08

Table 1e: Summary of data base: GP characteristics - IHD in patients aged 45+ Apr00-Mar01

Data	n	%
Years in general practice	.	.
<2 years	1	0.2
2-5 years	27	4.7
6-10 years	60	10.4
11-19 years	168	29.1
20+ years	321	55.6
Missing	2	.
	.	.
Sessions	.	.
< 5 per week	72	12.6
6-10 per week	405	70.9
11+ per week	94	16.5
Missing	8	.
	.	.
Size of practice	.	.
Solo GP	115	20.4
2-4 GPs	221	39.3
5+ GPs	227	40.3
Missing	16	.
	.	.
Practice state	.	.
ACT	10	1.7
NSW	214	37.0
VIC	141	24.4
QLD	89	15.4
SA	48	8.3
WA	48	8.3
TAS	23	4.0
NT	6	1.0
	.	.
RRMA of main practice	.	.
Capital	361	62.3
Oth Met	43	7.4
Lge Rur	41	7.1
Sm Rur	43	7.4
Oth Rur	80	13.8
Rem Cen	6	1.0
Oth Rem, Offsh	5	0.9
	.	.
ASGC of main practice	.	.

BEACH Survey Report - Analysis date: 21NOV08

Table 1e: Summary of data base: GP characteristics - IHD in patients aged 45+ Apr00-Mar01

Data	n	%
Major Cities	384	66.7
Inner Regional	130	22.6
Outer Regional	52	9.0
Remote	8	1.4
Very Remote	2	0.3
Missing	3	.
	.	.
Country of graduation	.	.
Australia	428	74.7
New Zealand	7	1.2
Asia	24	4.2
UK/Ireland	52	9.1
Europe	4	0.7
Africa	3	0.5
Other	55	9.6
Missing	6	.
	.	.
> 50% consultations NESB	.	.
Yes	76	13.2
No	501	86.8
Missing	2	.
	.	.
Hold FRACGP	.	.
Yes	175	30.3
No	402	69.7
Missing	2	.
	.	.
Practice accredited	.	.
Yes	206	36.0
No	367	64.0
Missing	6	.
	.	.

Table 2.1 Age by gender of patient at encounter - IHD in patients aged 45+ Apr00-Mar01

The FREQ Procedure

Table of SEX by AGEGP

SEX(Sex of patient)		AGEGP(Age-group)			
Frequency	Percent	45-64	65-74	75+	Total
Row Pct	Col Pct				
Male	219	246	286	751	
	17.16	19.28	22.41	58.86	
	29.16	32.76	38.08		
	70.19	61.96	50.44		
Female	93	151	281	525	
	7.29	11.83	22.02	41.14	
	17.71	28.76	53.52		
	29.81	38.04	49.56		
Total	312	397	567	1276	
	24.45	31.11	44.44	100.00	

Frequency Missing = 13

Table 2.2 Age by gender of patient at encounter - New IHD in patients aged 45+ Apr00-Mar01

The FREQ Procedure

Table of SEX by AGEGP

SEX(Sex of patient)		AGEGP(Age-group)			
Frequency	Percent	45-64	65-74	75+	Total
Row Pct	Col Pct				
Male	32	15	12	59	
	27.83	13.04	10.43	51.30	
	54.24	25.42	20.34		
	64.00	45.45	37.50		
Female	18	18	20	56	
	15.65	15.65	17.39	48.70	
	32.14	32.14	35.71		
	36.00	54.55	62.50		
Total	50	33	32	115	
	43.48	28.70	27.83	100.00	

Frequency Missing = 2

Table 3.1 Number of reasons for encounter by sex of patient - IHD in patients aged 45+ Apr00-Mar01

The FREQ Procedure

Table of NUMRFE by SEX

NUMRFE(Number of reasons for encounter)  
SEX(Sex of patient)

Frequency Percent Row Pct Col Pct	SEX(Sex of patient)		Total
	Male	Female	
1	313	194	507
	24.53	15.20	39.73
	61.74	38.26	
	41.68	36.95	
2	253	191	444
	19.83	14.97	34.80
	56.98	43.02	
	33.69	36.38	
3	185	140	325
	14.50	10.97	25.47
	56.92	43.08	
	24.63	26.67	
Total	751	525	1276
	58.86	41.14	100.00

Frequency Missing = 13

BEACH Survey Report - Analysis date: 21NOV08

Table 3.2: Reasons for encounters (RFEs)- ICPC chapter - IHD in patients aged 45+ Apr00-Mar01

RFE chapter	n	% of total RFEs	Per 100 encs	Lower 95% CI	Upper 95% CI
General & unspecified	791	32.97	61.37	56.9	65.8
Circulatory	708	29.51	54.93	50.4	59.5
Respiratory	159	6.63	12.34	10.1	14.5
Musculoskeletal	150	6.25	11.64	9.7	13.6
Endocrine & metabolic	149	6.21	11.56	9.6	13.5
Skin	100	4.17	7.76	6.1	9.4
Digestive	81	3.38	6.28	4.8	7.8
Psychological	72	3.00	5.59	4.1	7.0
Neurological	49	2.04	3.80	2.7	4.9
Blood	32	1.33	2.48	1.5	3.4
Ear	27	1.13	2.09	1.3	2.9
Urology	23	0.96	1.78	1.1	2.5
Eye	21	0.88	1.63	0.9	2.3
Female genital system	18	0.75	1.40	0.7	2.1
Male genital system	13	0.54	1.01	0.4	1.6
Social	6	0.25	0.47	0.1	0.8
.	.	.	.	.	.
Subtotal	2399	100.00	.	.	.
.	.	.	.	.	.
Total RFEs	2399	100.00	186.11	180.5	191.7

BEACH Survey Report - Analysis date: 21NOV08

Table 3.3: Top 30 reasons for encounters (RFEs) - IHD in patients aged 45+ Apr00-Mar01

RFE label	n	% of total RFEs	Per 100 encs	Lower 95% CI	Upper 95% CI
Prescription all*	338	14.09	26.22	22.7	29.7
Ischaemic Heart Disease*	231	9.63	17.92	15.1	20.8
Cardiac check-up*	197	8.21	15.28	12.0	18.5
Pain, chest NOS	175	7.29	13.58	11.2	16.0
General check-up*	125	5.21	9.70	7.7	11.7
Test results*	69	2.88	5.35	3.9	6.8
Follow-up encounter unspecified cardiovascular	54	2.25	4.19	3.0	5.4
Shortness of breath/dyspnoea	46	1.92	3.57	2.5	4.6
Hypertension*	43	1.79	3.34	2.2	4.5
Diabetes*	39	1.63	3.03	2.0	4.0
Preventive imm/vacc/meds-all*	36	1.50	2.79	1.9	3.7
Weakness/tiredness general	31	1.29	2.40	1.5	3.3
Blood test NOS	27	1.13	2.09	1.2	3.0
Administrative procedure NOS	25	1.04	1.94	1.1	2.7
Follow-up encounter unspecified NOS	25	1.04	1.94	1.2	2.7
Vertigo/dizziness	24	1.00	1.86	1.1	2.6
Back complaint*	23	0.96	1.78	1.1	2.5
Endocrinology check-up*	21	0.88	1.63	0.9	2.4
Depression*	21	0.88	1.63	0.9	2.4
Cough	21	0.88	1.63	0.9	2.3
Blood test endocrine/metabolic	21	0.88	1.63	1.0	2.3
Lipid disorders*	20	0.83	1.55	0.9	2.2
Shoulder symptom/complaint	19	0.79	1.47	0.8	2.1
Rash*	17	0.71	1.32	0.6	2.0
Heart failure	17	0.71	1.32	0.6	2.0
Refer physician/specialist/clinic/hosp cardiovasc	16	0.67	1.24	0.6	1.8
Observation/health educat/advice/diet NOS	15	0.63	1.16	0.5	1.8
Skin symptom/complaint, other	15	0.63	1.16	0.6	1.8
Anxiety*	14	0.58	1.09	0.5	1.6
Arthritis*	13	0.54	1.01	0.4	1.6
.	.	.	.	.	.
Subtotal	1738	72.45	.	.	.
.	.	.	.	.	.
Other RFEs	661	27.55	.	.	.
.	.	.	.	.	.
Total RFEs	2399	100.00	186.11	180.5	191.7

Table 4.1: Number of reasons for encounter by sex of patient - New IHD in patients aged 45+ Apr00-Mar01

The FREQ Procedure

Table of NUMRFE by SEX

NUMRFE(Number of reasons for encounter)  
SEX(Sex of patient)

Frequency Percent Row Pct Col Pct	SEX(Sex of patient)		Total
	Male	Female	
1	26	23	49
	22.61	20.00	42.61
	53.06	46.94	
	44.07	41.07	
2	17	21	38
	14.78	18.26	33.04
	44.74	55.26	
	28.81	37.50	
3	16	12	28
	13.91	10.43	24.35
	57.14	42.86	
	27.12	21.43	
Total	59	56	115
	51.30	48.70	100.00

Frequency Missing = 2

BEACH Survey Report - Analysis date: 21NOV08

Table 4.2: Reasons for encounters (RFEs)- ICPC chapter - New IHD in patients aged 45+ Apr00-Mar01

RFE chapter	n	% of total RFEs	Per 100 encs	Lower 95% CI	Upper 95% CI
General & unspecified	92	43.19	78.63	68.1	89.2
Circulatory	41	19.25	35.04	24.2	45.9
Musculoskeletal	19	8.92	16.24	7.7	24.7
Respiratory	17	7.98	14.53	7.6	21.4
Neurological	10	4.69	8.55	2.0	15.1
Psychological	8	3.76	6.84	1.1	12.6
Endocrine & metabolic	8	3.76	6.84	1.7	12.0
Digestive	6	2.82	5.13	0.5	9.8
Ear	4	1.88	3.42	0.1	6.8
Blood	3	1.41	2.56	0.0	5.5
Skin	2	0.94	1.71	.	.
Female genital system	2	0.94	1.71	.	.
Social	1	0.47	0.85	.	.
.	.	.	.	.	.
Subtotal	213	100.00	.	.	.
.	.	.	.	.	.
Total RFEs	213	100.00	182.05	167.1	197.0

BEACH Survey Report - Analysis date: 21NOV08

Table 4.3: Top 30 reasons for encounters (RFEs) - New IHD in patients aged 45+ Apr00-Mar01

RFE label	n	% of total RFEs	Per 100 encs	Lower 95% CI	Upper 95% CI
Pain, chest NOS	64	30.05	54.70	44.8	64.6
Prescription all*	14	6.57	11.97	5.7	18.3
Test results*	10	4.69	8.55	2.9	14.2
Ischaemic Heart Disease*	10	4.69	8.55	3.4	13.7
Shortness of breath/dyspnoea	9	4.23	7.69	2.8	12.6
General check-up*	8	3.76	6.84	2.2	11.5
Cardiac check-up*	8	3.76	6.84	1.6	12.1
Vertigo/dizziness	7	3.29	5.98	1.7	10.3
Weakness/tiredness general	4	1.88	3.42	0.1	6.8
Anxiety*	4	1.88	3.42	0.1	6.7
Hypertension*	4	1.88	3.42	0.1	6.7
Arm symptom/complaint	4	1.88	3.42	0.1	6.7
Hearing complaint	3	1.41	2.56	0.0	5.5
Palpitations/awareness of heart	3	1.41	2.56	0.0	5.5
Chest symptom/complaint	3	1.41	2.56	0.0	5.5
Shoulder symptom/complaint	3	1.41	2.56	0.0	5.5
Leg/thigh symptom/complaint	3	1.41	2.56	0.0	5.5
Administrative procedure NOS	2	0.94	1.71	.	.
Dyspepsia/indigestion	2	0.94	1.71	.	.
Electrical tracings cardiovascular	2	0.94	1.71	.	.
Sensation disturbance, other	2	0.94	1.71	.	.
Sleep disturbance	2	0.94	1.71	.	.
Blood test endocrine/metabolic	2	0.94	1.71	.	.
Follow-up encounter unspecified endocrine/metabol	2	0.94	1.71	.	.
Feeling ill	1	0.47	0.85	.	.
General symptom/complaint, other	1	0.47	0.85	.	.
Blood test blood/lymph	1	0.47	0.85	.	.
Vomiting	1	0.47	0.85	.	.
Diarrhoea	1	0.47	0.85	.	.
Oesophagus disease	1	0.47	0.85	.	.
.	.	.	.	.	.
Subtotal	181	84.98	.	.	.
.	.	.	.	.	.
Other RFEs	32	15.02	.	.	.
.	.	.	.	.	.
Total RFEs	213	100.00	182.05	167.1	197.0

Table 5.1 Number of problems by gender of patient - IHD in patients aged 45+ Apr00-Mar01

The FREQ Procedure

Table of NUMPROB by SEX

NUMPROB(Number of problems managed)  
SEX(Sex of patient)

Frequency Percent Row Pct Col Pct	SEX(Sex of patient)		Total
	Male	Female	
1	196 15.36 64.90 26.10	106 8.31 35.10 20.19	302 23.67
2	268 21.00 59.42 35.69	183 14.34 40.58 34.86	451 35.34
3	196 15.36 57.31 26.10	146 11.44 42.69 27.81	342 26.80
4	91 7.13 50.28 12.12	90 7.05 49.72 17.14	181 14.18
Total	751 58.86	525 41.14	1276 100.00

Frequency Missing = 13

BEACH Survey Report - Analysis date: 21NOV08

Table 5.2: Other problems managed - ICPC chapter - IHD in patients aged 45+ Apr00-Mar01

Problem chapter	n	% of total problems	Per 100 encs	Lower 95% CI	Upper 95% CI
Circulatory	396	23.42	30.72	27.3	34.2
Endocrine & metabolic	313	18.51	24.28	21.2	27.3
Musculoskeletal	194	11.47	15.05	12.9	17.2
Respiratory	133	7.87	10.32	8.4	12.2
Psychological	119	7.04	9.23	7.5	11.0
Digestive	118	6.98	9.15	7.4	10.9
Skin	115	6.80	8.92	7.2	10.6
General & unspecified	105	6.21	8.15	6.5	9.8
Eye	32	1.89	2.48	1.6	3.3
Ear	31	1.83	2.40	1.6	3.3
Blood	29	1.71	2.25	1.3	3.2
Neurological	28	1.66	2.17	1.3	3.0
Urology	25	1.48	1.94	1.1	2.7
Male genital system	25	1.48	1.94	1.2	2.7
Female genital system	24	1.42	1.86	1.1	2.6
Social	4	0.24	0.31	0.0	0.6
.	.	.	.	.	.
Subtotal	1691	100.00	.	.	.
.	.	.	.	.	.
Total problems	1691	100.00	131.19	123.8	138.5

BEACH Survey Report - Analysis date: 21NOV08

Table 5.3: Top 30 other problems managed - IHD in patients aged 45+ Apr00-Mar01

Problem label	n	% of total other problems	Per 100 encs	Lower 95% CI	Upper 95% CI
Hypertension*	204	12.06	15.83	13.5	18.2
Lipid disorders*	131	7.75	10.16	8.3	12.0
Diabetes*	120	7.10	9.31	7.7	10.9
Osteoarthritis*	68	4.02	5.28	4.0	6.6
Oesophagus disease	52	3.08	4.03	2.9	5.2
Heart failure	52	3.08	4.03	2.8	5.2
Depression*	36	2.13	2.79	1.9	3.7
Sleep disturbance	36	2.13	2.79	1.9	3.7
Atrial fibrillation/flutter	31	1.83	2.40	1.5	3.3
Preventive immun/vacc/meds-all*	29	1.71	2.25	1.4	3.1
Atherosclerosis/peripheral vascular disease	27	1.60	2.09	1.3	2.9
Prescription all*	26	1.54	2.02	1.2	2.8
Arthritis*	25	1.48	1.94	1.1	2.8
Asthma	25	1.48	1.94	1.1	2.7
Anxiety*	23	1.36	1.78	1.1	2.5
Chronic obstructive pulmonary disease	22	1.30	1.71	0.9	2.5
General check-up*	20	1.18	1.55	0.8	2.3
Anaemia*	17	1.01	1.32	0.6	2.0
Gout	17	1.01	1.32	0.7	1.9
Back complaint*	16	0.95	1.24	0.6	1.8
Solar keratosis/sunburn	16	0.95	1.24	0.6	1.9
UTI*	15	0.89	1.16	0.5	1.8
Upper respiratory infection, acute	15	0.89	1.16	0.6	1.8
Acute bronchitis/bronchiolitis	14	0.83	1.09	0.5	1.7
Dermatitis, contact/allergic	14	0.83	1.09	0.5	1.7
Hypothyroidism/myxoedema	14	0.83	1.09	0.5	1.7
Malignant neoplasm of skin	13	0.77	1.01	0.5	1.5
Skin disease, other	12	0.71	0.93	0.4	1.4
Musculoskeletal disease, other	11	0.65	0.85	0.3	1.4
Dementia (incl senile, Alzheimer's)	11	0.65	0.85	0.4	1.4
.	.	.	.	.	.
Subtotal	1112	65.76	.	.	.
.	.	.	.	.	.
Other problems managed	579	34.24	.	.	.
.	.	.	.	.	.
Total problems	1691	100.00	131.19	123.8	138.5

Table 6.1 Number of problems by sex of patient - New IHD in patients aged 45+ Apr00-Mar01

The FREQ Procedure

Table of NUMPROB by SEX

NUMPROB(Number of problems managed)  
SEX(Sex of patient)

Frequency Percent Row Pct Col Pct	SEX		Total
	Male	Female	
1	26 22.61 50.98 44.07	25 21.74 49.02 44.64	51 44.35
2	16 13.91 42.11 27.12	22 19.13 57.89 39.29	38 33.04
3	13 11.30 65.00 22.03	7 6.09 35.00 12.50	20 17.39
4	4 3.48 66.67 6.78	2 1.74 33.33 3.57	6 5.22
Total	59 51.30	56 48.70	115 100.00

Frequency Missing = 2

BEACH Survey Report - Analysis date: 21NOV08

Table 6.2: Other problems managed - ICPC chapter - New IHD in patients aged 45+ Apr00-Mar01

Problem chapter	n	% of total problems	Per 100 encs	Lower 95% CI	Upper 95% CI
Circulatory	27	27.55	23.08	14.9	31.2
Endocrine & metabolic	15	15.31	12.82	5.9	19.7
General & unspecified	9	9.18	7.69	2.8	12.6
Digestive	9	9.18	7.69	2.3	13.1
Psychological	8	8.16	6.84	2.2	11.5
Respiratory	8	8.16	6.84	2.2	11.5
Musculoskeletal	7	7.14	5.98	1.0	11.0
Neurological	4	4.08	3.42	0.1	6.7
Skin	4	4.08	3.42	0.1	6.8
Ear	3	3.06	2.56	0.0	5.5
Female genital system	2	2.04	1.71	.	.
Urology	1	1.02	0.85	.	.
Male genital system	1	1.02	0.85	.	.
.	.	.	.	.	.
Subtotal	98	100.00	.	.	.
.	.	.	.	.	.
Total problems	98	100.00	.	.	.

BEACH Survey Report - Analysis date: 21NOV08

Table 6.3: Top 30 other problems managed - New IHD in patients aged 45+ Apr00-Mar01

Problem label	n	% of total other problems	Per 100 encs	Lower 95% CI	Upper 95% CI
Hypertension*	16	16.33	13.68	7.4	19.9
Lipid disorders*	9	9.18	7.69	2.3	13.1
Anxiety*	5	5.10	4.27	0.6	8.0
Prescription all*	5	5.10	4.27	0.5	8.0
Oesophagus disease	4	4.08	3.42	0.1	6.8
Diabetes*	4	4.08	3.42	0.1	6.7
Heart disease, other	3	3.06	2.56	0.0	6.3
Atherosclerosis/peripheral vascular disease	3	3.06	2.56	0.0	5.5
Administrative procedure NOS	2	2.04	1.71	.	.
Back complaint*	2	2.04	1.71	.	.
Gastroenteritis*	2	2.04	1.71	.	.
Upper respiratory infection, acute	2	2.04	1.71	.	.
Asthma	2	2.04	1.71	.	.
Risk factor NOS	1	1.02	0.85	.	.
Limited function/disability NOS	1	1.02	0.85	.	.
Dyspepsia/indigestion	1	1.02	0.85	.	.
Malignant neoplasm colon/rectum	1	1.02	0.85	.	.
Abdominal hernia, other	1	1.02	0.85	.	.
Arthritis*	1	1.02	0.85	.	.
General check-up*	1	1.02	0.85	.	.
Cardiac check-up*	1	1.02	0.85	.	.
UTI*	1	1.02	0.85	.	.
Depression*	1	1.02	0.85	.	.
Osteoarthritis*	1	1.02	0.85	.	.
Sprain/Strain*	1	1.02	0.85	.	.
Rheumatoid arthritis*	1	1.02	0.85	.	.
Abnormal test results*	1	1.02	0.85	.	.
Hearing complaint	1	1.02	0.85	.	.
Otitis externa	1	1.02	0.85	.	.
Excessive ear wax	1	1.02	0.85	.	.
.	.	.	.	.	.
Subtotal	76	77.55	.	.	.
.	.	.	.	.	.
Other problems managed	22	22.45	.	.	.
.	.	.	.	.	.
Total problems	98	100.00	.	.	.

BEACH Survey Report - Analysis date: 21NOV08

Table 7.1: Frequency of medication provision - IHD in patients aged 45+ Apr00-Mar01

Data	n	Per 100 IHD in patients aged 45+ probs	Lower 95% CI	Upper 95% CI	% meds for IHD in patients aged 45+ probs	Lower 95% CI	Upper 95% CI
Medications	1533	118.29	110.0	126.5	100.00	100.0	100.0
- Prescribed	1439	111.03	103.1	119.0	93.87	90.9	96.8
- GP supplied	81	6.25	2.8	9.7	5.28	2.5	8.1
- Advised OTC	13	1.00	0.5	1.5	0.85	0.4	1.3

Table 7.2.1: Top 30 medications prescribed (grouped by 4 digit ATC code) - IHD in patients aged 45+ Apr00-Mar01

ATC label	ATC 4 digit code	n	Per 100 IHD in patients aged 45+		% of prescribed meds for IHD in patients aged 45+		Lower 95% CI	Upper 95% CI
			probs	95% CI	Lower 95% CI	Upper 95% CI		
VASODILATORS USED IN CARDIAC DISEASES	C01D	531	40.97	36.9	45.0	36.90	33.7	40.1
OTHER ANALGESICS AND ANTIPYRETICS	N02B	180	13.89	11.6	16.2	12.51	10.8	14.3
BETA BLOCKING AGENTS	C07A	160	12.35	10.2	14.4	11.12	9.4	12.8
SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS	C08D	111	8.56	7.0	10.2	7.71	6.3	9.1
LIPID MODIFYING AGENTS, PLAIN	C10A	104	8.02	6.3	9.8	7.23	5.8	8.7
ACE INHIBITORS, PLAIN	C09A	85	6.56	4.8	8.3	5.91	4.5	7.3
ANTITHROMBOTIC AGENTS	B01A	53	4.09	2.9	5.3	3.68	2.6	4.7
HIGH-CEILING DIURETICS	C03C	43	3.32	2.1	4.5	2.99	2.0	4.0
SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS	C08C	41	3.16	2.0	4.3	2.85	1.9	3.8
CARDIAC GLYCOSIDES	C01A	33	2.55	1.7	3.4	2.29	1.5	3.1
POTASSIUM	A12B	12	0.93	0.4	1.5	0.83	0.3	1.3
ANGIOTENSIN II ANTAGONISTS, PLAIN	C09C	11	0.85	0.4	1.3	0.76	0.3	1.2
ANTIARRHYTHMICS, CLASS I AND III	C01B	9	0.69	0.2	1.1	0.63	0.2	1.0
NON-SELECTIVE CALCIUM CHANNEL BLOCKERS	C08E	7	0.54	0.1	0.9	0.49	0.1	0.8
ANXIOLYTICS	N05B	6	0.46	0.1	0.8	0.42	0.1	0.7
VIRAL VACCINES	J07B	5	0.39	0.0	0.7	0.35	0.0	0.7
OPIOIDS	N02A	5	0.39	0.0	0.7	0.35	0.0	0.7
HYPNOTICS AND SEDATIVES	N05C	5	0.39	0.0	0.7	0.35	0.0	0.6
DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION	C03E	4	0.31	0.0	0.6	0.28	0.0	0.5
LOW-CEILING DIURETICS, EXCL. THIAZIDES	C03B	3	0.23	0.0	0.5	0.21	0.0	0.4
DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)	A02B	2	0.15	.	.	0.14	.	.
PROPULSIVES	A03F	2	0.15	.	.	0.14	.	.
VITAMIN B12 AND FOLIC ACID	B03B	2	0.15	.	.	0.14	.	.
ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING	C02C	2	0.15	.	.	0.14	.	.
LOW-CEILING DIURETICS, THIAZIDES	C03A	2	0.15	.	.	0.14	.	.
ANTIGOUT PREPARATIONS	M04A	2	0.15	.	.	0.14	.	.
ADRENERGICS, INHALANTS	R03A	2	0.15	.	.	0.14	.	.
VARIOUS	V	2	0.15	.	.	0.14	.	.
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS	A10B	1	0.08	.	.	0.07	.	.
CALCIUM	A12A	1	0.08	.	.	0.07	.	.
Subtotal		1426	.	.	.	99.10	.	.

Note: Some medications were recorded with insufficient specificity to be coded at 4 digit ATC level, but could be coded at 1, or 3 digit ATC level. Also some medications were mapped to 1 or 3 digit ATC codes, because there was not an appropriate 4 digit or ATC code available at the time.

Table 7.2.1: Top 30 medications prescribed (grouped by 4 digit ATC code) - IHD in patients aged 45+ Apr00-Mar01

ATC label	ATC 4 digit code	n	Per 100 IHD in patients aged 45+ probs	Lower 95% CI	Upper 95% CI	% of prescribed meds for IHD in patients aged 45+	Lower 95% CI	Upper 95% CI
Other Meds	.	13	.	.	.	0.90	.	.
Total Meds	.	1439	111.03	103.1	119.0	100.00	.	.

Note: Some medications were recorded with insufficient specificity to be coded at 4 digit ATC level, but could be coded at 1, or 3 digit ATC level. Also some medications were mapped to 1 or 3 digit ATC codes, because there was not an appropriate 4 digit or ATC code available at the time.

Table 7.2.2: Top 30 medications prescribed (grouped by 5 digit ATC code) - IHD in patients aged 45+ Apr00-Mar01

ATC label	ATC 5 digit code	n	Per 100 IHD in patients aged 45+		% of prescribed meds for IHD in patients aged 45+			
			probs	Lower 95% CI	Upper 95% CI	Lower 95% CI	Upper 95% CI	
Organic nitrates	C01DA	514	39.66	35.8	43.5	35.72	32.5	39.0
Salicylic acid and derivatives	N02BA	176	13.58	11.3	15.8	12.23	10.5	14.0
Beta blocking agents, selective	C07AB	145	11.19	9.2	13.2	10.08	8.5	11.7
Benzothiazepine derivatives	C08DB	98	7.56	6.1	9.1	6.81	5.5	8.1
HMG CoA reductase inhibitors	C10AA	97	7.48	5.9	9.1	6.74	5.4	8.1
ACE inhibitors, plain	C09AA	85	6.56	4.8	8.3	5.91	4.5	7.3
Sulfonamides, plain	C03CA	43	3.32	2.1	4.5	2.99	2.0	4.0
Dihydropyridine derivatives	C08CA	41	3.16	2.0	4.3	2.85	1.9	3.8
Digitalis glycosides	C01AA	33	2.55	1.7	3.4	2.29	1.5	3.1
Vitamin K antagonists	B01AA	27	2.08	1.2	3.0	1.88	1.1	2.7
Platelet aggregation inhibitors excl. heparin	B01AC	25	1.93	1.2	2.7	1.74	1.1	2.4
Other vasodilators used in cardiac diseases	C01DX	16	1.23	0.3	2.1	1.11	0.3	1.9
Phenylalkylamine derivatives	C08DA	13	1.00	0.5	1.5	0.90	0.4	1.4
Potassium	A12BA	12	0.93	0.4	1.5	0.83	0.3	1.3
Beta blocking agents, non-selective	C07AA	11	0.85	0.3	1.4	0.76	0.3	1.2
Angiotensin II antagonists, plain	C09CA	11	0.85	0.4	1.3	0.76	0.3	1.2
Antiarrhythmics, class III	C01BD	9	0.69	0.2	1.1	0.63	0.2	1.0
Other non-selective calcium channel blockers	C08EX	7	0.54	0.1	0.9	0.49	0.1	0.8
Fibrates	C10AB	7	0.54	0.1	1.0	0.49	0.1	0.9
Benzodiazepine derivatives	N05BA	6	0.46	0.1	0.8	0.42	0.1	0.7
Influenza vaccines	J07BB	5	0.39	0.0	0.7	0.35	0.0	0.7
Benzodiazepine derivatives	N05CD	5	0.39	0.0	0.7	0.35	0.0	0.6
Low-ceiling diuretics and potassium-sparing agents	C03EA	4	0.31	0.0	0.6	0.28	0.0	0.5
Alpha and beta blocking agents	C07AG	4	0.31	0.0	0.6	0.28	0.0	0.6
Natural opium alkaloids	N02AA	4	0.31	0.0	0.6	0.28	0.0	0.6
Anilides	N02BE	4	0.31	0.0	0.6	0.28	0.0	0.6
Sulfonamides, plain	C03BA	3	0.23	0.0	0.5	0.21	0.0	0.4
Proton pump inhibitors	A02BC	2	0.15	.	.	0.14	.	.
Propulsives	A03FA	2	0.15	.	.	0.14	.	.
Vitamin B12 (cyanocobalamin and analogues)	B03BA	2	0.15	.	.	0.14	.	.
Subtotal		1411	.	.	.	98.05	.	.

Note: Some medications were recorded with insufficient specificity to be coded at 5 digit ATC level, but could be coded at 1, 3 or 4 digit ATC level. Also some medications were mapped to 1, 3 or 4 digit ATC codes, because there was not an appropriate 5 digit or ATC code available at the time.

Table 7.2.2: Top 30 medications prescribed (grouped by 5 digit ATC code) - IHD in patients aged 45+ Apr00-Mar01

ATC label	ATC 5 digit code	n	Per 100 IHD in patients aged 45+ probs	Lower 95% CI	Upper 95% CI	% of prescribed meds for IHD in patients aged 45+	Lower 95% CI	Upper 95% CI
Other Meds	.	28	.	.	.	1.95	.	.
Total Meds	.	1439	111.03	103.1	119.0	100.00	.	.

Note: Some medications were recorded with insufficient specificity to be coded at 5 digit ATC level, but could be coded at 1, 3 or 4 digit ATC level. Also some medications were mapped to 1, 3 or 4 digit ATC codes, because there was not an appropriate 5 digit or ATC code available at the time.

BEACH Survey Report - Analysis date: 21NOV08

Table 7.2.3.1: Top 60 brands of prescribed medications in alphabetic order  
 - IHD in patients aged 45+ Apr00-Mar01

brand	n	% of prescribed meds for IHD in patients aged 45+ probs	per 100 IHD in patients aged 45+ probs	% of total prescribed meds	per 100 total probs
Accupril	3	0.21	0.23	0.01	0.00
Adalat	11	0.76	0.85	0.02	0.01
Amiodarone hcl	6	0.42	0.46	0.01	0.01
Anginine	73	5.07	5.63	0.13	0.09
Asig	4	0.28	0.31	0.01	0.00
Aspirin	41	2.85	3.16	0.07	0.05
Astrix	63	4.38	4.86	0.11	0.08
Atenolol	24	1.67	1.85	0.04	0.03
Avapro	8	0.56	0.62	0.01	0.01
Betaloc	43	2.99	3.32	0.08	0.05
Capoten	10	0.69	0.77	0.02	0.01
Cardiprin	15	1.04	1.16	0.03	0.02
Cardizem anti-angina	15	1.04	1.16	0.03	0.02
Cardizem cd anti-hypertensive	69	4.79	5.32	0.12	0.08
Cartia	27	1.88	2.08	0.05	0.03
Coversyl	13	0.90	1.00	0.02	0.02
Digoxin	8	0.56	0.62	0.01	0.01
Diltiazem anti-angina	3	0.21	0.23	0.01	0.00
Diltiazem anti-hypertensive	8	0.56	0.62	0.01	0.01
Duride	17	1.18	1.31	0.03	0.02
Enalapril mal	4	0.28	0.31	0.01	0.00
Fluvax	5	0.35	0.39	0.01	0.01
Frusemide (Furosemide)	8	0.56	0.62	0.01	0.01
GTN (glyceryl trinitrate)	16	1.11	1.23	0.03	0.02
Gopten	6	0.42	0.46	0.01	0.01
Ikorel	15	1.04	1.16	0.03	0.02
Imdur	179	12.44	13.81	0.32	0.22
Inderal	5	0.35	0.39	0.01	0.01
Iscover	5	0.35	0.39	0.01	0.01
Isoptin	4	0.28	0.31	0.01	0.00
Isoptin oral/njection	3	0.21	0.23	0.01	0.00
Isordil	22	1.53	1.70	0.04	0.03
Lanoxin	25	1.74	1.93	0.05	0.03
Lasix	34	2.36	2.62	0.06	0.04

BEACH Survey Report - Analysis date: 21NOV08

Table 7.2.3.1: Top 60 brands of prescribed medications in alphabetic order  
 - IHD in patients aged 45+ Apr00-Mar01

brand	n	% of prescribed meds for IHD in patients aged 45+ probs	per 100 IHD in patients aged 45+ probs	% of total prescribed meds	per 100 total probs
Lipex	18	1.25	1.39	0.03	0.02
Lipitor	29	2.02	2.24	0.05	0.03
Lopid	6	0.42	0.46	0.01	0.01
Metoprolol	11	0.76	0.85	0.02	0.01
Monodur	17	1.18	1.31	0.03	0.02
Nitro-dur	27	1.88	2.08	0.05	0.03
Nitrolingual	98	6.81	7.56	0.18	0.12
Norvasc	23	1.60	1.77	0.04	0.03
Noten	37	2.57	2.85	0.07	0.04
Pexsig	4	0.28	0.31	0.01	0.00
Plavix	15	1.04	1.16	0.03	0.02
Plendil	5	0.35	0.39	0.01	0.01
Pravachol	18	1.25	1.39	0.03	0.02
Prinivil	6	0.42	0.46	0.01	0.01
Ramipril	4	0.28	0.31	0.01	0.00
Renitec	10	0.69	0.77	0.02	0.01
Slow-K	9	0.63	0.69	0.02	0.01
Solprin	26	1.81	2.01	0.05	0.03
Sotalol	4	0.28	0.31	0.01	0.00
Tenormin	29	2.02	2.24	0.05	0.03
Transiderm Nitro	54	3.75	4.17	0.10	0.07
Tritace	9	0.63	0.69	0.02	0.01
Verapamil hydrochloride	4	0.28	0.31	0.01	0.00
Warfarin sodium	26	1.81	2.01	0.05	0.03
Zestril	5	0.35	0.39	0.01	0.01
Zocor	26	1.81	2.01	0.05	0.03
.	.	.	.	.	.
Subtotal	1312	91.17	101.23	2.36	1.58
.	.	.	.	.	.
Other Meds	127	8.83	9.80	0.23	0.15
.	.	.	.	.	.
Total Meds	1439	100.00	111.03	2.59	1.74

BEACH Survey Report - Analysis date: 21NOV08

Table 7.2.3.2: Top 60 brands of prescribed medications in descending frequency order  
- IHD in patients aged 45+ Apr00-Mar01

brand	n	% of prescribed meds for IHD in patients aged 45+	per 100 IHD in patients aged 45+	% of total prescribed meds	per 100 total problems
Imdur	179	12.44	13.81	0.32	0.22
Nitrolingual	98	6.81	7.56	0.18	0.12
Anginine	73	5.07	5.63	0.13	0.09
Cardizem cd anti-hypertensive	69	4.79	5.32	0.12	0.08
Astrix	63	4.38	4.86	0.11	0.08
Transiderm Nitro	54	3.75	4.17	0.10	0.07
Betaloc	43	2.99	3.32	0.08	0.05
Aspirin	41	2.85	3.16	0.07	0.05
Noten	37	2.57	2.85	0.07	0.04
Lasix	34	2.36	2.62	0.06	0.04
Lipitor	29	2.02	2.24	0.05	0.03
Tenormin	29	2.02	2.24	0.05	0.03
Cartia	27	1.88	2.08	0.05	0.03
Nitro-dur	27	1.88	2.08	0.05	0.03
Solprin	26	1.81	2.01	0.05	0.03
Warfarin sodium	26	1.81	2.01	0.05	0.03
Zocor	26	1.81	2.01	0.05	0.03
Lanoxin	25	1.74	1.93	0.05	0.03
Atenolol	24	1.67	1.85	0.04	0.03
Norvasc	23	1.60	1.77	0.04	0.03
Isordil	22	1.53	1.70	0.04	0.03
Lipex	18	1.25	1.39	0.03	0.02
Pravachol	18	1.25	1.39	0.03	0.02
Duride	17	1.18	1.31	0.03	0.02
Monodur	17	1.18	1.31	0.03	0.02
GTN (glyceryl trinitrate)	16	1.11	1.23	0.03	0.02
Cardiprin	15	1.04	1.16	0.03	0.02
Cardizem anti-angina	15	1.04	1.16	0.03	0.02
Ikorel	15	1.04	1.16	0.03	0.02
Plavix	15	1.04	1.16	0.03	0.02
Coversyl	13	0.90	1.00	0.02	0.02
Adalat	11	0.76	0.85	0.02	0.01
Metoprolol	11	0.76	0.85	0.02	0.01
Capoten	10	0.69	0.77	0.02	0.01
Renitec	10	0.69	0.77	0.02	0.01

BEACH Survey Report - Analysis date: 21NOV08

Table 7.2.3.2: Top 60 brands of prescribed medications in descending frequency order  
 - IHD in patients aged 45+ Apr00-Mar01

brand	n	% of prescribed meds for IHD in patients aged 45+	per 100 IHD in patients aged 45+	% of total prescribed meds	per 100 total problems
Slow-K	9	0.63	0.69	0.02	0.01
Tritace	9	0.63	0.69	0.02	0.01
Avapro	8	0.56	0.62	0.01	0.01
Digoxin	8	0.56	0.62	0.01	0.01
Diltiazem anti-hypertensive	8	0.56	0.62	0.01	0.01
Frusemide (Furosemide)	8	0.56	0.62	0.01	0.01
Amiodarone hcl	6	0.42	0.46	0.01	0.01
Gopten	6	0.42	0.46	0.01	0.01
Lopid	6	0.42	0.46	0.01	0.01
Prinivil	6	0.42	0.46	0.01	0.01
Fluvax	5	0.35	0.39	0.01	0.01
Inderal	5	0.35	0.39	0.01	0.01
Iscover	5	0.35	0.39	0.01	0.01
Plendil	5	0.35	0.39	0.01	0.01
Zestril	5	0.35	0.39	0.01	0.01
Asig	4	0.28	0.31	0.01	0.00
Enalapril mal	4	0.28	0.31	0.01	0.00
Isoptin	4	0.28	0.31	0.01	0.00
Pexsig	4	0.28	0.31	0.01	0.00
Ramipril	4	0.28	0.31	0.01	0.00
Sotalol	4	0.28	0.31	0.01	0.00
Verapamil hydrochloride	4	0.28	0.31	0.01	0.00
Accupril	3	0.21	0.23	0.01	0.00
Diltiazem anti-angina	3	0.21	0.23	0.01	0.00
Isoptin oral/njection	3	0.21	0.23	0.01	0.00
.	.	.	.	.	.
Subtotal	1312	91.17	101.23	2.36	1.58
.	.	.	.	.	.
Other Meds	127	8.83	9.80	0.23	0.15
.	.	.	.	.	.
Total Meds	1439	100.00	111.03	2.59	1.74

BEACH Survey Report - Analysis date: 21NOV08

Table 7.2.4: Prescribed medications (generic and products within each generic)- IHD in patients aged 45+ Apr00-Mar01

Generic	/product	n	% of total prescribed meds	per 100 total probs	per 100 IHD in patients aged 45+ probs	% of prescribed meds for IHD in patients aged 45+ probs	% of generic
Total prescribed IHD in patients aged 45+ medications		1439	2.589	1.74	.	.	.
GTN (glyceryl trinitrate)		274	0.493	0.33	21.14	19.04	.
	GTN (glyceryl trinitrate) NOS	12	0.022	0.01	0.93	0.83	4.38
	GTN (glyceryl trinitrate) Sublingual 400 mcg	4	0.007	0.00	0.31	0.28	1.46
	Transiderm Nitro NOS	24	0.043	0.03	1.85	1.67	8.76
	Transiderm Nitro patch 5 mg	13	0.023	0.02	1.00	0.90	4.74
	Transiderm Nitro patch 10 mg	17	0.031	0.02	1.31	1.18	6.20
	Anginine NOS	4	0.007	0.00	0.31	0.28	1.46
	Anginine tablets 600 mcg	69	0.124	0.08	5.32	4.79	25.18
	Minitran NOS	1	0.002	0.00	0.08	0.07	0.36
	Minitran patch 10 mg	1	0.002	0.00	0.08	0.07	0.36
	Minitran patches 15 mg	1	0.002	0.00	0.08	0.07	0.36
	Nitrolingual spray sublingual 400 mcg	98	0.176	0.12	7.56	6.81	35.77
	Nitro-dur NOS	1	0.002	0.00	0.08	0.07	0.36
	Nitro-dur patches 5 mg	13	0.023	0.02	1.00	0.90	4.74
	Nitro-dur patches 10 mg	10	0.018	0.01	0.77	0.69	3.65
	Nitro-dur patches 15 mg	3	0.005	0.00	0.23	0.21	1.09
	Nitradisc NOS	1	0.002	0.00	0.08	0.07	0.36
	Nitradisc patches 5 mg	1	0.002	0.00	0.08	0.07	0.36
	Nitradisc patches 10 mg	1	0.002	0.00	0.08	0.07	0.36
Isosorbide dinitrate		222	0.399	0.27	17.13	15.43	.
	Isosorbide nitrate Tablets 60 mg	2	0.004	0.00	0.15	0.14	0.90
	Duride NOS	2	0.004	0.00	0.15	0.14	0.90
	Sorbidin tablets 10 mg	1	0.002	0.00	0.08	0.07	0.45
	Duride tablets 60 mg	15	0.027	0.02	1.16	1.04	6.76
	Imdur NOS	4	0.007	0.00	0.31	0.28	1.80
	Imdur tablets 60 mg	138	0.248	0.17	10.65	9.59	62.16
	Imdur tablets 120 mg	37	0.067	0.04	2.85	2.57	16.67
	Isordil NOS	1	0.002	0.00	0.08	0.07	0.45
	Isordil tablets 10 mg	11	0.020	0.01	0.85	0.76	4.95
	Isordil tablets sublingual 5 mg	10	0.018	0.01	0.77	0.69	4.50

BEACH Survey Report - Analysis date: 21NOV08

Table 7.2.4: Prescribed medications (generic and products within each generic)- IHD in patients aged 45+ Apr00-Mar01

Generic	/product	n	% of total prescribed meds	per 100 total probs	per 100 IHD in patients aged 45+ probs	% of prescribed meds for IHD in patients aged 45+ probs	% of generic
Aspirin	Imtrate tablets 60 mg	1	0.002	0.00	0.08	0.07	0.45
		176	0.317	0.21	13.58	12.23	.
	Aspirin NOS	17	0.031	0.02	1.31	1.18	9.66
	Aspirin capsules 100 mg	1	0.002	0.00	0.08	0.07	0.57
	Aspirin capsules 300 mg	1	0.002	0.00	0.08	0.07	0.57
	Aspirin tablets 100 mg	11	0.020	0.01	0.85	0.76	6.25
	Aspirin tablets 300 mg	11	0.020	0.01	0.85	0.76	6.25
	Astrix NOS	7	0.013	0.01	0.54	0.49	3.98
	Astrix capsules 100 mg	50	0.090	0.06	3.86	3.47	28.41
	Astrix tablets 100 mg	6	0.011	0.01	0.46	0.42	3.41
	Cardiprin NOS	2	0.004	0.00	0.15	0.14	1.14
	Solprin NOS	3	0.005	0.00	0.23	0.21	1.70
	Disprin NOS	2	0.004	0.00	0.15	0.14	1.14
	Cardiprin tablets 100 mg	13	0.023	0.02	1.00	0.90	7.39
Atenolol	Solprin tablets 300 mg	23	0.041	0.03	1.77	1.60	13.07
	Spren tablets 300 mg	2	0.004	0.00	0.15	0.14	1.14
	Cartia tablets 100 mg	27	0.049	0.03	2.08	1.88	15.34
		90	0.162	0.11	6.94	6.25	.
	Atenolol NOS	2	0.004	0.00	0.15	0.14	2.22
	Atenolol Tablets 50 mg	22	0.040	0.03	1.70	1.53	24.44
	Noten NOS	2	0.004	0.00	0.15	0.14	2.22
	Noten tablets 50 mg	35	0.063	0.04	2.70	2.43	38.89
	Tenormin NOS	1	0.002	0.00	0.08	0.07	1.11
	Tenormin tablets 50 mg	28	0.050	0.03	2.16	1.95	31.11
Diltiazem anti-hypertensive		79	0.142	0.10	6.10	5.49	.
	Diltiazem anti-hypertensive NOS	1	0.002	0.00	0.08	0.07	1.27
	Diltiazem anti-hypertensive Capsules 180 mg	3	0.005	0.00	0.23	0.21	3.80
	Diltiazem anti-hypertensive Capsules 240 mg	4	0.007	0.00	0.31	0.28	5.06
	Cardizem cd anti-hypertensive capsules 180 mg	39	0.070	0.05	3.01	2.71	49.37
	Cardizem cd anti-hypertensive capsules 240 mg	30	0.054	0.04	2.31	2.08	37.97
Metoprolol	Vasocardol	2	0.004	0.00	0.15	0.14	2.53
		55	0.099	0.07	4.24	3.82	.

BEACH Survey Report - Analysis date: 21NOV08

Table 7.2.4: Prescribed medications (generic and products within each generic)- IHD in patients aged 45+ Apr00-Mar01

Generic	/product	n	% of total prescribed meds	per 100 total probs	per 100 IHD in patients aged 45+ probs	% of prescribed meds for IHD in patients aged 45+ probs	% of generic
	Metoprolol NOS	1	0.002	0.00	0.08	0.07	1.82
	Metoprolol Tablets 50 mg	10	0.018	0.01	0.77	0.69	18.18
	Minax tablets 50 mg	1	0.002	0.00	0.08	0.07	1.82
	Betaloc NOS	3	0.005	0.00	0.23	0.21	5.45
	Betaloc tablets 50 mg	33	0.059	0.04	2.55	2.29	60.00
	Betaloc tablets 100 mg	7	0.013	0.01	0.54	0.49	12.73
Simvastatin		46	0.083	0.06	3.55	3.20	.
	Simvastatin Tablets 40 mg	2	0.004	0.00	0.15	0.14	4.35
	Lipex tablets 5 mg	1	0.002	0.00	0.08	0.07	2.17
	Lipex tablets 10 mg	8	0.014	0.01	0.62	0.56	17.39
	Lipex tablets 20 mg	7	0.013	0.01	0.54	0.49	15.22
	Lipex tablets 40 mg	2	0.004	0.00	0.15	0.14	4.35
	Zocor tablets 5 mg	1	0.002	0.00	0.08	0.07	2.17
	Zocor tablets 10 mg	8	0.014	0.01	0.62	0.56	17.39
	Zocor tablets 20 mg	12	0.022	0.01	0.93	0.83	26.09
	Zocor tablets 40 mg	4	0.007	0.00	0.31	0.28	8.70
	Zocor tablets 80 mg	1	0.002	0.00	0.08	0.07	2.17
Frusemide (Furosemide)		43	0.077	0.05	3.32	2.99	.
	Frusemide (Furosemide) Tablets 20 mg	2	0.004	0.00	0.15	0.14	4.65
	Frusemide (Furosemide) Tablets 40 mg	6	0.011	0.01	0.46	0.42	13.95
	Uremide tablets 40 mg	1	0.002	0.00	0.08	0.07	2.33
	Lasix NOS	1	0.002	0.00	0.08	0.07	2.33
	Lasix tablets 40 mg	30	0.054	0.04	2.31	2.08	69.77
	Lasix tablets 20 mg	2	0.004	0.00	0.15	0.14	4.65
	Lasix high dose tablets 500 mg	1	0.002	0.00	0.08	0.07	2.33
Digoxin		33	0.059	0.04	2.55	2.29	.
	Digoxin NOS	1	0.002	0.00	0.08	0.07	3.03
	Digoxin Tablets 62.5 mcg	4	0.007	0.00	0.31	0.28	12.12
	Digoxin Tablets 250 mcg	3	0.005	0.00	0.23	0.21	9.09
	Lanoxin tablets 250 mcg	13	0.023	0.02	1.00	0.90	39.39
	Lanoxin pg tablets 62.5 mcg	12	0.022	0.01	0.93	0.83	36.36
Atorvastatin		29	0.052	0.03	2.24	2.02	.

BEACH Survey Report - Analysis date: 21NOV08

Table 7.2.4: Prescribed medications (generic and products within each generic)- IHD in patients aged 45+ Apr00-Mar01

Generic	/product	n	% of total prescribed meds	per 100 total probs	per 100 IHD in patients aged 45+ probs	% of prescribed meds for IHD in patients aged 45+ probs	% of generic
	Lipitor NOS	1	0.002	0.00	0.08	0.07	3.45
	Lipitor tablets 10 mg	9	0.016	0.01	0.69	0.63	31.03
	Lipitor tablets 20 mg	8	0.014	0.01	0.62	0.56	27.59
	Lipitor tablets 40 mg	11	0.020	0.01	0.85	0.76	37.93
Warfarin sodium		27	0.049	0.03	2.08	1.88	.
	Warfarin sodium NOS	4	0.007	0.00	0.31	0.28	14.81
	Warfarin sodium tablets 1 mg	4	0.007	0.00	0.31	0.28	14.81
	Warfarin sodium tablets 2 mg	10	0.018	0.01	0.77	0.69	37.04
	Warfarin sodium tablets 3 mg	5	0.009	0.01	0.39	0.35	18.52
	Warfarin sodium tablets 5 mg	3	0.005	0.00	0.23	0.21	11.11
	Coumadin tablets 1 mg	1	0.002	0.00	0.08	0.07	3.70
Amlodipine		24	0.043	0.03	1.85	1.67	.
	Amlodipine tablets 10 mg	1	0.002	0.00	0.08	0.07	4.17
	Norvasc tablets 5 mg	16	0.029	0.02	1.23	1.11	66.67
	Norvasc tablets 10 mg	7	0.013	0.01	0.54	0.49	29.17
Clopidogrel		21	0.038	0.03	1.62	1.46	.
	Clopidogrel Tablets 75 mg	1	0.002	0.00	0.08	0.07	4.76
	Iscover tablets 75 mg	5	0.009	0.01	0.39	0.35	23.81
	Plavix tablets 75 mg	15	0.027	0.02	1.16	1.04	71.43
Diltiazem anti-angina		19	0.034	0.02	1.47	1.32	.
	Diltiazem anti-angina Tablets 60 mg	3	0.005	0.00	0.23	0.21	15.79
	Coras tablets 60 mg	1	0.002	0.00	0.08	0.07	5.26
	Cardizem anti-angina tablets 60 mg	15	0.027	0.02	1.16	1.04	78.95
Pravastatin		19	0.034	0.02	1.47	1.32	.
	Pravastatin Tablets 20 mg	1	0.002	0.00	0.08	0.07	5.26
	Pravachol tablets 10 mg	2	0.004	0.00	0.15	0.14	10.53
	Pravachol tablets 20 mg	6	0.011	0.01	0.46	0.42	31.58
	Pravachol tablets 40 mg	10	0.018	0.01	0.77	0.69	52.63
Isosorbide mononitrate		18	0.032	0.02	1.39	1.25	.
	Isosorbide mononitrate Tablets 60 mg	1	0.002	0.00	0.08	0.07	5.56
	Monodur tablets 60 mg	11	0.020	0.01	0.85	0.76	61.11
	Monodur tablets 120 mg	6	0.011	0.01	0.46	0.42	33.33

BEACH Survey Report - Analysis date: 21NOV08

Table 7.2.4: Prescribed medications (generic and products within each generic)- IHD in patients aged 45+ Apr00-Mar01

Generic	/product	n	% of total prescribed meds	per 100 total probs	per 100 IHD in patients aged 45+ probs	% of prescribed meds for IHD in patients aged 45+ probs	% of generic
Nicorandil		16	0.029	0.02	1.23	1.11	.
	Nicorandil Tablets 10 mg	1	0.002	0.00	0.08	0.07	6.25
	Ikorel NOS	1	0.002	0.00	0.08	0.07	6.25
	Ikorel tablets 10 mg	11	0.020	0.01	0.85	0.76	68.75
Enalapril mal	Ikorel tablets 20 mg	3	0.005	0.00	0.23	0.21	18.75
		15	0.027	0.02	1.16	1.04	.
	Enalapril mal NOS	3	0.005	0.00	0.23	0.21	20.00
	Enalapril mal Tablets 20 mg	1	0.002	0.00	0.08	0.07	6.67
	Amprace tablets 10 mg	1	0.002	0.00	0.08	0.07	6.67
	Renitec NOS	5	0.009	0.01	0.39	0.35	33.33
	Renitec tablets 5 mg	1	0.002	0.00	0.08	0.07	6.67
	Renitec tablets 10 mg	2	0.004	0.00	0.15	0.14	13.33
Perindopril	Renitec tablets 20 mg	2	0.004	0.00	0.15	0.14	13.33
		14	0.025	0.02	1.08	0.97	.
	Perindopril Tablets 4 mg	1	0.002	0.00	0.08	0.07	7.14
	Coversyl tablets 2 mg	6	0.011	0.01	0.46	0.42	42.86
Ramipril	Coversyl tablets 4 mg	7	0.013	0.01	0.54	0.49	50.00
		14	0.025	0.02	1.08	0.97	.
	Ramipril Tablets 1.25 mg	1	0.002	0.00	0.08	0.07	7.14
	Ramipril Tablets 2.5 mg	1	0.002	0.00	0.08	0.07	7.14
	Ramipril Tablets 5 mg	2	0.004	0.00	0.15	0.14	14.29
	Tritace tablets 2.5 mg	6	0.011	0.01	0.46	0.42	42.86
	Tritace tablets 5 mg	3	0.005	0.00	0.23	0.21	21.43
Captopril	Ramace tablets 5 mg	1	0.002	0.00	0.08	0.07	7.14
		13	0.023	0.02	1.00	0.90	.
	Captopril tablets 25 mg	1	0.002	0.00	0.08	0.07	7.69
	Acenorm tablets 50 mg	2	0.004	0.00	0.15	0.14	15.38
	Capoten tablets 12.5 mg	3	0.005	0.00	0.23	0.21	23.08
	Capoten tablets 25 mg	6	0.011	0.01	0.46	0.42	46.15
Verapamil hydrochloride	Capoten tablets 50 mg	1	0.002	0.00	0.08	0.07	7.69
		13	0.023	0.02	1.00	0.90	.
	Verapamil hydrochloride NOS	3	0.005	0.00	0.23	0.21	23.08

BEACH Survey Report - Analysis date: 21NOV08

Table 7.2.4: Prescribed medications (generic and products within each generic)- IHD in patients aged 45+ Apr00-Mar01

Generic	/product	n	% of total prescribed meds	per 100 total probs	per 100 IHD in patients aged 45+ probs	% of prescribed meds for IHD in patients aged 45+ probs	% of generic
	Verapamil hydrochloride tablets 40 mg	1	0.002	0.00	0.08	0.07	7.69
	Anpec tablets SR 240 mg	1	0.002	0.00	0.08	0.07	7.69
	Isoptin oral tablets 40 mg	2	0.004	0.00	0.15	0.14	15.38
	Isoptin tablets SR 180 mg	2	0.004	0.00	0.15	0.14	15.38
	Isoptin oral tablets 80 mg	1	0.002	0.00	0.08	0.07	7.69
	Isoptin tablets SR 240 mg	2	0.004	0.00	0.15	0.14	15.38
	Veracaps capsules SR 240 mg	1	0.002	0.00	0.08	0.07	7.69
Lisinopril		13	0.023	0.02	1.00	0.90	.
	Lisinopril Tablets 10 mg	1	0.002	0.00	0.08	0.07	7.69
	Lisinopril Tablets 20 mg	1	0.002	0.00	0.08	0.07	7.69
	Prinivil NOS	1	0.002	0.00	0.08	0.07	7.69
	Prinivil tablets 5 mg	2	0.004	0.00	0.15	0.14	15.38
	Prinivil tablets 10 mg	2	0.004	0.00	0.15	0.14	15.38
	Prinivil tablets 20 mg	1	0.002	0.00	0.08	0.07	7.69
	Zestril tablets 5 mg	2	0.004	0.00	0.15	0.14	15.38
	Zestril tablets 10 mg	2	0.004	0.00	0.15	0.14	15.38
	Zestril tablets 20 mg	1	0.002	0.00	0.08	0.07	7.69
Nifedipine		11	0.020	0.01	0.85	0.76	.
	Adalat tablets 10 mg	1	0.002	0.00	0.08	0.07	9.09
	Adalat oros tablets 30 mg	7	0.013	0.01	0.54	0.49	63.64
	Adalat oros tablets 60 mg	3	0.005	0.00	0.23	0.21	27.27
Potassium chloride		10	0.018	0.01	0.77	0.69	.
	Slow-K tablets 600 mg	9	0.016	0.01	0.69	0.63	90.00
	Span-K tablets 600 mg	1	0.002	0.00	0.08	0.07	10.00
Irbesartan		9	0.016	0.01	0.69	0.63	.
	Avapro tablets 75 mg	2	0.004	0.00	0.15	0.14	22.22
	Avapro tablets 150 mg	3	0.005	0.00	0.23	0.21	33.33
	Avapro tablets 300 mg	3	0.005	0.00	0.23	0.21	33.33
	Karvea tablets 300 mg	1	0.002	0.00	0.08	0.07	11.11
Amiodarone hcl		9	0.016	0.01	0.69	0.63	.
	Amiodarone hcl tablets 100 mg	2	0.004	0.00	0.15	0.14	22.22
	Amiodarone hcl tablets 200 mg	4	0.007	0.00	0.31	0.28	44.44

BEACH Survey Report - Analysis date: 21NOV08

Table 7.2.4: Prescribed medications (generic and products within each generic)- IHD in patients aged 45+ Apr00-Mar01

Generic	/product	n	% of total prescribed meds	per 100 total probs	per 100 IHD in patients aged 45+ probs	% of prescribed meds for IHD in patients aged 45+ probs	% of generic
Quinapril	Aratac tablets 200 mg	1	0.002	0.00	0.08	0.07	11.11
	Cordarone x tablets 200 mg	2	0.004	0.00	0.15	0.14	22.22
		7	0.013	0.01	0.54	0.49	.
	Accupril tablets 10 mg	2	0.004	0.00	0.15	0.14	28.57
	Accupril tablets 5 mg	1	0.002	0.00	0.08	0.07	14.29
	Asig NOS	1	0.002	0.00	0.08	0.07	14.29
	Asig tablets 5 mg	2	0.004	0.00	0.15	0.14	28.57
Perhexiline	Asig tablets 10 mg	1	0.002	0.00	0.08	0.07	14.29
		7	0.013	0.01	0.54	0.49	.
	Perhexiline Tablets 100 mg	3	0.005	0.00	0.23	0.21	42.86
	Pexsig NOS	1	0.002	0.00	0.08	0.07	14.29
Gemfibrozil	Pexsig tablets 100 mg	3	0.005	0.00	0.23	0.21	42.86
		7	0.013	0.01	0.54	0.49	.
	Jezil tablets 600 mg	1	0.002	0.00	0.08	0.07	14.29
Felodipine	Lopid tablets 600 mg	6	0.011	0.01	0.46	0.42	85.71
		6	0.011	0.01	0.46	0.42	.
	Felodipine Tablets 2.5 mg	1	0.002	0.00	0.08	0.07	16.67
	Plendil tablets 2.5 mg	1	0.002	0.00	0.08	0.07	16.67
	Plendil tablets 5 mg	2	0.004	0.00	0.15	0.14	33.33
	Plendil tablets 10 mg	2	0.004	0.00	0.15	0.14	33.33
Trandolapril		6	0.011	0.01	0.46	0.42	.
	Gopten capsules 1 mg	2	0.004	0.00	0.15	0.14	33.33
	Gopten capsules 2 mg	4	0.007	0.00	0.31	0.28	66.67
Sotalol		6	0.011	0.01	0.46	0.42	.
	Sotalol NOS	1	0.002	0.00	0.08	0.07	16.67
	Sotalol Tablets 160 mg	2	0.004	0.00	0.15	0.14	33.33
	Sotalol Tablets 80 mg	1	0.002	0.00	0.08	0.07	16.67
	Sotacor tablets 160 mg	2	0.004	0.00	0.15	0.14	33.33
Propranolol hydrochloride		5	0.009	0.01	0.39	0.35	.
	Inderal NOS	1	0.002	0.00	0.08	0.07	20.00
	Inderal tablets 10 mg	2	0.004	0.00	0.15	0.14	40.00
	Inderal tablets 40 mg	1	0.002	0.00	0.08	0.07	20.00

BEACH Survey Report - Analysis date: 21NOV08

Table 7.2.4: Prescribed medications (generic and products within each generic)- IHD in patients aged 45+ Apr00-Mar01

Generic	/product	n	% of total prescribed meds	per 100 total probs	per 100 IHD in patients aged 45+ probs	% of prescribed meds for IHD in patients aged 45+ probs	% of generic
Influenza virus vaccine	Inderal tablets 160 mg	1	.002	0.00	0.08	0.07	20.00
		5	.009	0.01	0.39	0.35	.
Carvedilol	Fluvax injection 0.5 ml	5	.009	0.01	0.39	0.35	100.00
		4	.007	0.00	0.31	0.28	.
Morphine sulphate	Carvedilol tablets 6.25 mg	1	.002	0.00	0.08	0.07	25.00
	Carvedilol tablets 12.5 mg	1	.002	0.00	0.08	0.07	25.00
	Dilatrend tablets 6.25 mg	2	.004	0.00	0.15	0.14	50.00
		4	.007	0.00	0.31	0.28	.
Temazepam	Morphine sulphate NOS	3	.005	0.00	0.23	0.21	75.00
	Kapanol capsules 20 mg	1	.002	0.00	0.08	0.07	25.00
Indapamide		4	.007	0.00	0.31	0.28	.
	Temazepam NOS	2	.004	0.00	0.15	0.14	50.00
	Temazepam Capsules 10 mg	1	.002	0.00	0.08	0.07	25.00
Fosinopril	Euhypnos capsules 10 mg	1	.002	0.00	0.08	0.07	25.00
		3	.005	0.00	0.23	0.21	.
	Indapamide Tablets 2.5 mg	1	.002	0.00	0.08	0.07	33.33
	Dapa-tabs tablets 2.5 mg	1	.002	0.00	0.08	0.07	33.33
Paracetamol	Natrilix tablets 2.5 mg	1	.002	0.00	0.08	0.07	33.33
		3	.005	0.00	0.23	0.21	.
Diazepam	Monopril NOS	1	.002	0.00	0.08	0.07	33.33
	Monopril tablets 20 mg	2	.004	0.00	0.15	0.14	66.67
Oxazepam		3	.005	0.00	0.23	0.21	.
	Panamax NOS	2	.004	0.00	0.15	0.14	66.67
Thiazide + Amiloride	Panamax tablets 500 mg	1	.002	0.00	0.08	0.07	33.33
		3	.005	0.00	0.23	0.21	.
	Valium tablets 5 mg	1	.002	0.00	0.08	0.07	33.33
Thiazide + Amiloride	Ducene tablets 5 mg	2	.004	0.00	0.15	0.14	66.67
		3	.005	0.00	0.23	0.21	.
	Murelax NOS	1	.002	0.00	0.08	0.07	33.33
Thiazide + Amiloride	Murelax tablets 30 mg	1	.002	0.00	0.08	0.07	33.33
	Serepax tablets 30 mg	1	.002	0.00	0.08	0.07	33.33
		3	.005	0.00	0.23	0.21	.

BEACH Survey Report - Analysis date: 21NOV08

Table 7.2.4: Prescribed medications (generic and products within each generic)- IHD in patients aged 45+ Apr00-Mar01

Generic	/product	n	% of total prescribed meds	per 100 total probs	per 100 IHD in patients aged 45+ probs	% of prescribed meds for IHD in patients aged 45+ probs	% of generic
Vitamin B12 (Cobalamin)	Moduretic tablets 55 mg	3	.005	0	0.23	0.21	100
		2	.004	0	0.15	0.14	.
Prazosin hydrochloride	Neocytagen injection 1 mg 1 ml	2	.004	0	0.15	0.14	100
		2	.004	0	0.15	0.14	.
Dipyridamole	Minipress tablets 2 mg	2	.004	0	0.15	0.14	100
		2	.004	0	0.15	0.14	.
Dipyridamole/Aspirin	Persantin sr capsules 200 mg	2	.004	0	0.15	0.14	100
		2	.004	0	0.15	0.14	.
Cerivastatin	Asasantin capsules 225 mg	2	.004	0	0.15	0.14	100
		2	.004	0	0.15	0.14	.
Metoclopramide	Lipobay tablets 300 mcg	2	.004	0	0.15	0.14	100
		2	.004	0	0.15	0.14	.
Potassium bicarbonate	Maxolon NOS	1	.002	0	0.08	0.07	50
	Maxolon injection 10 mg 2 ml	1	.002	0	0.08	0.07	50
Illegible	Chlorvescent	2	.004	0	0.15	0.14	100
		2	.004	0	0.15	0.14	.
Heparin	Illegible	2	.004	0	0.15	0.14	100
		1	.002	0	0.08	0.07	.
Cardiovascular system	Heparin NOS	1	.002	0	0.08	0.07	100
		1	.002	0	0.08	0.07	.
Hydralazine	Cardiovascular n/s	1	.002	0	0.08	0.07	100
		1	.002	0	0.08	0.07	.
Methyldopa	Hydralazine Tablets 25 mg	1	.002	0	0.08	0.07	100
		1	.002	0	0.08	0.07	.
Candesartan cilexetil	Aldomet NOS	1	.002	0	0.08	0.07	100
		1	.002	0	0.08	0.07	.
Telmisartan	Atacand tablets 16 mg	1	.002	0	0.08	0.07	100
		1	.002	0	0.08	0.07	.
Perindopril/Indapamide	Pritor tablets 40 mg	1	.002	0	0.08	0.07	100
		1	.002	0	0.08	0.07	.
	Coversyl Plus tablets 5.25 mg	1	.002	0	0.08	0.07	100

BEACH Survey Report - Analysis date: 21NOV08

Table 7.2.4: Prescribed medications (generic and products within each generic)- IHD in patients aged 45+ Apr00-Mar01

Generic	/product	n	% of total prescribed meds	per 100 total probs	per 100 IHD in patients aged 45+ probs	% of prescribed meds for IHD in patients aged 45+ probs	% of generic
Antiangina		1	.002	0	0.08	0.07	.
	Anti angina drug	1	.002	0	0.08	0.07	100
Fluvastatin		1	.002	0	0.08	0.07	.
	Vastin capsules 40 mg	1	.002	0	0.08	0.07	100
Omeprazole		1	.002	0	0.08	0.07	.
	Losec tablets 20 mg	1	.002	0	0.08	0.07	100
Lansoprazole		1	.002	0	0.08	0.07	.
	Zoton capsules 30 mg	1	.002	0	0.08	0.07	100
Hypromellose		1	.002	0	0.08	0.07	.
	Isopto tears NOS	1	.002	0	0.08	0.07	100
Betamethasone systemic		1	.002	0	0.08	0.07	.
	Celestone chronodose injection 5.7 mg 1 ml	1	.002	0	0.08	0.07	100
Glipizide		1	.002	0	0.08	0.07	.
	Minidiab tablets 5 mg	1	.002	0	0.08	0.07	100
Thyroxine		1	.002	0	0.08	0.07	.
	Thyroxine Tablets 0.05 mg	1	.002	0	0.08	0.07	100
Ibuprofen		1	.002	0	0.08	0.07	.
	Brufen tablets 400 mg	1	.002	0	0.08	0.07	100
Allopurinol		1	.002	0	0.08	0.07	.
	Zyloprim tablets 100 mg	1	.002	0	0.08	0.07	100
Colchicine		1	.002	0	0.08	0.07	.
	Colgout tablets 500 mcg	1	.002	0	0.08	0.07	100
Quinine sulphate/bisulphate		1	.002	0	0.08	0.07	.
	Quinate tablets 300 mg	1	.002	0	0.08	0.07	100
Tramadol		1	.002	0	0.08	0.07	.
	Tramal capsules 50 mg	1	.002	0	0.08	0.07	100
Paracetamol/Codeine		1	.002	0	0.08	0.07	.
	Panadeine forte tablets 530 mg	1	.002	0	0.08	0.07	100
Prochlorperazine		1	.002	0	0.08	0.07	.
	Stemetil tablets 5 mg	1	.002	0	0.08	0.07	100
Nitrazepam		1	.002	0	0.08	0.07	.
	Mogadon tablets 5 mg	1	.002	0	0.08	0.07	100

BEACH Survey Report - Analysis date: 21NOV08

Table 7.2.4: Prescribed medications (generic and products within each generic)- IHD in patients aged 45+ Apr00-Mar01

Generic	/product	n	% of total prescribed meds	per 100 total probs	per 100 IHD in patients aged 45+ probs	% of prescribed meds for IHD in patients aged 45+ probs	% of generic
Fluvoxamine		1	.002	0	0.08	0.07	.
	Fluvoxamine Tablets 100 mg	1	.002	0	0.08	0.07	100
Salbutamol		1	.002	0	0.08	0.07	.
	Ventolin inhaler 100 mcg	1	.002	0	0.08	0.07	100
Terbutaline		1	.002	0	0.08	0.07	.
	Bricanyl NOS	1	.002	0	0.08	0.07	100
Budesonide		1	.002	0	0.08	0.07	.
	Pulmicort NOS	1	.002	0	0.08	0.07	100
Calcium carbonate		1	.002	0	0.08	0.07	.
	Caltrate tablets 600 mg	1	.002	0	0.08	0.07	100
Chlorothiazide		1	.002	0	0.08	0.07	.
	Chlotride tablets 500 mg	1	.002	0	0.08	0.07	100
Hydrochlorothiazide		1	.002	0	0.08	0.07	.
	Dichlotride tablets 50 mg	1	.002	0	0.08	0.07	100
Trianterene/Hydrochlorothiazide		1	.002	0	0.08	0.07	.
	Hydrene tablets 75 mg	1	.002	0	0.08	0.07	100
Spirolactone		1	.002	0	0.08	0.07	.
	Aldactone tablets 25 mg	1	.002	0	0.08	0.07	100

BEACH Survey Report - Analysis date: 21NOV08

Table 7.3: Medications (generic and products within each generic)- IHD in patients aged 45+ Apr00-Mar01

Generic	/product	n	% of total meds	per 100 total probs	per 100 IHD in patients aged 45+ probs	% of IHD in patients aged 45+ meds	% of generic
Total IHD in patients aged 45+ medications		1533	2.472	1.85	118.29	.	.
GTN (glyceryl trinitrate)		288	0.464	0.35	22.22	18.79	.
	GTN (glyceryl trinitrate) NOS	12	0.019	0.01	0.93	0.78	4.17
	GTN (glyceryl trinitrate) Sublingual 400 mcg	4	0.006	0.00	0.31	0.26	1.39
	GTN (glyceryl trinitrate) Transdermal 5 mg	1	0.002	0.00	0.08	0.07	0.35
	Transiderm Nitro NOS	26	0.042	0.03	2.01	1.70	9.03
	Transiderm Nitro patch 5 mg	14	0.023	0.02	1.08	0.91	4.86
	Transiderm Nitro patch 10 mg	19	0.031	0.02	1.47	1.24	6.60
	Anginine NOS	6	0.010	0.01	0.46	0.39	2.08
	Anginine tablets 600 mcg	70	0.113	0.08	5.40	4.57	24.31
	Minitran NOS	1	0.002	0.00	0.08	0.07	0.35
	Minitran patch 10 mg	1	0.002	0.00	0.08	0.07	0.35
	Minitran patches 15 mg	1	0.002	0.00	0.08	0.07	0.35
	Nitrolingual spray sublingual 400 mcg	103	0.166	0.12	7.95	6.72	35.76
	Nitro-dur NOS	1	0.002	0.00	0.08	0.07	0.35
	Nitro-dur patches 5 mg	13	0.021	0.02	1.00	0.85	4.51
	Nitro-dur patches 10 mg	10	0.016	0.01	0.77	0.65	3.47
	Nitro-dur patches 15 mg	3	0.005	0.00	0.23	0.20	1.04
	Nitradisc NOS	1	0.002	0.00	0.08	0.07	0.35
	Nitradisc patches 5 mg	1	0.002	0.00	0.08	0.07	0.35
	Nitradisc patches 10 mg	1	0.002	0.00	0.08	0.07	0.35
Isosorbide dinitrate		229	0.369	0.28	17.67	14.94	.
	Isosorbide nitrate Tablets 60 mg	2	0.003	0.00	0.15	0.13	0.87
	Duride NOS	2	0.003	0.00	0.15	0.13	0.87
	Sorbidin tablets 10 mg	1	0.002	0.00	0.08	0.07	0.44
	Duride tablets 60 mg	15	0.024	0.02	1.16	0.98	6.55
	Imdur NOS	4	0.006	0.00	0.31	0.26	1.75
	Imdur tablets 60 mg	141	0.227	0.17	10.88	9.20	61.57
	Imdur tablets 120 mg	40	0.064	0.05	3.09	2.61	17.47
	Isordil NOS	1	0.002	0.00	0.08	0.07	0.44
	Isordil tablets 10 mg	11	0.018	0.01	0.85	0.72	4.80
	Isordil tablets sublingual 5 mg	11	0.018	0.01	0.85	0.72	4.80
	Imtrate tablets 60 mg	1	0.002	0.00	0.08	0.07	0.44

BEACH Survey Report - Analysis date: 21NOV08

Table 7.3: Medications (generic and products within each generic)- IHD in patients aged 45+ Apr00-Mar01

Generic	/product	n	% of total meds	per 100 total probs	per 100 IHD in patients aged 45+ probs	% of IHD in patients aged 45+ meds	% of generic
Aspirin		195	0.314	0.24	15.05	12.72	.
	Aspirin NOS	21	0.034	0.03	1.62	1.37	10.77
	Aspirin capsules 100 mg	1	0.002	0.00	0.08	0.07	0.51
	Aspirin capsules 300 mg	1	0.002	0.00	0.08	0.07	0.51
	Aspirin tablets 100 mg	16	0.026	0.02	1.23	1.04	8.21
	Aspirin tablets 300 mg	12	0.019	0.01	0.93	0.78	6.15
	Astrix NOS	7	0.011	0.01	0.54	0.46	3.59
	Astrix capsules 100 mg	51	0.082	0.06	3.94	3.33	26.15
	Astrix tablets 100 mg	6	0.010	0.01	0.46	0.39	3.08
	Cardiprin NOS	2	0.003	0.00	0.15	0.13	1.03
	Solprin NOS	3	0.005	0.00	0.23	0.20	1.54
	Disprin NOS	2	0.003	0.00	0.15	0.13	1.03
	Cardiprin tablets 100 mg	15	0.024	0.02	1.16	0.98	7.69
	Solprin tablets 300 mg	24	0.039	0.03	1.85	1.57	12.31
	Spren tablets 300 mg	2	0.003	0.00	0.15	0.13	1.03
	Cartia tablets 100 mg	32	0.052	0.04	2.47	2.09	16.41
Atenolol		93	0.150	0.11	7.18	6.07	.
	Atenolol NOS	2	0.003	0.00	0.15	0.13	2.15
	Atenolol Tablets 50 mg	22	0.035	0.03	1.70	1.44	23.66
	Noten NOS	2	0.003	0.00	0.15	0.13	2.15
	Noten tablets 50 mg	37	0.060	0.04	2.85	2.41	39.78
	Tenormin NOS	2	0.003	0.00	0.15	0.13	2.15
	Tenormin tablets 50 mg	28	0.045	0.03	2.16	1.83	30.11
Diltiazem anti-hypertensive		85	0.137	0.10	6.56	5.54	.
	Diltiazem anti-hypertensive NOS	1	0.002	0.00	0.08	0.07	1.18
	Diltiazem anti-hypertensive Capsules 180 mg	4	0.006	0.00	0.31	0.26	4.71
	Diltiazem anti-hypertensive Capsules 240 mg	4	0.006	0.00	0.31	0.26	4.71
	Cardizem cd anti-hypertensive capsules 180 mg	40	0.064	0.05	3.09	2.61	47.06
	Cardizem cd anti-hypertensive capsules 240 mg	34	0.055	0.04	2.62	2.22	40.00
	Vasocardol	2	0.003	0.00	0.15	0.13	2.35
Metoprolol		58	0.094	0.07	4.48	3.78	.
	Metoprolol NOS	1	0.002	0.00	0.08	0.07	1.72
	Metoprolol Tablets 50 mg	10	0.016	0.01	0.77	0.65	17.24
	Minax tablets 50 mg	1	0.002	0.00	0.08	0.07	1.72

BEACH Survey Report - Analysis date: 21NOV08

Table 7.3: Medications (generic and products within each generic)- IHD in patients aged 45+ Apr00-Mar01

Generic	/product	n	% of total meds	per 100 total probs	per 100 IHD in patients aged 45+ probs	% of IHD in patients aged 45+ meds	% of generic	
Simvastatin	Minax tablets 100 mg	1	0.002	0.00	0.08	0.07	1.72	
	Betaloc NOS	3	0.005	0.00	0.23	0.20	5.17	
	Betaloc tablets 50 mg	35	0.056	0.04	2.70	2.28	60.34	
	Betaloc tablets 100 mg	7	0.011	0.01	0.54	0.46	12.07	
			50	0.081	0.06	3.86	3.26	.
	Simvastatin Tablets 20 mg	1	0.002	0.00	0.08	0.07	2.00	
	Simvastatin Tablets 40 mg	2	0.003	0.00	0.15	0.13	4.00	
	Lipex tablets 5 mg	1	0.002	0.00	0.08	0.07	2.00	
	Lipex tablets 10 mg	9	0.015	0.01	0.69	0.59	18.00	
	Lipex tablets 20 mg	7	0.011	0.01	0.54	0.46	14.00	
Frusemide (Furosemide)	Lipex tablets 40 mg	2	0.003	0.00	0.15	0.13	4.00	
	Zocor tablets 5 mg	1	0.002	0.00	0.08	0.07	2.00	
	Zocor tablets 10 mg	9	0.015	0.01	0.69	0.59	18.00	
	Zocor tablets 20 mg	13	0.021	0.02	1.00	0.85	26.00	
	Zocor tablets 40 mg	4	0.006	0.00	0.31	0.26	8.00	
	Zocor tablets 80 mg	1	0.002	0.00	0.08	0.07	2.00	
			45	0.073	0.05	3.47	2.94	.
	Frusemide (Furosemide) Tablets 20 mg	2	0.003	0.00	0.15	0.13	4.44	
	Frusemide (Furosemide) Tablets 40 mg	6	0.010	0.01	0.46	0.39	13.33	
	Uremide tablets 40 mg	1	0.002	0.00	0.08	0.07	2.22	
Digoxin	Lasix NOS	1	0.002	0.00	0.08	0.07	2.22	
	Lasix tablets 40 mg	32	0.052	0.04	2.47	2.09	71.11	
	Lasix tablets 20 mg	2	0.003	0.00	0.15	0.13	4.44	
	Lasix high dose tablets 500 mg	1	0.002	0.00	0.08	0.07	2.22	
			35	0.056	0.04	2.70	2.28	.
Atorvastatin	Digoxin NOS	1	0.002	0.00	0.08	0.07	2.86	
	Digoxin Tablets 62.5 mcg	4	0.006	0.00	0.31	0.26	11.43	
	Digoxin Tablets 250 mcg	3	0.005	0.00	0.23	0.20	8.57	
	Lanoxin tablets 250 mcg	13	0.021	0.02	1.00	0.85	37.14	
	Lanoxin pg tablets 62.5 mcg	14	0.023	0.02	1.08	0.91	40.00	
Lipitor		34	0.055	0.04	2.62	2.22	.	
	Lipitor NOS	1	0.002	0.00	0.08	0.07	2.94	
	Lipitor tablets 10 mg	11	0.018	0.01	0.85	0.72	32.35	
	Lipitor tablets 20 mg	9	0.015	0.01	0.69	0.59	26.47	

BEACH Survey Report - Analysis date: 21NOV08

Table 7.3: Medications (generic and products within each generic)- IHD in patients aged 45+ Apr00-Mar01

Generic	/product	n	% of total meds	per 100 total probs	per 100 IHD in patients aged 45+ probs	% of IHD in patients aged 45+ meds	% of generic
Amlodipine	Lipitor tablets 40 mg	13	0.021	0.02	1.00	0.85	38.24
		29	0.047	0.03	2.24	1.89	.
	Amlodipine tablets 5 mg	1	0.002	0.00	0.08	0.07	3.45
	Amlodipine tablets 10 mg	1	0.002	0.00	0.08	0.07	3.45
	Norvasc tablets 5 mg	18	0.029	0.02	1.39	1.17	62.07
Warfarin sodium	Norvasc tablets 10 mg	9	0.015	0.01	0.69	0.59	31.03
		28	0.045	0.03	2.16	1.83	.
	Warfarin sodium NOS	4	0.006	0.00	0.31	0.26	14.29
	Warfarin sodium tablets 1 mg	4	0.006	0.00	0.31	0.26	14.29
	Warfarin sodium tablets 2 mg	10	0.016	0.01	0.77	0.65	35.71
	Warfarin sodium tablets 3 mg	5	0.008	0.01	0.39	0.33	17.86
	Warfarin sodium tablets 5 mg	4	0.006	0.00	0.31	0.26	14.29
Clopidogrel	Coumadin tablets 1 mg	1	0.002	0.00	0.08	0.07	3.57
		22	0.035	0.03	1.70	1.44	.
	Clopidogrel Tablets 75 mg	1	0.002	0.00	0.08	0.07	4.55
	Iscover tablets 75 mg	6	0.010	0.01	0.46	0.39	27.27
Diltiazem anti-angina	Plavix tablets 75 mg	15	0.024	0.02	1.16	0.98	68.18
		19	0.031	0.02	1.47	1.24	.
	Diltiazem anti-angina Tablets 60 mg	3	0.005	0.00	0.23	0.20	15.79
	Coras tablets 60 mg	1	0.002	0.00	0.08	0.07	5.26
	Cardizem anti-angina tablets 60 mg	15	0.024	0.02	1.16	0.98	78.95
Pravastatin		19	0.031	0.02	1.47	1.24	.
	Pravastatin Tablets 20 mg	1	0.002	0.00	0.08	0.07	5.26
	Pravachol tablets 10 mg	2	0.003	0.00	0.15	0.13	10.53
	Pravachol tablets 20 mg	6	0.010	0.01	0.46	0.39	31.58
	Pravachol tablets 40 mg	10	0.016	0.01	0.77	0.65	52.63
Isosorbide mononitrate		18	0.029	0.02	1.39	1.17	.
	Isosorbide mononitrate Tablets 60 mg	1	0.002	0.00	0.08	0.07	5.56
	Monodur tablets 60 mg	11	0.018	0.01	0.85	0.72	61.11
	Monodur tablets 120 mg	6	0.010	0.01	0.46	0.39	33.33
Nicorandil		17	0.027	0.02	1.31	1.11	.
	Nicorandil Tablets 10 mg	1	0.002	0.00	0.08	0.07	5.88
	Ikorel NOS	1	0.002	0.00	0.08	0.07	5.88
	Ikorel tablets 10 mg	12	0.019	0.01	0.93	0.78	70.59

BEACH Survey Report - Analysis date: 21NOV08

Table 7.3: Medications (generic and products within each generic)- IHD in patients aged 45+ Apr00-Mar01

Generic	/product	n	% of total meds	per 100 total probs	per 100 IHD in patients aged 45+ probs	% of IHD in patients aged 45+ meds	% of generic	
Enalapril mal	Ikorel tablets 20 mg	3	0.005	0.00	0.23	0.20	17.65	
		15	0.024	0.02	1.16	0.98	.	
	Enalapril mal NOS	3	0.005	0.00	0.23	0.20	20.00	
	Enalapril mal Tablets 20 mg	1	0.002	0.00	0.08	0.07	6.67	
	Amprace tablets 10 mg	1	0.002	0.00	0.08	0.07	6.67	
	Renitec NOS	5	0.008	0.01	0.39	0.33	33.33	
	Renitec tablets 5 mg	1	0.002	0.00	0.08	0.07	6.67	
	Renitec tablets 10 mg	2	0.003	0.00	0.15	0.13	13.33	
	Renitec tablets 20 mg	2	0.003	0.00	0.15	0.13	13.33	
Verapamil hydrochloride		15	0.024	0.02	1.16	0.98	.	
	Verapamil hydrochloride NOS	3	0.005	0.00	0.23	0.20	20.00	
	Verapamil hydrochloride tablets 40 mg	1	0.002	0.00	0.08	0.07	6.67	
	Anpec tablets SR 240 mg	1	0.002	0.00	0.08	0.07	6.67	
	Anpec tablets 80 mg	1	0.002	0.00	0.08	0.07	6.67	
	Isoptin oral tablets 40 mg	2	0.003	0.00	0.15	0.13	13.33	
	Isoptin tablets SR 180 mg	2	0.003	0.00	0.15	0.13	13.33	
	Isoptin oral tablets 80 mg	2	0.003	0.00	0.15	0.13	13.33	
	Isoptin tablets SR 240 mg	2	0.003	0.00	0.15	0.13	13.33	
	Veracaps capsules SR 240 mg	1	0.002	0.00	0.08	0.07	6.67	
		15	0.024	0.02	1.16	0.98	.	
	Perindopril	Perindopril Tablets 4 mg	2	0.003	0.00	0.15	0.13	13.33
		Coversyl tablets 2 mg	6	0.010	0.01	0.46	0.39	40.00
	Coversyl tablets 4 mg	7	0.011	0.01	0.54	0.46	46.67	
Lisinopril		15	0.024	0.02	1.16	0.98	.	
	Lisinopril Tablets 10 mg	1	0.002	0.00	0.08	0.07	6.67	
	Lisinopril Tablets 20 mg	1	0.002	0.00	0.08	0.07	6.67	
	Prinivil NOS	1	0.002	0.00	0.08	0.07	6.67	
	Prinivil tablets 5 mg	2	0.003	0.00	0.15	0.13	13.33	
	Prinivil tablets 10 mg	2	0.003	0.00	0.15	0.13	13.33	
	Prinivil tablets 20 mg	1	0.002	0.00	0.08	0.07	6.67	
	Zestril NOS	1	0.002	0.00	0.08	0.07	6.67	
	Zestril tablets 5 mg	3	0.005	0.00	0.23	0.20	20.00	
	Zestril tablets 10 mg	2	0.003	0.00	0.15	0.13	13.33	
	Zestril tablets 20 mg	1	0.002	0.00	0.08	0.07	6.67	

BEACH Survey Report - Analysis date: 21NOV08

Table 7.3: Medications (generic and products within each generic)- IHD in patients aged 45+ Apr00-Mar01

Generic	/product	n	% of total meds	per 100 total probs	per 100 IHD in patients aged 45+ probs	% of IHD in patients aged 45+ meds	% of generic
Ramipril		14	0.023	0.02	1.08	0.91	.
	Ramipril Tablets 1.25 mg	1	0.002	0.00	0.08	0.07	7.14
	Ramipril Tablets 2.5 mg	1	0.002	0.00	0.08	0.07	7.14
	Ramipril Tablets 5 mg	2	0.003	0.00	0.15	0.13	14.29
	Tritace tablets 2.5 mg	6	0.010	0.01	0.46	0.39	42.86
	Tritace tablets 5 mg	3	0.005	0.00	0.23	0.20	21.43
Captopril	Ramace tablets 5 mg	1	0.002	0.00	0.08	0.07	7.14
		13	0.021	0.02	1.00	0.85	.
	Captopril tablets 25 mg	1	0.002	0.00	0.08	0.07	7.69
	Acenorm tablets 50 mg	2	0.003	0.00	0.15	0.13	15.38
	Capoten tablets 12.5 mg	3	0.005	0.00	0.23	0.20	23.08
	Capoten tablets 25 mg	6	0.010	0.01	0.46	0.39	46.15
Nifedipine	Capoten tablets 50 mg	1	0.002	0.00	0.08	0.07	7.69
		13	0.021	0.02	1.00	0.85	.
	Adalat tablets 10 mg	1	0.002	0.00	0.08	0.07	7.69
	Adalat tablets 20 mg	1	0.002	0.00	0.08	0.07	7.69
	Adalat oros tablets 30 mg	8	0.013	0.01	0.62	0.52	61.54
	Adalat oros tablets 60 mg	3	0.005	0.00	0.23	0.20	23.08
Potassium chloride		10	0.016	0.01	0.77	0.65	.
	Slow-K tablets 600 mg	9	0.015	0.01	0.69	0.59	90.00
	Span-K tablets 600 mg	1	0.002	0.00	0.08	0.07	10.00
Irbesartan		9	0.015	0.01	0.69	0.59	.
	Avapro tablets 75 mg	2	0.003	0.00	0.15	0.13	22.22
	Avapro tablets 150 mg	3	0.005	0.00	0.23	0.20	33.33
	Avapro tablets 300 mg	3	0.005	0.00	0.23	0.20	33.33
Amiodarone hcl	Karvea tablets 300 mg	1	0.002	0.00	0.08	0.07	11.11
		9	0.015	0.01	0.69	0.59	.
	Amiodarone hcl tablets 100 mg	2	0.003	0.00	0.15	0.13	22.22
	Amiodarone hcl tablets 200 mg	4	0.006	0.00	0.31	0.26	44.44
	Aratac tablets 200 mg	1	0.002	0.00	0.08	0.07	11.11
Trandolapril	Cordarone x tablets 200 mg	2	0.003	0.00	0.15	0.13	22.22
		8	0.013	0.01	0.62	0.52	.
	Trandolapril NOS	1	0.002	0.00	0.08	0.07	12.50
	Gopten capsules 0.5 mg	1	0.002	0.00	0.08	0.07	12.50

BEACH Survey Report - Analysis date: 21NOV08

Table 7.3: Medications (generic and products within each generic)- IHD in patients aged 45+ Apr00-Mar01

Generic	/product	n	% of total meds	per 100 total probs	per 100 IHD in patients aged 45+ probs	% of IHD in patients aged 45+ meds	% of generic
Quinapril	Gopten capsules 1 mg	2	0.003	0.00	0.15	0.13	25.00
	Gopten capsules 2 mg	4	0.006	0.00	0.31	0.26	50.00
		7	0.011	0.01	0.54	0.46	.
	Accupril tablets 10 mg	2	0.003	0.00	0.15	0.13	28.57
	Accupril tablets 5 mg	1	0.002	0.00	0.08	0.07	14.29
	Asig NOS	1	0.002	0.00	0.08	0.07	14.29
	Asig tablets 5 mg	2	0.003	0.00	0.15	0.13	28.57
Sotalol	Asig tablets 10 mg	1	0.002	0.00	0.08	0.07	14.29
		7	0.011	0.01	0.54	0.46	.
	Sotalol NOS	1	0.002	0.00	0.08	0.07	14.29
	Sotalol Tablets 160 mg	2	0.003	0.00	0.15	0.13	28.57
	Sotalol Tablets 80 mg	1	0.002	0.00	0.08	0.07	14.29
	Sotacor tablets 160 mg	3	0.005	0.00	0.23	0.20	42.86
		7	0.011	0.01	0.54	0.46	.
Perhexiline	Perhexiline Tablets 100 mg	3	0.005	0.00	0.23	0.20	42.86
	Pexsig NOS	1	0.002	0.00	0.08	0.07	14.29
	Pexsig tablets 100 mg	3	0.005	0.00	0.23	0.20	42.86
		7	0.011	0.01	0.54	0.46	.
Gemfibrozil	Jezil tablets 600 mg	1	0.002	0.00	0.08	0.07	14.29
	Lopid tablets 600 mg	6	0.010	0.01	0.46	0.39	85.71
		7	0.011	0.01	0.54	0.46	.
Influenza virus vaccine	Fluvax injection 0.5 ml	7	0.011	0.01	0.54	0.46	100.00
		6	0.010	0.01	0.46	0.39	.
Felodipine	Felodipine Tablets 2.5 mg	1	0.002	0.00	0.08	0.07	16.67
	Plendil tablets 2.5 mg	1	0.002	0.00	0.08	0.07	16.67
	Plendil tablets 5 mg	2	0.003	0.00	0.15	0.13	33.33
	Plendil tablets 10 mg	2	0.003	0.00	0.15	0.13	33.33
		6	0.010	0.01	0.46	0.39	.
Morphine sulphate	Morphine sulphate NOS	5	0.008	0.01	0.39	0.33	83.33
	Kapanol capsules 20 mg	1	0.002	0.00	0.08	0.07	16.67
		5	0.008	0.01	0.39	0.33	.
Propranolol hydrochloride	Inderal NOS	1	0.002	0.00	0.08	0.07	20.00
	Inderal tablets 10 mg	2	0.003	0.00	0.15	0.13	40.00
	Inderal tablets 40 mg	1	0.002	0.00	0.08	0.07	20.00

BEACH Survey Report - Analysis date: 21NOV08

Table 7.3: Medications (generic and products within each generic)- IHD in patients aged 45+ Apr00-Mar01

Generic	/product	n	% of total meds	per 100 total probs	per 100 IHD in patients aged 45+ probs	% of IHD in patients aged 45+ meds	% of generic
Carvedilol	Inderal tablets 160 mg	1	.002	0	0.08	0.07	20.00
		4	.006	0	0.31	0.26	.
	Carvedilol tablets 6.25 mg	1	.002	0	0.08	0.07	25.00
	Carvedilol tablets 12.5 mg	1	.002	0	0.08	0.07	25.00
Temazepam	Dilatrend tablets 6.25 mg	2	.003	0	0.15	0.13	50.00
		4	.006	0	0.31	0.26	.
	Temazepam NOS	2	.003	0	0.15	0.13	50.00
	Temazepam Capsules 10 mg	1	.002	0	0.08	0.07	25.00
Indapamide	Euhypnos capsules 10 mg	1	.002	0	0.08	0.07	25.00
		3	.005	0	0.23	0.20	.
	Indapamide Tablets 2.5 mg	1	.002	0	0.08	0.07	33.33
	Dapa-tabs tablets 2.5 mg	1	.002	0	0.08	0.07	33.33
Fosinopril	Natrilix tablets 2.5 mg	1	.002	0	0.08	0.07	33.33
		3	.005	0	0.23	0.20	.
	Monopril NOS	1	.002	0	0.08	0.07	33.33
	Monopril tablets 20 mg	2	.003	0	0.15	0.13	66.67
Dipyridamole	Persantin sr capsules 200 mg	3	.005	0	0.23	0.20	100.00
Paracetamol		3	.005	0	0.23	0.20	.
	Panamax NOS	2	.003	0	0.15	0.13	66.67
	Panamax tablets 500 mg	1	.002	0	0.08	0.07	33.33
		3	.005	0	0.23	0.20	.
Metoclopramide	Maxolon NOS	1	.002	0	0.08	0.07	33.33
	Maxolon injection 10 mg 2 ml	2	.003	0	0.15	0.13	66.67
		3	.005	0	0.23	0.20	.
Diazepam	Valium tablets 5 mg	1	.002	0	0.08	0.07	33.33
	Ducene tablets 5 mg	2	.003	0	0.15	0.13	66.67
		3	.005	0	0.23	0.20	.
Oxazepam	Murelax NOS	1	.002	0	0.08	0.07	33.33
	Murelax tablets 30 mg	1	.002	0	0.08	0.07	33.33
	Serepax tablets 30 mg	1	.002	0	0.08	0.07	33.33
		3	.005	0	0.23	0.20	.
Thiazide + Amiloride	Moduretic tablets 55 mg	3	.005	0	0.23	0.20	100.00
Vitamin B12 (Cobalamin)		2	.003	0	0.15	0.13	.

BEACH Survey Report - Analysis date: 21NOV08

Table 7.3: Medications (generic and products within each generic)- IHD in patients aged 45+ Apr00-Mar01

Generic	/product	n	% of total meds	per 100 total probs	per 100 IHD in patients aged 45+ probs	% of IHD in patients aged 45+ meds	% of generic
Prazosin hydrochloride	Neocytagen injection 1 mg 1 ml	2	.003	0	0.15	0.13	100
		2	.003	0	0.15	0.13	.
Candesartan cilexetil	Minipress tablets 2 mg	2	.003	0	0.15	0.13	100
		2	.003	0	0.15	0.13	.
Dipyridamole/Aspirin	Atacand tablets 8 mg	1	.002	0	0.08	0.07	50
	Atacand tablets 16 mg	1	.002	0	0.08	0.07	50
Cerivastatin	Asasantin capsules 225 mg	2	.003	0	0.15	0.13	100
		2	.003	0	0.15	0.13	.
Prochlorperazine	Lipobay tablets 300 mcg	2	.003	0	0.15	0.13	100
		2	.003	0	0.15	0.13	.
Potassium bicarbonate	Prochlorperazine Injection 12.5 mg 1 ml	1	.002	0	0.08	0.07	50
	Stemetil tablets 5 mg	1	.002	0	0.08	0.07	50
Illegible	Chlorvescent	2	.003	0	0.15	0.13	100
		2	.003	0	0.15	0.13	.
Oxygen	Illegible	2	.003	0	0.15	0.13	100
		2	.003	0	0.15	0.13	.
Heparin	Oxygen	2	.003	0	0.15	0.13	100
		1	.002	0	0.08	0.07	.
Enoxaparin	Heparin NOS	1	.002	0	0.08	0.07	100
		1	.002	0	0.08	0.07	.
Cardiovascular system	Clexane NOS	1	.002	0	0.08	0.07	100
		1	.002	0	0.08	0.07	.
Hydralazine	Cardiovascular n/s	1	.002	0	0.08	0.07	100
		1	.002	0	0.08	0.07	.
Methyldopa	Hydralazine Tablets 25 mg	1	.002	0	0.08	0.07	100
		1	.002	0	0.08	0.07	.
Telmisartan	Aldomet NOS	1	.002	0	0.08	0.07	100
		1	.002	0	0.08	0.07	.
Perindopril/Indapamide	Pritor tablets 40 mg	1	.002	0	0.08	0.07	100
		1	.002	0	0.08	0.07	.
Antiangina	Coversyl Plus tablets 5.25 mg	1	.002	0	0.08	0.07	100

BEACH Survey Report - Analysis date: 21NOV08

Table 7.3: Medications (generic and products within each generic)- IHD in patients aged 45+ Apr00-Mar01

Generic	/product	n	% of total meds	per 100 total probs	per 100 IHD in patients aged 45+ probs	% of IHD in patients aged 45+ meds	% of generic
Fluvastatin	Anti angina drug	1	.002	0	0.08	0.07	100
		1	.002	0	0.08	0.07	.
Omeprazole	Vastin capsules 40 mg	1	.002	0	0.08	0.07	100
		1	.002	0	0.08	0.07	.
Lansoprazole	Losec tablets 20 mg	1	.002	0	0.08	0.07	100
		1	.002	0	0.08	0.07	.
Hypromellose	Zoton capsules 30 mg	1	.002	0	0.08	0.07	100
		1	.002	0	0.08	0.07	.
Betamethasone systemic	Isopto tears NOS	1	.002	0	0.08	0.07	100
		1	.002	0	0.08	0.07	.
Glipizide	Celestone chronodose injection 5.7 mg 1 ml	1	.002	0	0.08	0.07	100
		1	.002	0	0.08	0.07	.
Thyroxine	Minidiab tablets 5 mg	1	.002	0	0.08	0.07	100
		1	.002	0	0.08	0.07	.
Ibuprofen	Thyroxine Tablets 0.05 mg	1	.002	0	0.08	0.07	100
		1	.002	0	0.08	0.07	.
Allopurinol	Brufen tablets 400 mg	1	.002	0	0.08	0.07	100
		1	.002	0	0.08	0.07	.
Colchicine	Zyloprim tablets 100 mg	1	.002	0	0.08	0.07	100
		1	.002	0	0.08	0.07	.
Quinine sulphate/bisulphate	Colgout tablets 500 mcg	1	.002	0	0.08	0.07	100
		1	.002	0	0.08	0.07	.
Tramadol	Quinate tablets 300 mg	1	.002	0	0.08	0.07	100
		1	.002	0	0.08	0.07	.
Paracetamol/Codeine	Tramal capsules 50 mg	1	.002	0	0.08	0.07	100
		1	.002	0	0.08	0.07	.
Nitrazepam	Panadeine forte tablets 530 mg	1	.002	0	0.08	0.07	100
		1	.002	0	0.08	0.07	.
Fluvoxamine	Mogadon tablets 5 mg	1	.002	0	0.08	0.07	100
		1	.002	0	0.08	0.07	.
Salbutamol	Fluvoxamine Tablets 100 mg	1	.002	0	0.08	0.07	100
		1	.002	0	0.08	0.07	.
Terbutaline	Ventolin inhaler 100 mcg	1	.002	0	0.08	0.07	100
		1	.002	0	0.08	0.07	.

Table 7.3: Medications (generic and products within each generic)- IHD in patients aged 45+ Apr00-Mar01

Generic	/product	n	% of total meds	per 100 total probs	per 100 IHD in patients aged 45+ probs	% of IHD in patients aged 45+ meds	% of generic
Budesonide	Bricanyl NOS	1	.002	0	0.08	0.07	100
	Pulmicort NOS	1	.002	0	0.08	0.07	.
Calcium carbonate	Caltrate tablets 600 mg	1	.002	0	0.08	0.07	100
	Chlorothiazide	1	.002	0	0.08	0.07	.
Hydrochlorothiazide	Chlotride tablets 500 mg	1	.002	0	0.08	0.07	100
	Dichlotride tablets 50 mg	1	.002	0	0.08	0.07	.
Trianterene/Hydrochlorothiazide		1	.002	0	0.08	0.07	100
Spironolactone	Hydrene tablets 75 mg	1	.002	0	0.08	0.07	.
	Aldactone tablets 25 mg	1	.002	0	0.08	0.07	100

BEACH Survey Report - Analysis date: 21NOV08

Table 7.4: Prescribed daily dose - IHD in patients aged 45+ Apr00-Mar01

Generic label	n	Mean	Measure	Median	Measure	Minimum	Measure	Maximum	Measure
		PDD		PDD					
Isosorbide dinitrate	194	70.2	mg	60.0	mg	20.00	mg	240.00	mg
Aspirin	155	118.6	mg	100.0	mg	50.00	mg	300.00	mg
Atenolol	86	46.8	mg	50.0	mg	12.50	mg	100.00	mg
Diltiazem anti-hypertensive	75	209.6	mg	180.0	mg	180.00	mg	360.00	mg
Metoprolol	49	92.3	mg	100.0	mg	25.00	mg	600.00	mg
Simvastatin	45	20.9	mg	20.0	mg	5.00	mg	80.00	mg
Frusemide (Furosemide)	42	75.7	mg	40.0	mg	20.00	mg	750.00	mg
GTN (glyceryl trinitrate)	31	23.4	mg	10.0	mg	0.03	mg	200.00	mg
Digoxin	31	0.2	mg	0.2	mg	0.06	mg	0.75	mg
Atorvastatin	25	26.8	mg	20.0	mg	10.00	mg	60.00	mg
Amlodipine	23	6.3	mg	5.0	mg	2.50	mg	10.00	mg
Warfarin sodium	22	3.0	mg	3.0	mg	1.00	mg	5.00	mg
Clopidogrel	19	75.0	mg	75.0	mg	75.00	mg	75.00	mg
Pravastatin	18	30.0	mg	40.0	mg	10.00	mg	40.00	mg
Diltiazem anti-angina	17	162.4	mg	180.0	mg	60.00	mg	360.00	mg
Isosorbide mononitrate	17	77.6	mg	60.0	mg	30.00	mg	120.00	mg
Nicorandil	15	23.0	mg	20.0	mg	5.00	mg	40.00	mg
Enalapril mal	14	16.8	mg	15.0	mg	5.00	mg	40.00	mg
Perindopril	13	3.4	mg	4.0	mg	2.00	mg	8.00	mg
Ramipril	13	3.6	mg	2.5	mg	1.25	mg	5.00	mg
Captopril	12	61.5	mg	62.5	mg	25.00	mg	100.00	mg
Verapamil hydrochloride	12	200.0	mg	240.0	mg	80.00	mg	240.00	mg
Lisinopril	12	10.2	mg	10.0	mg	2.50	mg	20.00	mg
Nifedipine	10	38.0	mg	30.0	mg	20.00	mg	60.00	mg
Potassium chloride	10	1260.0	mg	1200.0	mg	600.00	mg	2400.00	mg
Amiodarone hcl	9	155.6	mg	200.0	mg	100.00	mg	200.00	mg
Irbesartan	8	206.3	mg	225.0	mg	75.00	mg	300.00	mg
Felodipine	6	5.8	mg	5.0	mg	2.50	mg	10.00	mg
Quinapril	6	7.5	mg	7.5	mg	5.00	mg	10.00	mg
Trandolapril	6	1.7	mg	2.0	mg	1.00	mg	2.00	mg
Gemfibrozil	6	1100.0	mg	1200.0	mg	600.00	mg	1200.00	mg
Sotalol	5	160.0	mg	160.0	mg	80.00	mg	320.00	mg
Perhexiline	5	180.0	mg	200.0	mg	100.00	mg	300.00	mg
Propranolol hydrochloride	4	70.0	mg	55.0	mg	20.00	mg	150.00	mg
Carvedilol	4	15.6	mg	12.5	mg	12.50	mg	25.00	mg
Temazepam	4	12.5	mg	10.0	mg	10.00	mg	20.00	mg

BEACH Survey Report - Analysis date: 21NOV08

Table 7.4: Prescribed daily dose - IHD in patients aged 45+ Apr00-Mar01

Generic label	n	Mean		Median		Minimum	Measure	Maximum	Measure
		PDD	Measure	PDD	Measure				
Indapamide	3	2.5	mg	2.5	mg	2.50	mg	2.50	mg
Fosinopril	3	15.0	mg	20.0	mg	5.00	mg	20.00	mg
Prazosin hydrochloride	2	3.0	mg	3.0	mg	2.00	mg	4.00	mg
Dipyridamole	2	300.0	mg	300.0	mg	200.00	mg	400.00	mg
Dipyridamole/Aspirin	2	450.0	mg	450.0	mg	450.00	mg	450.00	mg
Cerivastatin	2	0.3	mg	0.3	mg	0.30	mg	0.30	mg
Oxazepam	2	30.0	mg	30.0	mg	30.00	mg	30.00	mg
Thiazide + Amiloride	2	41.3	mg	41.3	mg	27.50	mg	55.00	mg
Cardiovascular system	1	25.0	mg	25.0	mg	25.00	mg	25.00	mg
Candesartan cilexetil	1	16.0	mg	16.0	mg	16.00	mg	16.00	mg
Telmisartan	1	40.0	mg	40.0	mg	40.00	mg	40.00	mg
Perindopril/Indapamide	1	5.3	mg	5.3	mg	5.25	mg	5.25	mg
Fluvastatin	1	40.0	mg	40.0	mg	40.00	mg	40.00	mg
Omeprazole	1	40.0	mg	40.0	mg	40.00	mg	40.00	mg
Lansoprazole	1	30.0	mg	30.0	mg	30.00	mg	30.00	mg
Hypromellose	1	30.0	mg	30.0	mg	30.00	mg	30.00	mg
Glipizide	1	5.0	mg	5.0	mg	5.00	mg	5.00	mg
Thyroxine	1	0.1	mg	0.1	mg	0.05	mg	0.05	mg
Ibuprofen	1	1200.0	mg	1200.0	mg	1200.00	mg	1200.00	mg
Allopurinol	1	200.0	mg	200.0	mg	200.00	mg	200.00	mg
Colchicine	1	1.0	mg	1.0	mg	1.00	mg	1.00	mg
Quinine sulphate/bisulphate	1	300.0	mg	300.0	mg	300.00	mg	300.00	mg
Morphine sulphate	1	20.0	mg	20.0	mg	20.00	mg	20.00	mg
Tramadol	1	50.0	mg	50.0	mg	50.00	mg	50.00	mg
Paracetamol/Codeine	1	1060.0	mg	1060.0	mg	1060.00	mg	1060.00	mg
Diazepam	1	5.0	mg	5.0	mg	5.00	mg	5.00	mg
Fluvoxamine	1	50.0	mg	50.0	mg	50.00	mg	50.00	mg
Calcium carbonate	1	600.0	mg	600.0	mg	600.00	mg	600.00	mg
Chlorothiazide	1	500.0	mg	500.0	mg	500.00	mg	500.00	mg
Hydrochlorothiazide	1	25.0	mg	25.0	mg	25.00	mg	25.00	mg
Trianterene/Hydrochlorothiazide	1	75.0	mg	75.0	mg	75.00	mg	75.00	mg
Spirolactone	1	25.0	mg	25.0	mg	25.00	mg	25.00	mg
Illegible	1	80.0	mg	80.0	mg	80.00	mg	80.00	mg

BEACH Survey Report - Analysis date: 21NOV08

Table 8.1: Frequency of medication provision - New IHD in patients aged 45+ Apr00-Mar01

Data	n	Per 100 new IHD in patients aged 45+	Lower 95% CI	Upper 95% CI	% of meds for new IHD in patients aged 45+ probs	Lower 95% CI	Upper 95% CI
Medications	146	124.79	104.1	145.5	100.00	100.0	100.0
- Prescribed	135	115.38	95.0	135.8	92.47	85.9	99.0
- GP supplied	9	7.69	0.4	15.0	6.16	0.4	11.9
- Advised OTC	2	1.71	.	.	1.37	.	.

BEACH Survey Report - Analysis date: 21NOV08

Table 8.2.1: Top 30 medications prescribed (grouped by 4 digit ATC code) - New IHD in patients aged 45+ Apr00-Mar01

ATC label	ATC 4 digit code	n	Per 100 new IHD in patients aged 45+ probs		% of prescribed meds for new IHD in patients aged 45+		Lower 95% CI	Upper 95% CI
			Lower 95% CI	Upper 95% CI	Lower 95% CI	Upper 95% CI		
VASODILATORS USED IN CARDIAC DISEASES	C01D	78	66.67	54.1	79.3	57.78	48.7	66.9
OTHER ANALGESICS AND ANTIPYRETICS	N02B	19	16.24	9.2	23.2	14.07	8.5	19.6
BETA BLOCKING AGENTS	C07A	13	11.11	5.3	16.9	9.63	5.2	14.1
ANTITHROMBOTIC AGENTS	B01A	5	4.27	0.6	8.0	3.70	0.6	6.8
SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS	C08D	5	4.27	0.5	8.0	3.70	0.6	6.8
ACE INHIBITORS, PLAIN	C09A	3	2.56	0.0	5.5	2.22	0.0	4.7
LIPID MODIFYING AGENTS, PLAIN	C10A	3	2.56	0.0	5.4	2.22	0.0	4.7
PROPULSIVES	A03F	1	0.85	.	.	0.74	.	.
CARDIAC GLYCOSIDES	C01A	1	0.85	.	.	0.74	.	.
HIGH-CEILING DIURETICS	C03C	1	0.85	.	.	0.74	.	.
SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS	C08C	1	0.85	.	.	0.74	.	.
ACE INHIBITORS, COMBINATIONS	C09B	1	0.85	.	.	0.74	.	.
CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN	H02A	1	0.85	.	.	0.74	.	.
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS	M01A	1	0.85	.	.	0.74	.	.
OPIOIDS	N02A	1	0.85	.	.	0.74	.	.
ADRENERGICS, INHALANTS	R03A	1	0.85	.	.	0.74	.	.
Subtotal		135	.	.	.	100.00	.	.
Other Meds		0	.	.	.	0.00	.	.
Total Meds		135	115.38	95.0	135.8	100.00	.	.

Note: Some medications were recorded with insufficient specificity to be coded at 4 digit ATC level, but could be coded at 1, or 3 digit ATC level. Also some medications were mapped to 1 or 3 digit ATC codes, because there was not an appropriate 4 digit or ATC code available at the time.

Table 8.2.2: Top 30 medications prescribed (grouped by 5 digit ATC code) - New IHD in patients aged 45+ Apr00-Mar01

ATC label	ATC 5 digit code	n	Per 100 new IHD in patients aged 45+			% of prescribed meds for new IHD in patients aged 45+		
			probs	Lower 95% CI	Upper 95% CI	patients aged 45+	Lower 95% CI	Upper 95% CI
Organic nitrates	C01DA	75	64.10	51.6	76.6	55.56	46.2	64.9
Salicylic acid and derivatives	N02BA	17	14.53	7.8	21.3	12.59	7.1	18.1
Beta blocking agents, selective	C07AB	13	11.11	5.3	16.9	9.63	5.2	14.1
Benzothiazepine derivatives	C08DB	5	4.27	0.5	8.0	3.70	0.6	6.8
Platelet aggregation inhibitors excl. heparin	B01AC	4	3.42	0.1	6.7	2.96	0.1	5.8
ACE inhibitors, plain	C09AA	3	2.56	0.0	5.5	2.22	0.0	4.7
HMG CoA reductase inhibitors	C10AA	3	2.56	0.0	5.4	2.22	0.0	4.7
Other vasodilators used in cardiac diseases	C01DX	2	1.71	.	.	1.48	.	.
Anilides	N02BE	2	1.71	.	.	1.48	.	.
Propulsives	A03FA	1	0.85	.	.	0.74	.	.
Heparin group	B01AB	1	0.85	.	.	0.74	.	.
Digitalis glycosides	C01AA	1	0.85	.	.	0.74	.	.
VASODILATORS USED IN CARDIAC DISEASES	C01D	1	0.85	.	.	0.74	.	.
Sulfonamides, plain	C03CA	1	0.85	.	.	0.74	.	.
Dihydropyridine derivatives	C08CA	1	0.85	.	.	0.74	.	.
ACE inhibitors and diuretics	C09BA	1	0.85	.	.	0.74	.	.
Glucocorticoids	H02AB	1	0.85	.	.	0.74	.	.
Propionic acid derivatives	M01AE	1	0.85	.	.	0.74	.	.
Natural opium alkaloids	N02AA	1	0.85	.	.	0.74	.	.
Selective beta-2-adrenoreceptor agonists	R03AC	1	0.85	.	.	0.74	.	.
Subtotal		135	.	.	.	100.00	.	.
Other Meds		0	.	.	.	0.00	.	.
Total Meds		135	115.38	95.0	135.8	100.00	.	.

Note: Some medications were recorded with insufficient specificity to be coded at 5 digit ATC level, but could be coded at 1, 3 or 4 digit ATC level. Also some medications were mapped to 1, 3 or 4 digit ATC codes, because there was not an appropriate 5 digit or ATC code available at the time.

BEACH Survey Report - Analysis date: 21NOV08

Table 8.2.3.1: Top 60 medications prescribed (grouped by brand) in alphabetic order  
 -New IHD in patients aged 45+ Apr00-Mar01

brand	n	% of prescribed meds for new IHD in patients aged 45+	per 100 new IHD in patients aged 45+	% of total prescribed meds	per 100 total problems
Anginine	16	11.85	13.68	0.03	0.02
Anti angina drug	1	0.74	0.85	0.00	0.00
Aspirin	9	6.67	7.69	0.02	0.01
Astrix	4	2.96	3.42	0.01	0.00
Atenolol	1	0.74	0.85	0.00	0.00
Betaloc	4	2.96	3.42	0.01	0.00
Brufen	1	0.74	0.85	0.00	0.00
Cardiprin	1	0.74	0.85	0.00	0.00
Cardizem cd anti-hypertensive	3	2.22	2.56	0.01	0.00
Cartia	1	0.74	0.85	0.00	0.00
Celestone chronodose	1	0.74	0.85	0.00	0.00
Coversyl	1	0.74	0.85	0.00	0.00
Coversyl Plus	1	0.74	0.85	0.00	0.00
Digoxin	1	0.74	0.85	0.00	0.00
Diltiazem anti-angina	1	0.74	0.85	0.00	0.00
GTN (glyceryl trinitrate)	5	3.70	4.27	0.01	0.01
Gopten	1	0.74	0.85	0.00	0.00
Heparin	1	0.74	0.85	0.00	0.00
Ikorel	2	1.48	1.71	0.00	0.00
Imdur	14	10.37	11.97	0.03	0.02
Imtrate	1	0.74	0.85	0.00	0.00
Isordil	6	4.44	5.13	0.01	0.01
Isosorbide mononitrate	1	0.74	0.85	0.00	0.00
Lasix	1	0.74	0.85	0.00	0.00
Lipex	1	0.74	0.85	0.00	0.00
Maxolon	1	0.74	0.85	0.00	0.00
Metoprolol	4	2.96	3.42	0.01	0.00
Minitran	1	0.74	0.85	0.00	0.00
Morphine sulphate	1	0.74	0.85	0.00	0.00
Nitro-dur	3	2.22	2.56	0.01	0.00
Nitrolingual	23	17.04	19.66	0.04	0.03

BEACH Survey Report - Analysis date: 21NOV08

Table 8.2.3.1: Top 60 medications prescribed (grouped by brand) in alphabetic order  
 -New IHD in patients aged 45+ Apr00-Mar01

brand	n	% of prescribed meds for new IHD in patients aged 45+	per 100 new IHD in patients aged 45+	% of total prescribed meds	per 100 total problems
Norvasc	1	0.74	0.85	0.00	0.00
Noten	4	2.96	3.42	0.01	0.00
Panadeine forte	1	0.74	0.85	0.00	0.00
Panamax	1	0.74	0.85	0.00	0.00
Plavix	4	2.96	3.42	0.01	0.00
Pravachol	1	0.74	0.85	0.00	0.00
Ramipril	1	0.74	0.85	0.00	0.00
Solprin	2	1.48	1.71	0.00	0.00
Transiderm Nitro	5	3.70	4.27	0.01	0.01
Vasocardol	1	0.74	0.85	0.00	0.00
Ventolin	1	0.74	0.85	0.00	0.00
Zocor	1	0.74	0.85	0.00	0.00
.	.	.	.	.	.
Subtotal	135	100.00	115.38	0.24	0.16
.	.	.	.	.	.
Other Meds	0	0.00	0.00	0.00	0.00
.	.	.	.	.	.
Total Meds	135	100.00	115.38	0.24	0.16

BEACH Survey Report - Analysis date: 21NOV08

Table 8.2.3.2: Top 60 medications prescribed (grouped by brand) in frequency descending order  
 -New IHD in patients aged 45+ Apr00-Mar01

brand	n	% of prescribed meds for new IHD in patients aged 45+ probs	per 100 new IHD in patients aged 45+ probs	% of total prescribed meds	per 100 total probs
Nitrolingual	23	17.04	19.66	0.04	0.03
Anginine	16	11.85	13.68	0.03	0.02
Imdur	14	10.37	11.97	0.03	0.02
Aspirin	9	6.67	7.69	0.02	0.01
Isordil	6	4.44	5.13	0.01	0.01
GTN (glyceryl trinitrate)	5	3.70	4.27	0.01	0.01
Transiderm Nitro	5	3.70	4.27	0.01	0.01
Astrix	4	2.96	3.42	0.01	0.00
Betaloc	4	2.96	3.42	0.01	0.00
Metoprolol	4	2.96	3.42	0.01	0.00
Noten	4	2.96	3.42	0.01	0.00
Plavix	4	2.96	3.42	0.01	0.00
Cardizem cd anti-hypertensive	3	2.22	2.56	0.01	0.00
Nitro-dur	3	2.22	2.56	0.01	0.00
Ikorel	2	1.48	1.71	0.00	0.00
Solprin	2	1.48	1.71	0.00	0.00
Anti angina drug	1	0.74	0.85	0.00	0.00
Atenolol	1	0.74	0.85	0.00	0.00
Brufen	1	0.74	0.85	0.00	0.00
Cardiprin	1	0.74	0.85	0.00	0.00
Cartia	1	0.74	0.85	0.00	0.00
Celestone chronodose	1	0.74	0.85	0.00	0.00
Coversyl	1	0.74	0.85	0.00	0.00
Coversyl Plus	1	0.74	0.85	0.00	0.00
Digoxin	1	0.74	0.85	0.00	0.00
Diltiazem anti-angina	1	0.74	0.85	0.00	0.00
Gopten	1	0.74	0.85	0.00	0.00
Heparin	1	0.74	0.85	0.00	0.00
Imtrate	1	0.74	0.85	0.00	0.00
Isosorbide mononitrate	1	0.74	0.85	0.00	0.00

BEACH Survey Report - Analysis date: 21NOV08

Table 8.2.3.2: Top 60 medications prescribed (grouped by brand) in frequency descending order  
 -New IHD in patients aged 45+ Apr00-Mar01

brand	n	% of prescribed meds for new IHD in patients aged 45+ probs	per 100 new IHD in patients aged 45+ probs	% of total prescribed meds	per 100 total probs
Lasix	1	0.74	0.85	0.00	0.00
Lipex	1	0.74	0.85	0.00	0.00
Maxolon	1	0.74	0.85	0.00	0.00
Minitran	1	0.74	0.85	0.00	0.00
Morphine sulphate	1	0.74	0.85	0.00	0.00
Norvasc	1	0.74	0.85	0.00	0.00
Panadeine forte	1	0.74	0.85	0.00	0.00
Panamax	1	0.74	0.85	0.00	0.00
Pravachol	1	0.74	0.85	0.00	0.00
Ramipril	1	0.74	0.85	0.00	0.00
Vasocardol	1	0.74	0.85	0.00	0.00
Ventolin	1	0.74	0.85	0.00	0.00
Zocor	1	0.74	0.85	0.00	0.00
.	.	.	.	.	.
Subtotal	135	100.00	115.38	0.24	0.16
.	.	.	.	.	.
Other Meds	0	0.00	0.00	0.00	0.00
.	.	.	.	.	.
Total Meds	135	100.00	115.38	0.24	0.16

BEACH Survey Report - Analysis date: 21NOV08

Table 8.2.4: Prescribed medications (generic and products within each generic)  
 - New IHD in patients aged 45+ Apr00-Mar01

Generic	/product	n	% of total prescribed meds	Per 100 total probs	% of prescribed meds for new IHD in patients aged 45+ probs	% of generic
Total prescribed IHD in patients aged 45+ medications		135	0.243	0.163	.	.
GTN (glyceryl trinitrate)		53	0.095	0.064	39.26	.
	GTN (glyceryl trinitrate) NOS	2	0.004	0.002	1.48	3.77
	GTN (glyceryl trinitrate) Sublingual 400 mcg	3	0.005	0.004	2.22	5.66
	Transiderm Nitro NOS	1	0.002	0.001	0.74	1.89
	Transiderm Nitro patch 5 mg	1	0.002	0.001	0.74	1.89
	Transiderm Nitro patch 10 mg	3	0.005	0.004	2.22	5.66
	Anginine NOS	3	0.005	0.004	2.22	5.66
	Anginine tablets 600 mcg	13	0.023	0.016	9.63	24.53
	Minitran patch 10 mg	1	0.002	0.001	0.74	1.89
	Nitrolingual spray sublingual 400 mcg	23	0.041	0.028	17.04	43.40
	Nitro-dur patches 5 mg	2	0.004	0.002	1.48	3.77
	Nitro-dur patches 10 mg	1	0.002	0.001	0.74	1.89
Isosorbide dinitrate		21	0.038	0.025	15.56	.
	Imdur NOS	1	0.002	0.001	0.74	4.76
	Imdur tablets 60 mg	11	0.020	0.013	8.15	52.38
	Imdur tablets 120 mg	2	0.004	0.002	1.48	9.52
	Isordil tablets 10 mg	4	0.007	0.005	2.96	19.05
	Isordil tablets sublingual 5 mg	2	0.004	0.002	1.48	9.52
	Imtrate tablets 60 mg	1	0.002	0.001	0.74	4.76
Aspirin		17	0.031	0.021	12.59	.
	Aspirin NOS	5	0.009	0.006	3.70	29.41
	Aspirin tablets 100 mg	2	0.004	0.002	1.48	11.76
	Aspirin tablets 300 mg	2	0.004	0.002	1.48	11.76
	Astrix capsules 100 mg	4	0.007	0.005	2.96	23.53
	Cardiprin tablets 100 mg	1	0.002	0.001	0.74	5.88
	Solprin tablets 300 mg	2	0.004	0.002	1.48	11.76
	Cartia tablets 100 mg	1	0.002	0.001	0.74	5.88
Metoprolol		8	0.014	0.010	5.93	.

BEACH Survey Report - Analysis date: 21NOV08

Table 8.2.4: Prescribed medications (generic and products within each generic)  
 - New IHD in patients aged 45+ Apr00-Mar01

Generic	/product	n	% of total prescribed meds	Per 100 total probs	% of prescribed meds for new IHD in patients aged 45+ probs	% of generic
Atenolol	Metoprolol Tablets 50 mg	4	.007	.005	2.96	50.0
	Betaloc tablets 50 mg	3	.005	.004	2.22	37.5
	Betaloc tablets 100 mg	1	.002	.001	0.74	12.5
	Atenolol Tablets 50 mg	5	.009	.006	3.70	.
	Noten NOS	1	.002	.001	0.74	20.0
	Noten tablets 50 mg	3	.005	.004	2.22	60.0
Clopidogrel	Plavix tablets 75 mg	4	.007	.005	2.96	.
	Diltiazem anti-hypertensive	4	.007	.005	2.96	100.0
Diltiazem anti-hypertensive	Cardizem cd anti-hypertensive capsules 180 mg	2	.004	.002	1.48	50.0
	Cardizem cd anti-hypertensive capsules 240 mg	1	.002	.001	0.74	25.0
	Vasocardol	1	.002	.001	0.74	25.0
Nicorandil	Ikorel NOS	2	.004	.002	1.48	.
	Ikorel tablets 20 mg	1	.002	.001	0.74	50.0
Simvastatin	Lipex tablets 20 mg	2	.004	.002	1.48	.
	Zocor tablets 20 mg	1	.002	.001	0.74	50.0
	Heparin	1	.002	.001	0.74	50.0
Heparin	Heparin NOS	1	.002	.001	0.74	.
	Perindopril	1	.002	.001	0.74	100.0
Perindopril	Coversyl tablets 2 mg	1	.002	.001	0.74	.
	Ramipril	1	.002	.001	0.74	100.0
Ramipril	Ramipril Tablets 5 mg	1	.002	.001	0.74	.
	Amlodipine	1	.002	.001	0.74	100.0
Amlodipine	Norvasc tablets 5 mg	1	.002	.001	0.74	.
	Trandolapril	1	.002	.001	0.74	100.0
Trandolapril	Gopten capsules 1 mg	1	.002	.001	0.74	.
	Perindopril/Indapamide	1	.002	.001	0.74	100.0

BEACH Survey Report - Analysis date: 21NOV08

Table 8.2.4: Prescribed medications (generic and products within each generic)  
 - New IHD in patients aged 45+ Apr00-Mar01

Generic	/product	n	% of total prescribed meds	Per 100 total probs	% of prescribed meds for new IHD in patients aged 45+ probs	% of generic
Antiangina	Coversyl Plus tablets 5.25 mg	1	.002	.001	0.74	100
	Anti angina drug	1	.002	.001	0.74	.
Diltiazem anti-angina	Diltiazem anti-angina Tablets 60 mg	1	.002	.001	0.74	100
	Isosorbide mononitrate	1	.002	.001	0.74	.
Digoxin	Digoxin Tablets 62.5 mcg	1	.002	.001	0.74	100
	Pravastatin	1	.002	.001	0.74	.
Betamethasone systemic	Pravachol tablets 20 mg	1	.002	.001	0.74	100
	Celestone chronodose injection 5.7 mg 1 ml	1	.002	.001	0.74	.
Ibuprofen	Brufen tablets 400 mg	1	.002	.001	0.74	100
	Paracetamol	1	.002	.001	0.74	.
Morphine sulphate	Panamax NOS	1	.002	.001	0.74	100
	Morphine sulphate NOS	1	.002	.001	0.74	.
Paracetamol/Codeine	Panadeine forte tablets 530 mg	1	.002	.001	0.74	100
	Metoclopramide	1	.002	.001	0.74	.
Salbutamol	Maxolon injection 10 mg 2 ml	1	.002	.001	0.74	100
	Ventolin inhaler 100 mcg	1	.002	.001	0.74	.
Frusemide (Furosemide)	Lasix tablets 40 mg	1	.002	.001	0.74	100

BEACH Survey Report - Analysis date: 21NOV08

Table 8.3: Medications (generic and products within each generic)  
 - New IHD in patients aged 45+ Apr00-Mar01

Generic	/product	n	% of total meds	Per 100 total probs	% of meds for new IHD in patients aged 45+	% of generic
Total IHD in patients aged 45+ medications		146	0.235	0.176	.	.
GTN (glyceryl trinitrate)		55	0.089	0.066	37.67	.
	GTN (glyceryl trinitrate) NOS	2	0.003	0.002	1.37	3.64
	GTN (glyceryl trinitrate) Sublingual 400 mcg	3	0.005	0.004	2.05	5.45
	Transiderm Nitro NOS	2	0.003	0.002	1.37	3.64
	Transiderm Nitro patch 5 mg	1	0.002	0.001	0.68	1.82
	Transiderm Nitro patch 10 mg	3	0.005	0.004	2.05	5.45
	Anginine NOS	3	0.005	0.004	2.05	5.45
	Anginine tablets 600 mcg	14	0.023	0.017	9.59	25.45
	Minitran patch 10 mg	1	0.002	0.001	0.68	1.82
	Nitrolingual spray sublingual 400 mcg	23	0.037	0.028	15.75	41.82
	Nitro-dur patches 5 mg	2	0.003	0.002	1.37	3.64
	Nitro-dur patches 10 mg	1	0.002	0.001	0.68	1.82
Isosorbide dinitrate		22	0.035	0.027	15.07	.
	Imdur NOS	1	0.002	0.001	0.68	4.55
	Imdur tablets 60 mg	11	0.018	0.013	7.53	50.00
	Imdur tablets 120 mg	2	0.003	0.002	1.37	9.09
	Isordil tablets 10 mg	4	0.006	0.005	2.74	18.18
	Isordil tablets sublingual 5 mg	3	0.005	0.004	2.05	13.64
	Imtrate tablets 60 mg	1	0.002	0.001	0.68	4.55
Aspirin		22	0.035	0.027	15.07	.
	Aspirin NOS	7	0.011	0.008	4.79	31.82
	Aspirin tablets 100 mg	2	0.003	0.002	1.37	9.09
	Aspirin tablets 300 mg	3	0.005	0.004	2.05	13.64
	Astrix capsules 100 mg	4	0.006	0.005	2.74	18.18
	Cardiprin tablets 100 mg	1	0.002	0.001	0.68	4.55
	Solprin tablets 300 mg	3	0.005	0.004	2.05	13.64
	Cartia tablets 100 mg	2	0.003	0.002	1.37	9.09
Metoprolol		8	0.013	0.010	5.48	.
	Metoprolol Tablets 50 mg	4	0.006	0.005	2.74	50.00
	Betaloc tablets 50 mg	3	0.005	0.004	2.05	37.50
	Betaloc tablets 100 mg	1	0.002	0.001	0.68	12.50

BEACH Survey Report - Analysis date: 21NOV08

Table 8.3: Medications (generic and products within each generic)  
 - New IHD in patients aged 45+ Apr00-Mar01

Generic	/product	n	% of total meds	Per 100 total probs	% of meds for new IHD in patients aged 45+	% of generic
Atenolol		5	.008	.006	3.42	.
	Atenolol Tablets 50 mg	1	.002	.001	0.68	20.00
	Noten NOS	1	.002	.001	0.68	20.00
Clopidogrel	Noten tablets 50 mg	3	.005	.004	2.05	60.00
	Plavix tablets 75 mg	4	.006	.005	2.74	.
Diltiazem anti-hypertensive		4	.006	.005	2.74	.
	Cardizem cd anti-hypertensive capsules 180 mg	2	.003	.002	1.37	50.00
	Cardizem cd anti-hypertensive capsules 240 mg	1	.002	.001	0.68	25.00
	Vasocardol	1	.002	.001	0.68	25.00
Simvastatin		3	.005	.004	2.05	.
	Simvastatin Tablets 20 mg	1	.002	.001	0.68	33.33
	Lipex tablets 20 mg	1	.002	.001	0.68	33.33
Amlodipine	Zocor tablets 20 mg	1	.002	.001	0.68	33.33
		2	.003	.002	1.37	.
	Amlodipine tablets 5 mg	1	.002	.001	0.68	50.00
Trandolapril	Norvasc tablets 5 mg	1	.002	.001	0.68	50.00
		2	.003	.002	1.37	.
Nicorandil	Trandolapril NOS	1	.002	.001	0.68	50.00
	Gopten capsules 1 mg	1	.002	.001	0.68	50.00
		2	.003	.002	1.37	.
Heparin	Ikorel NOS	1	.002	.001	0.68	50.00
	Ikorel tablets 20 mg	1	.002	.001	0.68	50.00
Perindopril	Heparin NOS	1	.002	.001	0.68	100.00
		1	.002	.001	0.68	.
Ramipril	Coversyl tablets 2 mg	1	.002	.001	0.68	100.00
		1	.002	.001	0.68	.
Perindopril/Indapamide	Ramipril Tablets 5 mg	1	.002	.001	0.68	100.00
		1	.002	.001	0.68	.
Antiangina	Coversyl Plus tablets 5.25 mg	1	.002	.001	0.68	100.00
	Anti angina drug	1	.002	.001	0.68	.

BEACH Survey Report - Analysis date: 21NOV08

Table 8.3: Medications (generic and products within each generic)  
 - New IHD in patients aged 45+ Apr00-Mar01

Generic	/product	n	% of total meds	Per 100 total probs	% of meds for new IHD in patients aged 45+	% of generic
Diltiazem anti-angina		1	.002	.001	0.68	.
	Diltiazem anti-angina Tablets 60 mg	1	.002	.001	0.68	100
Isosorbide mononitrate		1	.002	.001	0.68	.
	Isosorbide mononitrate Tablets 60 mg	1	.002	.001	0.68	100
Digoxin		1	.002	.001	0.68	.
	Digoxin Tablets 62.5 mcg	1	.002	.001	0.68	100
Pravastatin		1	.002	.001	0.68	.
	Pravachol tablets 20 mg	1	.002	.001	0.68	100
Betamethasone systemic		1	.002	.001	0.68	.
	Celestone chronodose injection 5.7 mg 1 ml	1	.002	.001	0.68	100
Ibuprofen		1	.002	.001	0.68	.
	Brufen tablets 400 mg	1	.002	.001	0.68	100
Paracetamol		1	.002	.001	0.68	.
	Panamax NOS	1	.002	.001	0.68	100
Morphine sulphate		1	.002	.001	0.68	.
	Morphine sulphate NOS	1	.002	.001	0.68	100
Paracetamol/Codeine		1	.002	.001	0.68	.
	Panadeine forte tablets 530 mg	1	.002	.001	0.68	100
Metoclopramide		1	.002	.001	0.68	.
	Maxolon injection 10 mg 2 ml	1	.002	.001	0.68	100
Salbutamol		1	.002	.001	0.68	.
	Ventolin inhaler 100 mcg	1	.002	.001	0.68	100
Frusemide (Furosemide)		1	.002	.001	0.68	.
	Lasix tablets 40 mg	1	.002	.001	0.68	100

BEACH Survey Report - Analysis date: 21NOV08

Table 8.4.1: Prescribed daily dose (generic level) - New IHD in patients aged 45+

Generic label	n	Mean	Median		Minimum	Measure	Maximum	Measure	
		PDD	PDD	Measure					
Isosorbide dinitrate	17	63.5	mg	60.0	mg	30.00	mg	180.00	mg
Aspirin	15	120.0	mg	100.0	mg	100.00	mg	150.00	mg
Metoprolol	7	64.3	mg	50.0	mg	50.00	mg	100.00	mg
Atenolol	5	40.0	mg	50.0	mg	25.00	mg	50.00	mg
Clopidogrel	4	75.0	mg	75.0	mg	75.00	mg	75.00	mg
Diltiazem anti-hypertensive	4	240.0	mg	210.0	mg	180.00	mg	360.00	mg
GTN (glyceryl trinitrate)	4	16.5	mg	7.5	mg	0.80	mg	50.00	mg
Nicorandil	2	25.0	mg	25.0	mg	10.00	mg	40.00	mg
Simvastatin	2	20.0	mg	20.0	mg	20.00	mg	20.00	mg
Perindopril	1	2.0	mg	2.0	mg	2.00	mg	2.00	mg
Ramipril	1	5.0	mg	5.0	mg	5.00	mg	5.00	mg
Amlodipine	1	5.0	mg	5.0	mg	5.00	mg	5.00	mg
Trandolapril	1	1.0	mg	1.0	mg	1.00	mg	1.00	mg
Perindopril/Indapamide	1	5.3	mg	5.3	mg	5.25	mg	5.25	mg
Isosorbide mononitrate	1	60.0	mg	60.0	mg	60.00	mg	60.00	mg
Digoxin	1	0.1	mg	0.1	mg	0.13	mg	0.13	mg
Pravastatin	1	20.0	mg	20.0	mg	20.00	mg	20.00	mg
Ibuprofen	1	1200.0	mg	1200.0	mg	1200.00	mg	1200.00	mg
Paracetamol/Codeine	1	1060.0	mg	1060.0	mg	1060.00	mg	1060.00	mg
Furosemide (Furosemide)	1	40.0	mg	40.0	mg	40.00	mg	40.00	mg

Table 9.1.1: Top 10 Clinical treatments - IHD in patients aged 45+ Apr00-Mar01

Clinical treatments	n	% of total Clinical treatments for all IHD in patients aged 45+			Per 100 IHD in patients aged 45+		
		probs	Lower 95% CI	Upper 95% CI	problems	Lower 95% CI	Upper 95% CI
Advice/education - medication*	32	16.84	11.5	22.2	2.47	1.6	3.3
Counselling - problem*	30	15.79	9.2	22.4	2.31	1.3	3.4
Advice/education*	28	14.74	9.6	19.9	2.16	1.3	3.0
Counsel/advice - exercise*	20	10.53	6.0	15.1	1.54	0.8	2.3
Counsel/advice - nutrition/weight*	20	10.53	6.0	15.0	1.54	0.8	2.3
Counsel/advice - smoking*	16	8.42	3.7	13.1	1.23	0.5	1.9
Reassurance, support	13	6.84	0.1	13.6	1.00	0.0	2.0
Other admin/document*	13	6.84	2.8	10.8	1.00	0.4	1.6
Advice/education - treatment*	10	5.26	1.8	8.7	0.77	0.3	1.3
Counsel/advice - life style*	5	2.63	0.3	4.9	0.39	0.0	0.7
.	.	.	.	.	.	.	.
Subtotal	187	98.42	.	.	.	.	.
.	.	.	.	.	.	.	.
Other Clinical treatments	3	1.58	.	.	.	.	.
.	.	.	.	.	.	.	.
Total Clinical treatments	190	100.00	.	.	14.66	11.9	17.4

Table 9.1.2: Top 10 Procedural treatments - IHD in patients aged 45+ Apr00-Mar01

Procedural treatments	n	% of total Procedural treatments for all IHD in patients aged 45+		Per 100 IHD in patients aged 45+			
		probs	Lower 95% CI	Upper 95% CI	problems	Lower 95% CI	Upper 95% CI
Electrical tracings*	44	80.00	69.3	90.7	3.40	2.4	4.4
Physical function test*	4	7.27	0.1	14.4	0.31	0.0	0.6
Physical medicine/rehabilitation*	2	3.64	.	.	0.15	.	.
Other therapeutic procedures/surgery NEC*	2	3.64	.	.	0.15	.	.
Pap smear*	1	1.82	.	.	0.08	.	.
Other preventive procedures/high risk medication*	1	1.82	.	.	0.08	.	.
Local injection/infiltration*	1	1.82	.	.	0.08	.	.
.	.	.	.	.	.	.	.
Subtotal	55	100.00	.	.	.	.	.
.	.	.	.	.	.	.	.
Other Procedural treatments	0	0.00	.	.	.	.	.
.	.	.	.	.	.	.	.
Total Procedural treatments	55	100.00	.	.	4.24	3.1	5.4

Table 9.2.1: Top 10 Clinical treatments - New IHD in patients aged 45+ Apr00-Mar01

Clinical treatments	n	% of total Clinical treatments for new IHD in patients aged 45+ probs	% of total Clinical treatments for new IHD in patients aged 45+ probs		Per 100 new IHD in patients aged 45+ problems	Per 100 new IHD in patients aged 45+ problems	
			Lower 95% CI	Upper 95% CI		Lower 95% CI	Upper 95% CI
Advice/education*	3	25.00	0	55	2.56	0.0	5.5
Counsel/advice - exercise*	2	16.67	.	.	1.71	.	.
Advice/education - medication*	2	16.67	.	.	1.71	.	.
Counsel/advice - smoking*	2	16.67	.	.	1.71	.	.
Counsel/advice - nutrition/weight*	1	8.33	.	.	0.85	.	.
Counsel/advice - life style*	1	8.33	.	.	0.85	.	.
Counselling - problem*	1	8.33	.	.	0.85	.	.
.	.	.	.	.	.	.	.
Subtotal	12	100.00	.	.	.	.	.
.	.	.	.	.	.	.	.
Other Clinical treatments	0	0.00	.	.	.	.	.
.	.	.	.	.	.	.	.
Total Clinical treatments	12	100.00	.	.	10.26	4.3	16.2

Table 9.2.2: Top 10 Procedural treatments - New IHD in patients aged 45+ Apr00-Mar01

Procedural treatments	n	% of total Procedural treatments for new IHD in patients aged 45+ probs	% of total Procedural treatments for new IHD in patients aged 45+ probs		Per 100 new IHD in patients aged 45+ problems	Per 100 new IHD in patients aged 45+ problems	
			Lower 95% CI	Upper 95% CI		Lower 95% CI	Upper 95% CI
Electrical tracings*	15	93.75	80.1	100	12.82	6.1	19.6
Other therapeutic procedures/surgery NEC*	1	6.25	.	.	0.85	.	.
.	.	.	.	.	.	.	.
Subtotal	16	100.00	.	.	.	.	.
.	.	.	.	.	.	.	.
Other Procedural treatments	0	0.00	.	.	.	.	.
.	.	.	.	.	.	.	.
Total Procedural treatments	16	100.00	.	.	13.68	6.8	20.6

BEACH Survey Report - Analysis date: 21NOV08

Table 10.1.1: Top 10 Referrals to medical specialists - IHD in patients aged 45+ Apr00-Mar01

Referrals to specialists	n	% of total Referrals to specialists for all IHD in patients aged 45+			Per 100 IHD in patients aged 45+		
		probs	Lower 95% CI	Upper 95% CI	problems	Lower 95% CI	Upper 95% CI
Referral;cardiologist	99	91.67	86.4	96.9	7.64	6.2	9.1
Referral;physician	5	4.63	0.6	8.7	0.39	0.0	0.7
Referral;specialist	2	1.85	.	.	0.15	.	.
Referral;plastic surgeon	1	0.93	.	.	0.08	.	.
Referral;vascular surgeon	1	0.93	.	.	0.08	.	.
.	.	.	.	.	.	.	.
Subtotal	108	100.00	.	.	.	.	.
.	.	.	.	.	.	.	.
Other Referrals to specialists	0	0.00	.	.	.	.	.
.	.	.	.	.	.	.	.
Total Referrals to specialists	108	100.00	.	.	8.33	6.8	9.8

BEACH Survey Report - Analysis date: 21NOV08

Table 10.1.2: Top 10 Referrals to allied health professionals - IHD in patients aged 45+ Apr00-Mar01

Referrals to allied health	n	% of total Referrals to allied health for all IHD in patients aged 45+ probs	Lower		Upper		
			95% CI	95% CI	95% CI	95% CI	
Referrals to allied health					Per 100 IHD in patients aged 45+ problems		
Referral;health profess	4	50.0	5.3	94.7	0.31	0.0	0.6
Referral (for);ECG	3	37.5	0.0	80.8	0.23	0.0	0.5
Referral;occupational therap	1	12.5	.	.	0.08	.	.
.	.	.	.	.	.	.	.
Subtotal	8	100.0	.	.	.	.	.
.	.	.	.	.	.	.	.
Other Referrals to allied heal	0	0.0	.	.	.	.	.
.	.	.	.	.	.	.	.
Total Referrals to allied heal	8	100.0	.	.	0.62	0.2	1.0

BEACH Survey Report - Analysis date: 21NOV08

Table 10.2.1: Top 10 Referrals to medical specialists - New IHD in patients aged 45+ Apr00-Mar01

Referrals to specialists	n	% of total Referrals to specialists for new IHD in patients aged 45+			Per 100 new IHD in patients aged 45+ problems		
		probs	Lower 95% CI	Upper 95% CI	aged 45+ problems	Lower 95% CI	Upper 95% CI
Referral;cardiologist	35	89.74	79.7	99.7	29.91	21.6	38.2
Referral;physician	4	10.26	0.3	20.3	3.42	0.1	6.8
Subtotal	39	100.00	.	.	.	.	.
Other Referrals to specialists	0	0.00	.	.	.	.	.
Total Referrals to specialists	39	100.00	.	.	33.33	24.8	41.9

BEACH Survey Report - Analysis date: 21NOV08

Table 10.2.2: Top 10 Referrals to allied health professionals - New IHD in patients aged 45+ Apr00-Mar01

Referrals to allied health	n	% of total Referrals to allied health for new IHD in patients aged 45+ probs	95% CI		Per 100 new IHD in patients aged 45+ problems	95% CI	
			Lower	Upper		Lower	Upper
Referral;health profess	2	50	.	.	1.71	.	.
Referral (for);ECG	2	50	.	.	1.71	.	.
Subtotal	4	100	.	.	.	.	.
Other Referrals to allied heal	0	0	.	.	.	.	.
Total Referrals to allied heal	4	100	.	.	3.42	0.1	6.7

BEACH Survey Report - Analysis date: 21NOV08

Table 11.1.1: Pathology orders across MBS pathology groups- IHD in patients aged 45+ Apr00-Mar01

pathology	n	% of total pathology for IHD in patients aged 45+		Per 100 IHD in patients aged 45+			
		probs	Lower 95% CI	Upper 95% CI	probs	Lower 95% CI	Upper 95% CI
Chemistry	323	76.36	72.4	80.4	24.92	20.3	29.6
Haematology	85	20.09	16.3	23.9	6.56	4.7	8.4
Other NEC	12	2.84	1.2	4.5	0.93	0.4	1.5
Immunology	2	0.47	.	.	0.15	.	.
Cytopathology	1	0.24	.	.	0.08	.	.
.	.	.	.	.	.	.	.
Subtotal	423	100.00	.	.	.	.	.
.	.	.	.	.	.	.	.
Other pathology	0	0.00	.	.	.	.	.
.	.	.	.	.	.	.	.
Total pathology	423	100.00	.	.	32.64	26.7	38.6

Table 11.1.2: Pathology orders at individual test level- IHD in patients aged 45+ Apr00-Mar01

pathology	n	% of total pathology for IHD in patients aged 45+			Per 100 IHD in patients aged 45+		
		probs	Lower 95% CI	Upper 95% CI	probs	Lower 95% CI	Upper 95% CI
Lipids	108	25.53	21.3	29.8	8.33	6.5	10.2
Full blood count	58	13.71	11.1	16.4	4.48	3.2	5.7
EUC	44	10.40	7.7	13.1	3.40	2.3	4.5
Glucose tolerance	38	8.98	6.4	11.5	2.93	1.9	4.0
Cardiac enzymes	33	7.80	5.1	10.5	2.55	1.7	3.4
Multibiochemical analysis	30	7.09	4.0	10.2	2.31	1.2	3.4
Liver function	29	6.86	4.6	9.1	2.24	1.4	3.1
Coagulation	18	4.26	2.0	6.6	1.39	0.6	2.1
Drug screen	13	3.07	1.4	4.8	1.00	0.4	1.6
Thyroid function	12	2.84	1.1	4.5	0.93	0.3	1.5
Other test NEC	8	1.89	0.5	3.3	0.62	0.1	1.1
ESR	7	1.65	0.1	3.2	0.54	0.0	1.1
HbA1c	6	1.42	0.3	2.5	0.46	0.1	0.8
Chemistry; other	3	0.71	0.0	1.5	0.23	0.0	0.5
Blood test	3	0.71	0.0	1.5	0.23	0.0	0.5
Haemoglobin	2	0.47	.	.	0.15	.	.
Ferritin	2	0.47	.	.	0.15	.	.
Prostate specific antigen	2	0.47	.	.	0.15	.	.
C reactive protein	2	0.47	.	.	0.15	.	.
Immunology; other	2	0.47	.	.	0.15	.	.
Calcium phosphate	1	0.24	.	.	0.08	.	.
Pap smear	1	0.24	.	.	0.08	.	.
Urine test	1	0.24	.	.	0.08	.	.
.	.	.	.	.	.	.	.
Subtotal	423	100.00	.	.	.	.	.
.	.	.	.	.	.	.	.
Other pathology	0	0.00	.	.	.	.	.
.	.	.	.	.	.	.	.
Total pathology	423	100.00	.	.	32.64	26.7	38.6

BEACH Survey Report - Analysis date: 21NOV08

Table 11.2.1: Pathology orders across MBS pathology groups- New IHD in patients aged 45+ Apr00-Mar01

pathology	n	% of total pathology for new IHD in patients aged 45+ probs	% of total pathology for new IHD in patients aged 45+ probs		Per 100 new IHD in patients aged 45+ probs	Per 100 new IHD in patients aged 45+ probs	
			Lower 95% CI	Upper 95% CI		Lower 95% CI	Upper 95% CI
Chemistry	58	68.24	61.1	75.3	49.57	33.0	66.1
Haematology	24	28.24	21.1	35.4	20.51	11.4	29.6
Other NEC	2	2.35	.	.	1.71	.	.
Immunology	1	1.18	.	.	0.85	.	.
.	.	.	.	.	.	.	.
Subtotal	85	100.00	.	.	.	.	.
.	.	.	.	.	.	.	.
Other pathology	0	0.00	.	.	.	.	.
.	.	.	.	.	.	.	.
Total pathology	85	100.00	.	.	72.65	48.6	96.7

Table 11.2.2: Pathology orders at individual test level- New IHD in patients aged 45+ Apr00-Mar01

pathology	n	% of total pathology for new IHD in patients aged 45+			Per 100 new IHD in patients aged 45+		
		probs	Lower 95% CI	Upper 95% CI	probs	Lower 95% CI	Upper 95% CI
Full blood count	19	22.35	17.3	27.4	16.24	9.5	23.0
Cardiac enzymes	15	17.65	9.3	26.0	12.82	6.3	19.3
Lipids	14	16.47	10.2	22.8	11.97	6.1	17.9
Glucose tolerance	8	9.41	3.7	15.1	6.84	2.2	11.4
EUC	8	9.41	3.9	15.0	6.84	2.2	11.4
Multibiochemical analysis	4	4.71	0.1	9.3	3.42	0.1	6.8
ESR	3	3.53	0.0	7.3	2.56	0.0	5.5
Liver function	3	3.53	0.0	7.3	2.56	0.0	5.5
Coagulation	2	2.35	.	.	1.71	.	.
Chemistry; other	2	2.35	.	.	1.71	.	.
Thyroid function	1	1.18	.	.	0.85	.	.
Ferritin	1	1.18	.	.	0.85	.	.
Drug screen	1	1.18	.	.	0.85	.	.
C reactive protein	1	1.18	.	.	0.85	.	.
Immunology; other	1	1.18	.	.	0.85	.	.
Blood test	1	1.18	.	.	0.85	.	.
Other test NEC	1	1.18	.	.	0.85	.	.
.	.	.	.	.	.	.	.
Subtotal	85	100.00	.	.	.	.	.
.	.	.	.	.	.	.	.
Other pathology	0	0.00	.	.	.	.	.
.	.	.	.	.	.	.	.
Total pathology	85	100.00	.	.	72.65	48.6	96.7

Table 12.1.1: Imaging tests ordered by MBS group - IHD in patients aged 45+ Apr00-Mar01

imaging	n	% of total imaging for IHD in patients aged 45+ probs	Lower 95% CI	Upper 95% CI	Per 100 IHD in patients aged 45+ probs	Lower 95% CI	Upper 95% CI
Group I3 Diagnostic radiology	21	60.00	43.0	77.0	1.62	0.9	2.3
Group I1 Ultrasound	8	22.86	8.5	37.2	0.62	0.2	1.0
Group I4 Nuclear medicine imaging	5	14.29	1.9	26.6	0.39	0.0	0.7
Group I2 Computerised tomography	1	2.86	.	.	0.08	.	.
.	.	.	.	.	.	.	.
Subtotal	35	100.00	.	.	.	.	.
.	.	.	.	.	.	.	.
Other imaging	0	0.00	.	.	.	.	.
.	.	.	.	.	.	.	.
Total imaging	35	100.00	.	.	2.70	1.8	3.6

Table 12.1.2: Imaging tests ordered at ICPC-2 PLUS level - IHD in patients aged 45+ Apr00-Mar01

imaging	n	% of total imaging for IHD in patients aged 45+			Per 100 IHD in patients aged 45+		
		probs	Lower 95% CI	Upper 95% CI	probs	Lower 95% CI	Upper 95% CI
X-ray;chest	14	40.00	23.9	56.1	1.08	0.5	1.6
Echocardiography	6	17.14	4.3	30.0	0.46	0.1	0.8
Scan;thallium heart	5	14.29	1.9	26.6	0.39	0.0	0.7
Angiogram	4	11.43	0.2	22.6	0.31	0.0	0.6
Test;imaging;contrast/special	1	2.86	.	.	0.08	.	.
Ultrasound;abdomen upper	1	2.86	.	.	0.08	.	.
Angiography;coronary	1	2.86	.	.	0.08	.	.
CT scan;cardiac	1	2.86	.	.	0.08	.	.
X-ray;spine;thoracic	1	2.86	.	.	0.08	.	.
Ultrasound;kidney	1	2.86	.	.	0.08	.	.
.	.	.	.	.	.	.	.
Subtotal	35	100.00	.	.	.	.	.
.	.	.	.	.	.	.	.
Other imaging	0	0.00	.	.	.	.	.
.	.	.	.	.	.	.	.
Total imaging	35	100.00	.	.	2.70	1.8	3.6

BEACH Survey Report - Analysis date: 21NOV08

Table 12.2.1: Imaging tests ordered by MBS group - New IHD in patients aged 45+ Apr00-Mar01

imaging	n	% of total imaging for new IHD in patients aged 45+		Per 100 new IHD in patients aged 45+			
		probs	Lower 95% CI	Upper 95% CI	probs	Lower 95% CI	Upper 95% CI
Group I3 Diagnostic radiology	9	52.94	24.9	80.9	7.69	2.2	13.2
Group I1 Ultrasound	5	29.41	4.5	54.3	4.27	0.5	8.0
Group I4 Nuclear medicine imaging	3	17.65	0.0	38.3	2.56	0.0	5.5
Subtotal	17	100.00	.	.	.	.	.
Other imaging	0	0.00	.	.	.	.	.
Total imaging	17	100.00	.	.	14.53	7.6	21.5

BEACH Survey Report - Analysis date: 21NOV08

Table 12.2.2: Imaging tests ordered at ICPC-2 PLUS level - New IHD in patients aged 45+ Apr00-Mar01

imaging	n	% of total imaging for new IHD in patients aged 45+ probs	% of total imaging for new IHD in patients aged 45+ probs		Per 100 new IHD in patients aged 45+ probs	Per 100 new IHD in patients aged 45+ probs	
			Lower 95% CI	Upper 95% CI		Lower 95% CI	Upper 95% CI
X-ray;chest	7	41.18	16.5	65.9	5.98	1.6	10.4
Echocardiography	3	17.65	0.0	38.3	2.56	0.0	5.5
Scan;thallium heart	3	17.65	0.0	38.3	2.56	0.0	5.5
Test;imaging;contrast/special	1	5.88	.	.	0.85	.	.
Ultrasound;abdomen upper	1	5.88	.	.	0.85	.	.
X-ray;spine;thoracic	1	5.88	.	.	0.85	.	.
Ultrasound;kidney	1	5.88	.	.	0.85	.	.
.	.	.	.	.	.	.	.
Subtotal	17	100.00	.	.	.	.	.
.	.	.	.	.	.	.	.
Other imaging	0	0.00	.	.	.	.	.
.	.	.	.	.	.	.	.
Total imaging	17	100.00	.	.	14.53	7.6	21.5